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Introduction to Thesis 
The role of branding is very well established in all facets of life and especially in 
Fast moving Consumer industry. In age of hypercompetition, commoditization and 
rapid globalization, strong branding can provide a unique differentiation to the 
product offering that stands out as a relevant and superior in value to a clear target 
customer or market. In view of widespread acceptance nowadays of brands as 
valuable assets, it seems strange a little evidence exists in the pharmaceutical 
industry taking long-term brand building seriously. 
While Pharmaceutical branding currently remains at a nascent stage as opposed to 
its FMCG counterpart, globally there have been many studies done on role of 
branding in this Industry. Very less has been specifically studied in Indian context. 
Indian Pharmaceutical Industry faces a big challenge to compete with lots of "Me-
too" products, owing to the fact that the innovator (MNC) companies do not have 
exclusive marketing rights or patents in India. The market is constantly challenged 
by severe price competition and government price control. Creating real branding 
opportunities is a key challenge. 
In order to sustain competitive advantage, pharmaceutical companies have to 
develop and build brands that meet real needs and are differentiated in the minds of 
our customers. Whether this is possible in a highly cluttered and genericised 
pharmaceutical market like India and what role branding and communication play 
in differentiation, has formed the basis of this research and thesis. 
The thesis is an attempt to understand the role of branding and communication in 
Indian market where there are lots of "me-too" products, unlike in western world 
where the competition is very similar to a FMCG industry. The concept of "brand 
equity" has been used taking lead from David Aaker's brand equity. 
Primary research was conducted in India for this study in order to supplement 
information learned through secondary research and in order to answer specific 
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questions to gain a perspective on consumers. Further, the thesis will not only 
provide understanding on the role of branding but later give insights on how to 
effectively create sustainable brand strategies by building, measuring and 
managing brand equity. It also provide readers a clear view on which attributes to 
specifically focus on to build strong brand equity in the `'cluttered, me-too" Indian 
pharmaceutical industry. 
The overall approach, objective and attempt of the thesis have been to satisfy three 
key criteria's: 
- Depth: the narration in the thesis has been presented in the context of a 
conceptual framework that is comprehensive, internally consistent and 
cohesive, and well grounded in the academic literature. 
- Breadth: the thesis covers most topics on branding, brand management as a 
whole and then specifically focusing on pharmaceutical Industry that 
readers will find intriguing and/or important. 
- Relevance: the thesis is well grounded in Indian pharmaceutical context 
with its literature review and local research that can easily be related to past 
and present branding and communication activities. 
Finally, the books can help understand the issues, challenges and importance in 
developing strong branding and communication strategies to differentiate in the 
cluttered Indian market. Much work has been done into brand equity in FMCG 
industry but this area of marketing management still requires more research into its 
existence and development within pharmaceutical brands. The thesis will help 
make clear, however, that brand equity and its components do exist within the 
medical arena, to what extent is beyond the scope of this work. But it is my opinion 
as a researcher that we must continue to brand and consider the words of Tom 
Blackett wisely `In the 2151 century, branding ultimately will be the only unique 
differentiator between companies. Brand equity is now a key asset.' 
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Abstract 
Pharmaceutical companies face a series of significant challenges that are affecting 
their ability to maintain growth and sustain earning levels. To operate and succeed 
in the complex and highly regulated competitive environment, pharmaceutical 
companies know that brands are more than just products and services. 
In order to sustain competitive advantage, pharmaceutical companies have to 
develop and build brands that meet real needs and are differentiated in the minds of 
the customers. However, the role of branding in Indian pharmaceutical industry is 
yet to be completely understood in view of "no or very little patent protection". 
Unlike US & EU, Indian industry faces a bigger challenge from branded generics 
which makes branding more difficult. 
The study's research problem "what is the role of branding and communication in 
Indian pharmaceutical industry?" is justified both by the potential of the branding 
to create a brand equity to differentiate in the cluttered market, and by the lack of 
research in this area. 
Pharmaceutical branding describes the process whereby companies attempt to 
transform an active chemical compound into a recognizable package of associated 
brand values. These values, such as effectiveness, safety, trust and other more 
emotional associations, have become increasingly important levers through which 
pharmaceutical marketers can look to achieve greater market share and loyalty in 
an even more-competitive market space. Pharmaceutical branding efforts impact on 
a range of related strategies, including brand name development, Rx-to-OTC 
switching, DTC marketing, PR and corporate communications. 
The research problem was divided in two parts: 
1) To understand the role of branding, and if there is a role how does it 
impact brand equity to create differentiation in the cluttered market. 
2) To evaluate the impact of brand communication in this regulated industry 
and which are the most important attribute. 
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The thesis adopted a quantitative research approach and personal interviews were 
conducted with doctors across India. In the regulated pharmaceutical market, 
Doctors are the key customers and play a most important in building brand equity. 
Since there are many disease areas that can be studied, cardiovascular disease 
area was chosen. Since CV diseases are amongst one of the most prevalent and 
prescriptions for CV disease management are for life-long, branding can play an 
important role. Within CV, hypertension has the highest prevalence (17.1% in 
2010) and hence the products selected were from hypertension area. 
Hypertension and its associated condition are treated by Cardiologists and 
Physicians with cardiac practice. The sample chosen was from Cardiological 
Society of India which has —2500 Cardiologists and Physicians with Cardiac 
practice. 
The research was done with a sample size of 152 across the country taking into 
account cities like Metro and non-metros and also with small towns. 
The concept of David Aaker's Brand Equity model was used as a basis of research 
with minor modification to suit the research. To assess the brand equity primary 
driven by 4 attributes on Brand Awareness, Perceived Quality, Brand Loyalty and 
Communication were developed to understand if there is a role to play for branding 
in India Pharma industry, as the primary hypothesis. These four brand equity 
parameters were then compared to an MNC and a generic brand to understand the 
second hypothesis whether there is a difference in the two brand equity. The survey 
questionnaire had 29 attributes to be answered for Brand X (MNC brand) and 
brand Y (Generic). 
The research validated the two primary hypotheses that, branding does play an 
important role in building Brand Equity in Pharma industry. When we compared 
the equity on two parameters, Innovator (MNC) brands were scoring higher on the 
brand equity. 
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Chapter I 
Introduction & Research Problem 
This chapter introduces the topic for the study "role branding and communication in 
pharmaceutical industry`. Then the historical background of brands is presented, 
followed by a discussion of pharmaceutical brand and the role/value of branding and 
communication in the ethical Pharma market. Pharmaceutical brand building is 
examined from the perspective of a process and the people who are involved in that 
process. The chapter talks about the various dimension of the research problem and 
states the broad and specific research objectives. 
1.1 Introduction 
°A product is something that is made in factory; a brand is something that is bought 
by a customer. A product can be copied by a competitor; a brand is unique. A product 
can be quickly outdated; a successful brand is timeless (Aaker, D. 1991)". 
Brands has become a natural part of our lives, and appear almost everywhere. They 
help consumers navigate in a crowded market, reduce risk when purchasing, and 
enable us to express ourselves (Aaker, 1996). In view of the widespread acceptance of  
the brand as valuable strategic assets, it seems strange that there is little evidence that 
the pharmaceutical industry takes long-term branding very seriously. Perhaps this is 
because of the characteristic of the industry which apart from OTC sector is 
completely like any other. The prescription (Rx) only medicine sector, which 
contributes 90 per cent of the global pharmaceuticals revenue, is highly subject to 
government and political intervention. 
Pharmaceutical marketing has assumed that customers are only interested in the 
technical attributes a product, and base their decisions solely on selection of those 
attributes. As a result, pharmaceutical marketing probably has closer links to these 
areas than the more exciting and easily identifiable FMCG sector-although, in time, 
with the advent of DTC for medicines. this will change. The problem for 
pharmaceutical branding, and what it means to the industry is that, so far, out-of-the-
box thinking hasn't really been seen to be successful. 
1.2 Background 
1.2.1 A short history of the brand 
The English word brand descends from the old Norse word brandy, which refers to 
the branding of cattle. The word was spread in England by the Vikings and eventually 
incorporated into daily language (Rierebos, 2003). Evidence of the practice to "brand 
in" an ownership mark on cattle can be found on prehistoric Egyptian wall paintings 
and also in European cave paintings from the Bronze Age (Melin, 1999). 
The first branded product, an oil lamp, was produced in Roman times (Perry, 2005). 
The real breakthrough for brands in business did not come until the 19th century. A 
number of factors contributed to this: new production techniques, improved 
transportation, the evolution of mass media, and the availability of stores that enabled 
companies to reach large audiences (Perry, 2005; Riezebos, 2003). For the customer, 
brands became a sign of quality, thus reducing the risk of purchase (Perry, 2005). 
Brands like Schweppes (1798), Ballantine's (1809), Heinz (1869), Coca Cola (1886), 
and Kodak (1887) are examples of early brands that have not only survived but also 
prospered (Riezebos, 2003). Knox and Bickerton (2003) argue that the first attempt 
within brand management literature was the concept of brand image, which was 
studied by Boulding in 1956. 
Until the 1970s, brands were used for packaged consumer goods and owned by 
manufacturers (Perry, 2005; Melin, 1999). Manufacturers were then challenged by 
retail brands that offered lower prices and closer contact with customers (Melia, 
1999). In the 1980s and 1990s. brands became competitive tools for service 
companies. 
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1.2.2 The brand in pharmaceutical industry 
In today's brand centric society, the evidence of strong branding is all around us, from 
FMCG through to financial services. One industry, however, in which companies have 
been reluctant to jump onto the brand wagon is the pharmaceutical industry. 
Pharmaceutical companies have typically preferred to rely on the power of patent 
protection rather than the power of branding to drive sales and subsequently very few 
brands have managed to establish themselves. 
If we look at why people create brands, there are a number of reasons. Fundamentally, 
to include being able to sell a product at a higher price and being able to create a 
sustainable entity through which it can differentiate it from the competition and to 
leverage the brand going forward_ 
If we look at the traditional pharmaceutical model, the model was to invest a lot of 
money to develop an innovative product for which one gets a patent life and when that 
patent is over a new product is launched. Once a molecule was approved one could 
more-or-Less charge anything, and so pricing was never really an issue. The life of the 
brand was seen to last only as long as the life of the patent, and so it was not really 
possible to create a sustainable entity. Therefore, traditionally, pharmaceutical brands 
were created to build awareness. When pharmaceutical marketers talked about 
branding what they really meant was brand awareness and whether or not a physician 
recognizes the product. 
In India the environment in pharmaceutical is more to strive hard amongst the generic 
and MNCs are never willing to surrender the blockbusters to generic attack. Hence, in 
India it is not the patent but the brand differentiation, which will be the real enduring 
asset of a pharmaceutical company. 
The industry today is now being redefined by the way of patent power and advent of 
direct to consumer advertising (largely in US), resulting in increasingly informed end- 
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user. Therefore, branding will have an ever-crucial role to play in attracting and 
sustaining customer loyally and as an enduring source of competitive advantage. 
It seems extraordinary that one of the world's largest consumer good markets -
pharmaceuticals — should for so long have flourished with little help from brands. In 
most other industries, manufacturers, suppliers of services and retailers use branding 
techniques to help secure competitive advantage. Indeed, increasingly these days, it is 
the brand which provides the sole means of differentiation, as Tom Blackest famously 
said. 
"In the 21st century, branding ultimately will be the only unique differentiator 
between companies. Brand equity is now a key asset" (Blackett, T. 2001). 
The pharmaceuticals industry is a science-based industry and its huge success has 
been due largely to its ability to invent great new products for the benefit of mankind. 
Coca-Cola Corporation, without a patent to its name but with one of the world's oldest 
and most valuable trademarks, is a hugely successful business - while the 
pharmaceuticals industry, flush with patents but bereft largely of meaningful brands, 
expends huge amounts of cash and energy in the development of intellectual property 
of a comparatively evanescent quality. (Blackest, T. and Robins, R. 2001)  
In June 2000, lnterbrand published its list of the world's 75 most valuable brands. Not 
one pharmaceutical brand or company name featured in this list. The majority of the 
brands featured have been in existence at least since the Second World War, although 
it was notable that compared to the same league table published in 1999, several `new 
economy' brands, like Yahoo, Amazon.com and AOL had come into the reckoning 
Perhaps this is not surprising — but for the pharmaceutical industry it should be a 
matter of some concern. (Blackett, T. and Robins. R. 2001) 
1.3 Pharmaceutical branding 
Pharmaceutical branding describes the process whereby companies attempt to 
transform an active chemical compound into a recognizable package of associated . _ s:. 
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brand values. These values, such as effectiveness, safety, trust and other more 
emotional associations, have become increasingly important levers through which 
pharmaceutical marketers can look to achieve greater market share and loyalty in an 
ever more-competitive market space. Pharmaceutical branding efforts impact on a 
range of related strategies, including brand name development, Rx-to-OTC switching, 
DTC marketing, PR and corporate communications. 
Pharmaceutical Branding Strategies provides a unique window into the perspectives 
and experiences of those leaders at the forefront of shaping that future. There are a 
number of reasons why pharmaceutical brands have become more important. First of 
all one have got to create more value from the molecule above and beyond the 
obvious benefit. Secondly, one would want to create an entity that is differentiable 
from the competitors. In addition to that, one has the potential to create a sustainable 
entity through which it has to leverage the value of the brand. 
Pharmaceutical companies need to clearly define the value that their brands have in 
the marketplace above-and-beyond that of the competition. Only by clearly defining 
and managing that value can they begin to build and leverage brand equity moving 
forward. 
1.4 Building Pharmaceutical Brand 
Pharmaceutical markets are different than more typical consumer markets, and as a 
result the marketing of pharmaceutical brands cannot follow the established rules of 
consumer brands. However, by examining what has actually occurred in 
pharmaceutical markets and evaluating the relevant forces and relationships, 
pharmaceutical product managers can become more effective, efficient marketers. In 
the future, as this marketplace becomes tougher, evidence-based marketing will 
become a requirement for success. 
The critical success factors in terms of global branding really come down to one thing 
— one have to have a position that is single minded, that resonates well in the key 
markets, and that is applied consistently at local level. 
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Effective global brand teams will have to balance an inclusive branding process -
creating buy-in across the organization - with strong corporate leadership - limiting 
the rework of the global brand at the local level. The resulting brands, which have 
been developed from an early stage of the product lifecycle, will deliver a clear and 
consistent brand promise to their target audiences and a premium price and sustained 
market position for their marketers. 
In an industry where patent life is limited and the domain of market exclusivity is 
being toppled harder and faster by the onslaught of generics, a brand name needs to 
work that much harder throughout its on-patent life, while having the potential to live 
long beyond it. As companies are increasingly looking to lengthen the productive and 
profitable life of their brands, established equity in a brand name can provide a 
powerful platform for future wealth creation. It's about a name that will resonate with 
prescribers and consumers alike, and, ultimately, that will he relevant for the lifetime 
earnings potential of a brand. 
The pharmaceutical drug companies have chosen to focus on developing `products' 
rather than the brand. The traditional sources of value creation have been through 
extensive research and development (R&D). Brand managers in pharmaceutical 
companies usually take the help of expensive clinical data to demonstrate how their 
products differ from their competitors. This difference is often used as the basis for 
differentiation as it is easy to sell a "tangible" functional difference. Example, the 
lipid-lowering product Zocor (Simvastaein) is seen as the "first HMG-CoA reductase 
inhibitor", and licensed to reduce LDL cholesterol and increase HDL cholesterol. The 
concept of the brand is not well developed. 	 - 	- 
However, even though it is acknowledged that medicine has always been a function 
driven category, it is equally true that health is an emotive and personal subject. 
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1.5 The Research Problem 
Traditionally, the drug industry has focused on products rather than brands. The 
relatively short patent life, narrow exclusivity window, and rapidly changing medical 
environment make it essential to move onto the next product in R&D. 
Moss, G, (2001) reviews brand logic in Pharma industry and mentions that the 
industry talks about blockbuster products. how to make them bigger. and how to 
achieve it faster, but not about establishing brand. 
Since branding in pharmaceutical and more so in Indian branded generic dominance, 
is a relatively new area, there is a lack of research in this field. 
A plethora of academic literature exists surrounding the topic of branding, brand 
loyalty and equity development, but there is a paucity of specific research engaging 
pharmaceutical brands with traditional branding academia. Branding and brand equity 
have long been topics of interest to marketers and researchers. A brand can be defined 
as ' a name, term, sign, symbol /design, or a combination of all of these which is 
intended to differentiate them from those of competitors' according to one of the 
founders of modem marketing management (Kotler. P. 1991). A brand therefore adds 
emotional differentiation to the (rational) product features and benefits and therewith 
slows down, stops or prolongs commoditisation of a product. 
The easy growth environment has, however, changed. Industry growth has been 
slowing down, and firms have been searching for ways to maintain it. The three 
traditional success factors of the industry are less evident than in the past. First, it has 
become much more difficult to identify the blockbuster drugs that can fuel company 
momentum (additionally, product innovation remains costly and more elusive than 
ever). Second, many of the most successful drugs will soon suffer patent expiry. More 
than half of the global top fifty best sellers will go off patent in the next five years. 
Moreover, in view of the concentration of sales in fewer big products, the sales at 
stake are much larger than in the past. Third, sales force effort is reaching a saturation 
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level as the industry consolidates. It will not be possible in the future to base success 
just on increasing the number of sales representatives promoting a product. 
The pharmaceutical industry has traditionally focussed on marketing products rather 
than medicines according to Crites Moss (2001). Moss reviewed the drugs industry in 
considerable detail, and his findings strongly support the existence of `brands' despite 
the lack of research into pharmaceutical brand management. The industry has often 
talked about blockbusting' brands but does little in the way to establish brands 
properly. A significant factor was identified by Moss which highlighted the problems 
of establishing brands that are governed by patent life.  
Pharmaceutical brands are tuilikely to be protected by patent for more than 15 years 
and are rarely promoted once the generic alternatives have entered the market. In 
comparison to consumer brands, it was argued that pharmaceutical brands were 
relatively young as 64 per cent of the best known consumer brands in the US are more 
than 50 years old (Aaker, D. 1991). 
Academics have made some inroads into expanding the knowledge of pharmaceutical 
branding over recent years with considerable research from authors such as Tom 
Blacken, (2001) Handlin and colleagues (2003) and Graham Leask (2002). 
During Literature review it was also understood that, although there are many 
examples of excellent brand building in pharmaceuticals, the discipline has not yet 
reached a strategic level. 
If a company can create brand equity with a pharmaceutical product brand it adds 
value both to the customer and the company. The customer (prescribing physician) 
benefits from a reduced risk in drug choice for the physician, the patient benefits from 
increased personal care. In case of Indian Pharmaceutical industry where there are 
both branded and branded generics it becomes further difficult to understand the role 
of branding and the differentiation it brings. 
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Since branding in pharmaceutical and more so in Indian branded generic dominance, 
is a relatively new area, there is a lack of research in this field. The research problem 
is stated as: 
What is the role of branding in Indian pharmaceutical Industry and if there a 
role then how does it differ in branded vs. branded generics products? 
Developing a strong understanding and belief in the brand among our sales people 
will allow our brands to become even stronger in the minds of our customers. To 
maximise the selling process, our sales representatives must develop as advocates to 
the brand allowing them to maximise and defend the brand over competitors. This 
emphasis on maximising brand advocacy within the sales force becomes more 
apparent as we consider the importance of sales calls later in this research. This states 
the second research problem: 
What is the role and impact of communication in building brand equity in the 
Indian pharmaceutical industry? 
Blacken & Harrison (2001) reviews the use and future potential of branding and stresses 
the fact that careful brand management will play an important role in the future value 
creation in the pharmaceutical industry-much as it does in the majority of industries where 
the supply of goods and services is unrestricted and consumer choice is paramount. 
In the global pharmaceutical market, brands need to act as communication tools 
between the pharmaceutical companies and their geographically separated customers, 
whether that is the patient, the physician or the payers. One of the phenomena of 
recent brand histories has been the creation of brands that are based on an attitude 
rather than a category Amazon, Lastminute.com, and Yahoo! attract consumers to a 
Web site and are then able to sell them virtually anything. This illustrates the 
increasing complexity of communication in the modern world when one thing remains 
constant-satisfied customers become loyal customers and bring long-term 
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profitability. We know that the brand communication processes are becoming more 
complex, and yet, as an industry, we haven't found the right mix for that communication. 
Be that representative with physician, DTC adverts with the patient, endorsement 
lobbying with the general public, or a whole host of otherwise unmanaged interactions 
that occur on a day- to-day basis (Moss, G. 2007). 
In Indian context where there are so many companies specially the Indians who are 
producing largely generic products, branding will have to play a much bigger role in 
differentiation. Pharmaceutical branding and its role have been studied mostly in 
literature from a global point of view. Not many studies have focused on the Indian 
industry mainly because there is no patent protection which gives rise to generic 
products and makes it further difficult in branding. 
1.5.1 The Research Objectives 
Broad Objectives 
The study attempts to evaluate the role of branding in the India pharmaceutical 
industry and its role on in building brand equity. 
Specific objectives 
Most of the corporate brand building literature focuses on branding in pharmaceutical 
industry in western context and less on Indian pharmaceutical industry where the role 
of branding due to branded generics is still not well explored. This paper will focus on 
the role of brand building in Indian pharmaceutical industry: 
• To study broad branding strategies across different industries around the world 
• To understand specifically current branding strategies in Global and Indian 
Pharma Industry. 
• To understand the role of branding in context of Indian Pharma industry as 
measured by brand equity parameters. 
• To understand whether the brand equity parameters and drivers are same for an 
innovator (MNC) and a me-too generic brand in Indian Pharma Industry 
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• To understand the key factors that are important and to be considered for 
developing Pharma brands in Indian context 
1.5.2 The Research Framework 
Figure 1.1 Research Framework 
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1.6 Outline of thesis 
Table 1.1: Outline of thesis 
Chapter 1 Introduction & Research problem 
Chapter 2 The Indian Pharmaceutical Industry 
Chapter 3 Literature review 
Chapter 4 Theoretical framework & Hypothesis development 
Chapter 5 -Research Methodology 
Chapter 6 Analysis & Interpretation 
Chapter 7 Discussion and findings & Managerial implications 
Chapter 8 Contextualization & Directions for future research 
CHAPTER 2 
The Indian Pharma Industry study 
This chapter gives a brief overview of the Indian Pharmaceutical structure. It starts 
with brief history, origin and structure of Indian pharmaceutical Industry. 
2.1 Brief history 
From ancient times, two systems of medicines were in vogue in India. Firstly, there 
was Ayurvedic medicine, which dates back to the Vedic period. Ayurvedic medicine 
depends largely on the combination of various herbs, minerals and metals like copper, 
etc. Secondly, there was the Arabian system of medicine, Innumerable invasions had 
brought the Arabian system into India. In contrast to these, two other systems of 
medicine, namely Allopathic and Homeopathic, were in vogue in the western part of 
the world. (Chaganti, SR, 2005). 
Despite being a very advance indigenous system of medicine. Ayurvedic has not 
really become popular enough, probably because of a very long British rule and the 
consequent development of an educational system including medical education based 
on a typical British Model. As allopathic or modern medicine started taking roots in 
India, all the Research and Development activities the world over fuelled its growth in 
India as well. Conversely, there was hardly any research and development activity in 
the area of Ayurvedic medicine. Though the government has been making some 
efforts to promote Ayurvedic medicine, its development seems to be a long way off it 
is still popular in rural areas, may be because modern medicine cannot reach there. In 
urban areas it has yet to gain importance in so far as the prescription drug is 
concerned. The inclination of allopathic doctors towards prescribing an Ayurvedic 
medicine is very low indeed. (Chaganti, SR, 2005). 
Of late, however, the attitude of consumers towards Ayurvedic medicine seems to 
increasing favorable. Some of the pharmaceutical companies are planning to diversify 
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into Ayurvedic drugs mainly to improve profitability. Ayurvedic drugs are exempted 
from price control (Chaganti, SR, 2005). 
2.2 Origin of the Indian Pharmaceutical Industry 
The exact date on which Allopathic system of medicine made its entry into the 
country is not available (Chaganti. SR. 2005), but it is generally estimated that it 
happened sometime during the early part of 19 h` century. Medicines were imported by 
the British for their personal use when they came to do business. This was the 
beginning of pharmaceutical industry in India. Later, when they ultimately took over 
the country, the imports became a regular feature. These pharmaceutical products, 
which were introduced in India to provide relief to the British, soon gained popularity 
among people in urban areas. For the first few decades after their introduction, 
pharmaceutical products were being imported into the country mostly from Germany 
and UK. Indigenous production of these medicines, however, was started in 1901 with 
establishment of Bengal Chemical and Pharmaceutical works, due to the pioneering 
efforts of Acharya PC Ray. 
The world of medical treatment was witnessing some significant developments, like 
Pasteurs's discovery of pathogenic bacteria as the cause of infectious diseases, while 
the Indian Pharmaceutical industry was at its early stages. Scientists in India 
undertook research in tropical disease like Malaria, typhoid and cholera Between 1904 
and 1907 four research institutes, namely The Haftkine Institute, King institute, 
Central Research Institute and Pasteur Institute were established. Yet another 
significant development during this period was the use of chemicals for treating 
various diseases. Some very important drugs like aspirin and barbiturates were made 
available during this period. The First World War gave a real stimulus to domestic 
productions of pharmaceuticals. Consequently, the production of quinine salts 
registered a substantial increase for the first time. Production of caffeine from tea 
waste and manufacture of surgical dressings were also taken up during this period. 
However with the resumption of imports after the war, the industry was back to square 
one, it received a setback, as it was unable to compete with imported products. 
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The Bengal Chemical and Pharmaceutical Works started production of tetanus 
antitoxin, a basic drug, in 1930. Indigenous production in 1939 was sufficient to meet 
only about 13 percent of medical requirements. Thus a large part of domestic demand 
for drugs was still met by imports. The Second World War was another landmark in 
the history of Indian pharmaceutical industry. It provided a propitious atmosphere for 
further expansion of production. 
By 1941 the industry took up the manufacture of new drugs like the iodochloro-
hydroxy quiniline as well as a number of alkaloids like ephedrine and codeine. 
Besides this, the industry made a beginning in the production of chemotherapeutic 
drugs like arsenicals, anti-leprotic drugs and colloidal preparations of calcium, sliver, 
manganese and iodine. The production of glandular products like, liver-extracts was 
also undertaken. The production of several formulation based on imported bulk drugs 
also showed a significant expansion during the period. 
Post-war developments in the west resulted in a high degree of product obsolescence, 
replacing many older drugs with antibiotics and new chemotherapeutic agents. This 
put the fledgling Indian Pharmaceutical industry at a great advantage. As a result, 
Indian companies had to stop production of many items that were manufactured 
during the war-years. Instead, they started the manufacture of formulations based on 
imported bulk drugs and on the extraction of therapeutic agents from plant sources. 
Thus, at the time of independence, with the small base that existed for the production 
of medicines, the industry could not make much headway in the absence of consistent 
governmental support to a nascent industry. The industry value of production of 
pharmaceutical in 1947 was Rs 10 crore (Chaganti, SR. 2005). 
Post —independence era 
Immediately after independence, the government addressed itself to the task of 
achieving a high rate of economic progress with special emphasis on speedy 
industrialization. When the government of Independent India embarked on planned 
economic expansion about four decades ago, the development of the Indian 
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pharmaceutical industry was not commensurating with size of the country and the 
growing needs of its population. Since then, the progress of the pharmaceutical 
industry in the country has been substantial and many sided, and can best be described 
as dramatic (Chaganti, SR. 2005). 
Dramatic progress 
From mere Rs 10 crore (production value) in 1947 to a whopping Rs 26, 540 crore in 
2002-2003, the pharmaceutical industry has come a long way. The growth between 
2004-2010 has been over a 15% Compounded Annual Growth Rate has shown in 
Figure 2.1 (next page) 
The industry has more than 31,000 products and 20,000 registered units. While India 
ranks tenth globally in terms of value, it is ranked third in volumes. 
In the 1970s, India had hardly any noticeable activity that could have accounted for 
being part of a domestic pharmaceutical industry. Multinationals were dominating 
85% of the trade, and the country's industrialization wasn't considering Line chemicals 
as a priority. With the advent of the import substitution policy and the implementation 
of the 1970 Patents Act, the country started building chemical know-how and 
industrial tools that would be instrumental to the real birth of the Indian plrarma 
sector. 
Today, the contrast is sharp, to say the least India is home to more than 20,000 
production units, out of which just short of 300 forms the real backbone of the 	- 
industry, accounting for more than 80% of production. The country also has watched a 
number of local stars go global to become some of the world's best pharmaceutical 
performers in terms of delivering growth, market penetration, or cost-efficiency. The 
likes of Cipla (Mumbai). Ranbaxy (Delhi), Dr Reddy's laboratories (Hyderabad), and 
Lupin Limited (Mumbai) are indeed carrying the industry forward and aggressively 
penetrating the world market, displaying a mix of unabated confidence, know-how, 
and bold moves. Yet, the success of these players should not hide the many challenges 
faced by the industry, as their number has never been as high as today. 
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Figure 2.1: India Pharmaceutical industry growth evolution 
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The most recent and decisive factor of change was the enactment in 2005 of an 
amendment to the 1970 Patents Act that, in effect, has made copying drugs patented 
after 1995 illegal. An industry that had been developing and flourishing based on the 
production of pharmaceutical copies suddenly found itself in need of redefinition and 
redirection. After years of being shielded from the global market's realities, the 
industry has had to adapt fast. At the same time, a number of Indian patents were put 
at risk, and the cost of post-1995 patented drugs grew out of reach for many Indians, 
in a country where there is no real state health insurance, and where most of the 
population is unable to afford health coverage. 
23 Industry structure 
The Indian pharmaceutical market is in midst of exciting times. While growth has 
accelerated considerably, industry structure has changed through a spate of high-
profile acquisitions. Traditional commercial models are fast losing the ability to 
differentiate. New opportunities we gaining critical mass. Discontinuities in the 
broader healthcare landscape are further intensifying these dynamics (Bhadoria, V. et 
al., 2011). 
The entry into force of this new regime has led the Indian pharmaceutical industry to 
redeploy its efforts toward pre-1995 molecules, as well as to develop and nurture its 
strengths in innovative directions. The first, most noticeable avenue of growth has 
been in the export market. From an inward-looking industry enjoying the benefits of a 
cozy intellectual property regime, India has found itself exposed to the rigors of global 
competition and has succeeded rather convincingly in the exercise. 
In just over a decade, Indian manufacturers have mastered the secrets of global trade 
so well that the country today accounts for more than 20% of the world's generics 
production. The trend exemplifies how capable and swift-moving the industry is and 
has been to date. When examining some of the 300 players that account for most of 
India's pharmaceutical revenue generation, a number of business models appear, 
building on the industry's traditional strong points, from manufacturing know-how and 
reverse engineering capabilities to a solid chemical industry base and excellent human 
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resource pools. The fact that India has the largest number of FDA-approved facilities 
after the United States testifies to the radical transformation of the industry. The actors 
of change, local manufacturers in particular, are following diverse directions for their 
businesses, and respond to many different impulses. The pharmaceutical Industry is 
very aptly described as a "life line" industry. It plays a vital role in alleviating the 
sufferings of millions of people and controlling various ailments that affect human 
beings. Recognizing this, the planners of Indian economy have rightly included this 
industry in the core sector. The present day Indian pharmaceutical industry has three 
main sectors; the public sector, the Indian private sector (including the organized 
sector) and the foreign sector (MNCs). 
Multinationals are constantly increasing investment in the country, while domestic 
players are purchasing companies abroad to establish an international presence. 
Spending is increasing across all sub-sectors, especially for generic medicines, which 
are starting to be within reach of India's vast rural population. 
As seen in Figure 2.2, there are 20,000 manufacturers with 395 in the organized sector 
organized sector are domestic companies and the balances 41 are MNCs. Globally 
India is ranked 4th by volume but only 13th by value, which clearly shows that the 
pricing of pharmaceutical products is very less as compared to global, which is further 
reinforced in Table 2.2. 
The industry is highly fragmented having above of 20,000 products. Table 2.1 data 
also reinforces the facts that the out of top 10 brands in the industry, 7 are of MNCs 
(70%). Figure 2.3 lists the top 10 companies in the Indian Pharma Industry 
In a 2007 report, McKinsey said by 2015 India will rank No 10 in the global pharma 
ranking with drug sales of $20 billion (Rs 96,000 crore). Rising incomes, health 
insurance and improved healthcare delivery are expected to spur growth. India is one 
of the few remaining generics markets driven by doctor prescriptions and not just 
trade-push. In the US, prices collapse when a drug loses patent protection. But in 
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Figure 2.2 Industry Structure-Domestic vs. MNCs in India 
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Figure 2.3 TOP TEN Indian Pharmaceutical companies 
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Table 2.1: Indian Top 20,000 brands segmentation 
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2.4 Indian Pharma characteristics: 
The Indian pharmaceutical market has characteristics that make it unique. First, 
branded generics dominate, making 70 to 80 per cent of the retail market. Second 
local players have enjoyed a dominant position driven by formulation development 
capabilities and early investments. Third, price levels are low, driven by intense 
competition. As per Mckinsey report, going ahead Branded Generics (BGx) are likely 
to be sustainable, however patented brands share will also continue to increase. (See 
figure 2.6). 
Increasing government regulations and policy changes which Government regulates 
industry through Drug Controller General of India, Ministry of Health, National 
Pharmaceutical Pricing Authority, State Govt, Local FDA. Rigorous control on 
formulation and an absence of International patent protection resulting into "me-too" 
product maze with little or no product differentiation. 
Healthcare delivery in India is through various providers; 
• 10,500 hospitals/institutions, 
• 162 medical colleges, 
• 15 mio beds, 
• 163,000 primary health centers, 
• 504,000 practicing doctors: 
• GP: 336,000; 
• Specialists: 168,000, 
• 737,000 practicing nurses, 
• 18,000 stockists, 
• 550,000 pharmacies 
Large part of populations is self-pay with only 15% of population with some kind of 
Insurance cover; 1%: private health insurance, 5%: employer spend, 35%: social 
insurance (ESIS), 5%: community insurance. Only 15% of population has some kind 
of coverage. This further illustrated in Figure 2.5 
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Figure 2.4a: ('hanging equation of top 10 MN('s 
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Figure 2.5: Coverage forms in India 
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Figure 2,6 Pharmaceutical products distribution and evolution 
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2.5 The Generics policy 
The government of India announced on January 17, 1981. its decision to abolish brand 
names for single ingredient formulations, namely analgin, aspirin, chlorpromazine, 
ferrous sulphate and piperazine, and to permit and not to permit brand names for all 
single ingredient new drugs. In addition, generic names should be printed on the packs 
more conspicuously and above the brand names. The tariff commission as well as the 
Hathi Committee has examined the pros and cons of this new generic policy. 
2.6 Protection of "patents" & "IPR" 
IPR (Intellectual Property Rights) as name suggest, is basically a concept, an idea or 
thought leading to the actual invention of a product or process. Intellectual property 
right therefore is a legal protection for new inventions, products or processes, which 
are the results of an individual's ideas. The World Intellectual Property Organization 
(WIPO) defines and clarifies what exactly should be the nature of "Intellectual 
property". Currently about 140 countries give legal protection to both product and 
process patents as well as per Paris convention on International Patents and IPR. 
A Patent is a legal protection for an invention. At the same time, not all inventions are 
patentable. Generally, the invention must possess or meet certain criteria like; it must 
involve some inventive step, it must be obvious, it must be applicable industrially. A 
patent once granted for an invention is an "intellectual property" which remains in 
force for a specific period of time 97 years in India and 20 years which have signed 
the Paris convention on Patents and Intellectual Property Rights). 
If any person exploits the patent without prior authorization (license) of the owner of 
the patent, he infringes the right and commits an illegal act. However, if the patentee 
does not work the patent or he does not allow other to work the same, the patent can 
be revoked and the patentee is forced to give a "compulsory license", which is an 
authorization to exploit the invention. The conditions of granting a compulsory 
license are regulated in the act. The decision of granting a compulsory license includes 
fixing remuneration for the patent. 
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2.7 The pharmaceutical market segmentation 
There are three major segments in the pharmaceutical market. One is the "consumer 
market" or the "prescription market" which consists of individuals and households 
that go to the practicing doctor for the treatment of ailments. The other is the 
"institutional market" that is made up of the large hospitals in the public and private 
sectors, which buy the products for distribution among their employees, and the 
government hospitals including medical college and hospitals that provide free 
treatment to the poor. The third one is "the industrial market", which comprises the 
bulk drugs that are used in formulations. 
a. Patient (consumer or end users) 
Patients with similar illness fall under the same therapeutic category, e.g. diabetic 
patients, asthmatic patients, hypertensive patients. Patients can be classified depending 
on the stage of illness or disease has been progression e.g. patients with mild to 
moderate hypertension or patient with severe hypertension, according to their age 
group, e.g.. Pediatric patients, geriatric patients, elderly patient, or can be segmented 
according to sex, male or female. 
b. Doctors (intermediate-customers, who are influencers) 
In pharmaceutical marketing, it is the DOCTOR who acts as the customer and 
PATIENT who is suffering from a particular ailment, acts as the consumer, Doctor, 
acts as the influencer on behalf of the eventual consumer or the end user. Doctors can 
be classified according to their specialty, e.g. Cardiologists, Surgeons, Chest 
Physician who are highly qualified and are specialists in their area. General 
practitioners who treat common diseases, minor ailments, etc, according to the place 
they practice, e.g., Urban, rural, government hospitals, primary health centre, private 
nursing home etc, according to their usage rates, e.g., high prescribers, medium 
prescribers or low prescribers. 
The marketer can do the Pharmaceutical market segmentation in four primary ways 
viz: By demographic factors, by usage rate, by perceived product benefits and by 
lifestyle characteristics or psychographic. These ibur ways are commonly used for 
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segmenting a market. They are used often in combinations since no one basis is best 
for all situations. These four bases for segmentation are important because, it helps 
find ways of describing the customer groups in order to communicate with them 
effectively. 
c. Therapeutic segments 
The most important way segmenting the pharmaceutical market is by various 
therapeutic groups. Further there is a huge patient pool in India owing to high disease 
prevalence and mortality and morbidity burden. The market is divided into 12 major 
therapeutic segments out of which 7 are the most important one. It is lately been seen 
that the market is shifting towards lifestyle diseases like CARDIOVASCULAR and 
DIABETES. This is shown in table below and in Figure 2.8 (next page) 
Table 2.8: Market shifting towards lifestyle disease 
Anti-infectives 
IIiS 
Anti-infertives 
DIl 
Anti-infectives Anti-mfectives 
Castro Intestinal Castro Intestinal Castro Intestinal CARD 
Gastro Intestinal Vit/ Min / Nut Respiratory CARDIAC 
Respiratory Vit / Min / Nut Respiratory Respiratoy  
Pain /Analgesics Pain /Analgesics Vet, Min / Nut Pain /Analgesics 
Derma CARDIAC Pain /Analgesics Vit/ I'An / Nut 
CARDIAC Derma Derma Anti [Jibut 
Gynaec Gynaec Gynaec  
NeuroI CNS Neurol CNS Neuro! CHS NeurolCNS 
Anti-TB li 	tic, `-. 1 	i..• ~Ar1BD 	C- 	?,.a Derma 
Hormones Anti -T B Others Others 
Ano-Parasitic Hormones Ophthal / Otologicals Hormones 
Ophthal Hormones Ophthal/Otol 	icals 
Ophttual/Otol 	icals Others Anti-TB He etoprotedives 
Others Anti-Parasitic Hepato rotectives Sex Stimulants /R 	uvenalors 
Source: IMS prognosis 
2.8 Chapter Summary 
In summary, with more than 20,000 registered units, Indian Pharma has expanded 
drastically in the last two decades. At least as many as 250 pharmaceutical companies 
share lead of this market and are constantly challenged by severe price competition 
and government price control. In order to sustain competitive advantage, 
pharmaceutical companies have to develop and build brands that meet real needs and 
are differentiated in the minds of our customers. 
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Figure 2.8: Disease prevalence in India 
India - huge mortality and morbidity burden 
Disease prevalence in India 
Percent 
Share of 
mortality 
Share of 
morbidity 
• 3 m cardiac related deaths per 
year 
• 8m cancer patients 
• 169 m hypertensive patients 
• 45m diabetics patients (Will 
become - 80 m by 2030 (WHO 
20% 	estimates) 
• 50m asthmatics 
• 2.5m people HIV+ 
Coronary heart disease presents a huge, future threat to the 
health of Indians: The probability of an Indian getting a 
heart attack is 4 times greater than an American, 7 times 
greater than a Chinese and 20 times higher than a Japanese 
Source WHO, IMS Market Prognosis 2010-14 
CHAPTER 3 
Literature View 
The main objective of this chapter is to review relevant literature that is already in 
existence and to indicate where this study fits into debates around the subject. This 
chapter will also define key concepts and terminology. 
This chapter begins with a brief overview of branding, followed by review on 
literature related to both International & Indian pharmaceutical industry. It also gives 
an overview of past researches related to branding across the world and India Pharma 
Industry that helps set context and need for the current research. 
3.1 Introduction 
This chapter describes theories related to brand building and in addition focusing on 
pharmaceutical branding. 
Branding has persisted for centuries as a way to distinguish one producer's goods 
from another manufacturer's products and services. An understanding of customer-
based brand equity is essential in order to fully branding and its advantages. Customer 
based brand equity is the differential effect that brand knowledge has no consumer 
response to the marketing of the brand. The theory in this chapter is based on three 
theoretical areas: brand management literature, Pharmaceutical brands and 
communication. 
3.1.1 Branding and Brand Management 
Branding has been around for centuries as a means to distinguish the goods of one 
producer from those of another. The word brand is derived from the Old Norse word 
brandr, which means to bum, as brands were and still are the means by which owners 
of livestock mark their animals to identify them. (Interbrand, 1992) 
In the world of consumer goods and services, companies have used branding 
techniques to achieve competitive advantage for many decades. In fast moving 
consumer good (FMCG) brands are viewed as the key assets of the company, and all 
resources are utilized to create and develop brands. While core principles and 
strategies for branding a medical product is the sonic as for any product, there are 
differences in pharmaceutical industry. Due to differences in regulations of marketing 
and selling drugs, many of the strategies used to market consumer products are 
unacceptable practices in healthcare. 
3.1.2 Brand perspectives 
A number of definitions and perspectives on brands have been put forward by scholars 
(Kapferer, 2001). The complex entity of a brand is difficult to capture in a short 
definition. To illustrate the different perspectives of a brand, consider the definition by 
tnterbrand (2005): A brand is a mixture of attributes, tangible and intangible, 
symbolized in a trademark, which, if managed properly, creates value and influence. 
Value has different interpretations: from a marketing or consumer perspective it is 
"the promise and delivery of an experience;" from a business perspective it is the 
security of future earnings;" from a legal perspective it is "a separable piece of 
intellectual property". Brands offer customers a means to choose and enable 
recognition within cluttered markets. This comprehensive definition introduces the 
concept of a trademark a legal designation indicating that the owner has exclusive use 
of a brand (Rowley, 1997). 
interbrand (1997), brings up the tangible and intangible attributes that create value for 
the firm. The marketing perspective highlights the idea of a customer promise. It 
should be remembered that brands are created in the compaiw but what really matters 
is how they later exist in the mind of the customer (de Chernatony, 1993). De 
Chematony and Riley (1998) present several perspectives (that can be used in 
combination to capture the complex nature of brands. Brands can be understood from 
either an input or an output perspective, since both marketers and customers 
participate in the branding process. Input perspectives (Table 2.2) are based on the 
notion that branding is a tool of directing resources that influence consumers. Brands 
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can also be seen from an output perspective that refers to how customers 22 interpret 
the brand, either through an image or a relationship (de Chernatony & Riley, 1998). 
Finally, brands can also have a time perspective, thus recognizing the evolutionary 
nature of brands (de Chernatony and Riley, 1998). 
Table 3.1: Brand perspectives 
Input Perspective 
Logo Focuses on visual signifiers (i.e. color) to differentiate the brand; 
should be developed strategically  
Legal instrument The brand is seen as a le al protected statement of ownership. 
Company The brand is dominated by the corporation and the values associated 
with the company. 
Shorthand The brand represents information for the customer. This shortcut into 
the customer's memory aids decision-making. 
Risk Reducer Brands can reduce the risk for customers. Risk is divided into four 
types: performance, financial, social and psychological. 
Positioning A customer should instantly associate a brand with a certain benefit. 
Personality Human characteristics are associated to the brand, for instance, by 
using a celebrity. The customer will then more easily accept the 
emotional values of the brand. 
Cluster of Values A brand represents a cluster of values. For example, Virgin values 
quality, innovation, value for money, fun, and a sense of challenge. 
Vision In this perspective, the brand 	is seen 	as a 	beacon 	that directs 
management to where the company should be heading. It is strategic 
and will motivate staff. 
Adding Value The 	brand 	adds 	functional 	and/or 	emotional 	benefits 	to 	the 
(augmented) product. 
Identity Identity is about the ethos, aims, and values that present a sense of 
individuality differentiating the brand: it involves the whole company. 
Output perspective 
Image The brand image is how it is perceived by the customer. The image is 
formed 	through 	experience 	with 	the 	product 	and 	related 
communication. Each customer has a unique understanding of the 
brand but may share common features with other customers. 
Relationship Customers can form relationships with brands, which relate to the self 
image of the customer and legitimize the customer's thought about 
themselves. 
Time Perspective 
Evolving entry The brand consists of core and peripheral values. To keep up with 
changes 
in the environment, the brand is fine-tuned by changing the peripheral 
Values. 
Source: Based on de Charnatony and Riley, 1998 
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3.1.3 Brand Identity 
Brand identity is a concept that adopts the perspective of the firm, as seen from the 
following quote by Harris and de Chernatony, p. 442: "While brand image focuses on 
consumers' perceptions of brand identity, identity is more concerned with how 
managers and employees make a brand unique". Melin (1999) explains brand identity 
as what the brand stand for, gives it meaning, and makes it unique. The word identity 
is used in many disciplines and is derived from the Latin identitus, which means 
"complete conformity". Brand identity is something that is constructed and can be 
changed and has recently become one of the most interesting and important concepts 
of the branding literature. Kapferer (as cited in Melin, 1999) creates a conceptual 
model of brand identity (see Figure 3.1). 
Figure 3.1: Brand Identity Prism 
Picture of Sender 
Physique 
;......... _ ................. _............................._...._ 	........................................ 	-........................................... 
Externalization 
Relationship 
j...._......- .............. ..........................._._..................._.......................................... 	.............................................. 
Reflection 
Picture of Recipient 
Source: Kapferer (as cited in Melin, 1999, p.87) 
Personality 
Internalization 
Culture 
Self Image 
The overall goal is to develop a core identity that is consistent over time. Brand 
identity is communicated by the firm through physical aspects (product, name) of the 
brand and through the brand personality. If the firm is successful in communicating an 
intended identity, the picture of the sender corresponds with the picture of the 
recipient. 
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Aaker (1996) suggests that brand image refers to how the brand is perceived, while 
brand identity refers to how the brand would like to be perceived. Brand image 
therefore mirrors the current reality of the brand. According to Aaker, the brand 
identity consists of a unique set of brand associations that imply a promise to 
customers. Associations are either derived from a core identity or an extended 
identity. Core identity is defined as "the central, timeless essence of the brand"; the 
extended identity holds elements that are flexible and creates texture. Brand identity 
facilitates the creation of relationships towards customers as it generates value. Aaker 
also claims that companies should avoid having a limited, tactical perspective on 
brands; instead, they should broaden the meaning of their brand and grant it strategic 
importance. 
Brand identity is the core nature of the brand (Kapferer, 1996; Aaker, 1996; Urde, 
2003). Related concepts include brand soul (Randazzo, as cited in Upshaw, 1995), 
brand essence (de Chernatony, 2001, Upshaw, 1995), core values (Urde, 2003), brand 
values (de Chernatony, 2001b), brand covenant (Balmer, 2001), and brand mantra 
(Keller, 1999). Upshaw (1995) describes brand identity as consisting of a number of 
elements (Figure 3.2). 
Figure 3.2: Relationship between Brand essence and brand identi 
Marketing 
Communication 
Logo/Graphic 	 Brand 
Svstem Name 
BRAND ESSENCE 
Brand Positioning 
selling  
Strategies 	
Strategic Personality 	 Pro- 
motion 
Product/Service Performance 
TOTAL BRAND IDENTITY 
Source: Upshaw, 1995, p.24 
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Brand teams often focus on the two most crucial elements: positioning and 
personality. These elements dictate how customers perceive the attractiveness of the 
brand. The essence of the brand is the core of its identity, the singular way in which 
positioning and personality blends. The brand essence is proposed by the firm but can 
only exist if the target audience accepts the proposition .. A similar concept to brand 
identity is brand positioning. Roth concepts refer to how the company would like the 
brand to be perceived by others. Brand positioning is seen as the part of brand identity 
that is actively communicated. Thus, brand positioning is a narrower concept than 
brand identity (Aaker, 1996).  
3.1.4 Brand Positioning 
Positioning is an acknowledged marketing tool for coordinating the company's 
communication (Aaker, 1996; Keller, 1999; Bhat & Reddy, 1998; Kalafatis et al., 
2000; Ries & Trout, 2001). The concept of positioning relates to position the same 
way as a means relate to its goal (Melin, 1999). According to Ries and Trout (2001), 
positioning is the first concept that tries to resolve the difficult problem of getting 
heard in a crowded marketplace. Keller (1999) argues that positioning is essential to 
creating a strong brand and should be at the heart of all marketing activities. 
Positioning creates a positive image for a product or company (Kotler, 2000), giving 
the company an advantage over competitors. The set of perceptions, impressions, and 
feelings that a customer has for a product or company is also the position (Kotler, 
2001). 1-low to effectively reach the customer with the right associations is a major 
challenge for marketers today (Ries & Trout, 2001; Trout & Rivkin, 2000). 
Companies should not leave positioning to chance; they should plan and communicate 
how they wish to be perceived by customers (Kotler, 2001). 
In the early 1980s, Ries and Trout (2001) popularized the concept of brand 
positioning. Both brand image and brand positioning deal with how consumers create 
a mental picture of a brand, but positioning takes this thought one step further by 
realizing that consumers make choices based on comparisons with competing 
products. Companies must create a unique position in the minds of customers, 
sometimes referred to as psychological positioning. Objective attributes of brands can 
a 
also be compared, this is called product positioning (Melin, 1999). The company must 
integrate product positioning with psychological positioning in order to avoid striving 
for a position they cannot achieve. According to Arnott (as cited in Blankson & 
Kalafatis, 1999), the various terms that exists for positioning, are simply several sides 
of the same coin. There is a lack of a coherent definition for positioning, and difficult 
implementation has resulted in less appreciation of the concept (Blankson & Kalafatis, 
1999). Because of this, it has also been difficult to measure positioning. Adding to the 
confusion, positioning is both the part and the whole of branding. As Marsden (2002) 
states that "the entire enterprise of branding itself can be understood as an exercise in 
positioning; using product experience and marketing initiatives to increase 
profitability by associating trademarks with compelling consumer values". 
The customer is central to Ries and Trout's (2001) definition of positioning. A 
sensible approach to positioning is not to create something new but to reinforce 
existing connections. Companies must understand the place that competitors already 
have in the customer's mind in order to be successful with positioning. Claims that 
can be easily imitated should be avoided; companies should also stay away from 
something that requires a complex analysis to prove. Becoming the market leader is 
attractive, because if everyone else is buying a product, then customers will believe 
that it is good (Ries & Trout, 2003; Trout & Rivkin, 2000). Ries and Trout (2003), 
also suggest examining competitors and then eliminating message barriers. Using a 
purified and simplified message results has a greater chance of communicating 
successfully. A strong position can also be achieved by being first. Keller (1999) 
describes brand positioning as the creation of an optimal location in the minds of 
customers so that the brand is perceived in the desired way. The way that a brand 
differentiates itself depends on the choice of target market and relevant competitors. 
Core brand associations are consumer-derived and reflect the brand position. These 
associations consist of tangible or intangible attributes, benefits, experiences, or 
images that can be stored in memory. Core brand associations often capture the 
meaning of the brand position indirectly. Riezebos (2003) argues that brand 
positioning takes place along two dimensions: the relative price and the intrinsic 
dimension. 
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Although only the intrinsic dimension positioning is usually discussed (e.g., Ries and 
Trout, 2003), price is also a strong determinant. Three strategies exist for positioning 
along the price dimension: low-cost, premium, and prestige. When a low-cost strategy 
is used, the brand will add little value to the product and usually functions only as a 
sign of recognition. Riezebos argues that companies should try to tune the intrinsic 
attributes to more exclusive brands. By proposing this, Riezebos goes against what is 
often said in the positioning literature, that a brand should be distinguishable from 
other brands. For premium and prestige strategies, there are many possibilities to 
make the brand meaningful to consumers. These brands should definitely have their 
advantage based on material and/or immaterial aspects. When positioning on the 
intrinsic attributes, the brand either has a functional approach, in which the attributes 
remain central, or an emotional approach, in which the experience world around the 
brand is most important. The communication objectives that the brand positioning 
tries to obtain should be measurable. 
3.3 The Pharma brand 
As discussed in chapter 2, Pharma marketing in general have been studied in many 
literatures although more focused internationally (eg, Smith, MC., 1991; Angel M. 
2000; Blackett, T and Robins, R., 2001; Smith M C et al., 2002; Moss , G., 2001; 
Chaganti, SR, 2005; Biradar, S S, et al., 2006; Seget, S., 2006); Bhadoria, V, et al., 
2010). 
Pharmaceutical branding is an important way to create awareness among potential 
benefits of drugs and medicines. Brand building during the period a new drug remains 
under patent can help prolong the commercial life of a product. However, the patent 
protection today is most relevant in the International perspective and not so much in 
Indian context since there are no or very limited patent. What it implies is that in India 
we can have as many generics for a certain molecule making probably difficult for 
branding to play a role in the cluttered market. Literature review therefore looks at 
pharmaceutical brand both from an International and Indian perspective to understand 
what research has been conducted till date. 
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In the world of consumer goods and services, companies have used branding 
techniques to achieve competitive advantage for many decades. In fast moving 
consumer good (FMCG) brands are viewed as the key assets of the company, and all 
resources are utilized to create and develop brands. While core principles and 
strategies for branding a medical product is the same as for any product, there are 
differences in pharmaceutical industry. Due to differences in regulations of marketing 
and selling drugs, many of the strategies used to market consumer products are 
unacceptable practices in healthcare. 
To better understand the challenges associated with pharmaceutical branding, their 
special characteristics will be examined more closely. Successful pharmaceutical 
companies are rich in intellectual property. Historically this property has taken the 
form of patents. Now brand can add layers of sustainable value to these hard-won 
assets, and the skill in prolonging a good product's life lies in managing the branding 
process. This author believes will be the future of value creation in the pharmaceutical 
industry (Blackett, T. and Robins, R., 2001). 
3.3.1 Difference between consumer and Pharma brand building 
Most of the literatures whenever discuss about branding as a concept, 95% of the time 
examples will arise from FMCG, white good or automobile industry. Very less is 
mentioned about Pharmaceutical selling. The challenge is that in Pharmaceutical 
industry branding is usually not seen in full potential and almost nil spent is spent on 
Direct to Consumer (DTC) advertising which is major spent of FMCG companies. 
The reason being, Pharma industry is a complete science based industry and involves 
prescriptions from most respected customer "The doctors". Being a prescription drug, 
the regulatory authorities do not allow direct to patient initiative. 
A key difference between pharmaceuticals and FMCG is the relatively limited lifetime 
of pharmaceutical brands. They enjoy only 20 years of exclusivity as a maximum, and 
in general will go off-patent after an average of seven years from when they enter the 
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market. Some authors consider, therefore, that in view of this short life cycle, it is not 
worth investing in building brand equity. 
This is different to the FMCG sector where brands can live forever Procter & Gamble 
management, for instance, does not believe in the product life cycle concept. Within 
the consumer area, if brands are well managed, they should last forever. The authors 
do not believe that this important difference should prevent pharmaceutical firms from 
building brands. The authors consider that brand names should be more strongly 
linked than today to the corporate name. 
The latter can be used as a full name or as an umbrella name linked to the product 
brand name. This would he in line with the current trend in FMCG where companies 
try to link their products' brand names to their strong corporate name and image. 
Another important difference for pharmaceuticals, in contrast to FMCG, has been the 
often-highlighted additional layer that exists between the pharmaceutical manufacturer  
and the patients (consumers). 
Doctors and pharmacists inevitably make branding strategies much more complicated. 
The authors do not believe that this represents an insurmountable problem, however, 
as, contrary to what certain authors highlight; doctors can be convinced by arguments 
other than the purely logical. Doctors are also influenced by other factors such as trust 
or the quality image of the manufacturer. In addition they need to be reassured, and, 
as with many consumer purchases, they operate on a basis of limited information. 
they also make decisions for emotional reasons, not only rational ones (Chandler, J. 
and Owen, M., 2002). 
Consumer brands appear to have a different longevity to the brands that exist within 
the pharmaceutical world Fast moving consumer good (FMCG) brands can last 
decades and even centuries while pharmaceutical brands are thought to last only a 
very short period of time (Moss, G, 2007). When looking at a typical consumer 
product category, for example, cereals, soap or toothpaste, it can be seen that within 
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the US marketplace, the leading brands in 1925 still led the category 60 years later 
(Kellogg, Ivory and Colgate). 
Figure 3.3 Differences in attitude to brand building 
- 	. FMCG 
	
Aharmarpnti 
A brand creation Focus 	 A product creation focus 
• Time horizon long 	 • Time horizon short (years) 
• Lifecycle does'nt need to exist 	• Lifecycle management necessary 
• Huge marketing effort to create the • Huge R&D effort to create the 
brand 	 product 
• Investment maintains the brand over I • Patent expiry signals loss of resources 
time 	 I • Product cast out to provide revenue 
• Brand destruction does not exist, 	for new products 
portfolio rationalization does 
THE BRAND IS THE ASSET 
Strategy and brand management vital 
THE PRODUCT IS THE ASSET 
R&D and sales management vital 
Source: Giles D Moss, Pharmaceuticals — Where 's the brand Logic? 
Similarly when assessing the longevity of the most known brands in America, over 25 
per cent are older than 50 years, another 25 per cent have been around for more than 
75 and a further 10 per cent are over 100 years of age Consumer brands therefore not 
only last a very long time but continue to compete within their given category if 
enough attention is given to them. In relative terms, consumer brands also have short 
research and development (R & D) cycles, as well as short pre-marketing cycles, 
which can then be followed by decades of profitable brand building. The traditional 
product brand lifecycle does not need to exist as the brand is treated as the asset and 
strategy and brand management are seen as vital to ensure the brand creation focus 
permeates the whole organisation (Moss, G. 2007). 
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In contrast, within the pharmaceutical world of brands the R & D cycle is long, risky 
and extremely expensive. Product and patent creation can take at least a decade and 
this is then followed by a one or two year pre-marketing window before the product 
brand is launched, What traditionally then follows is massive investment in sales force 
coverage and frequency of target physicians and approximately 10-15 years of sales. 
As patent expiry approaches, some attempts to manage the lifecycle of the product 
brand occur through galenical development but as soon as the expiry date is reached, 
the product is cast out and treated as a cash cow for the next molecule coming through 
the pipeline (Moss, G. 2007). 
Brand destruction occurs when corporate resources are withdrawn internationally even 
though, perhaps, patent expiry only affects the US in the immediate near future. In 
essence, the product is the asset (rather than the brand) and R & D and sales 
management are the vital ingredients to success rather than brand expertise. What is 
little known, however, is that some pharmaceutical brands do have staying power, for 
example, Premarin from Wyeth was launched in 1942 and did not reach peak sales 
until 2001, a full 59 years later while both Augmentin and Sandimmun reached their 
peak sales more than 20 years post launch. 
Fieure 3.4: Business to business (B2B) brand model 
Medicine decision 
Making is complex 
And has multiple 
[ 	stakeholders 
Nigh 
Level of 
complexity 
of product 
or service 
Low Nigh 
Commercial risk 
Source: Adapted from Ellwood, in tune adapted from de Chematony and Macdonald) 
User Full decision- 
specialist making unR 
dominated 
Purchasing Purchasing 
manager and financial 
dominated management 
dominated 
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These three classical categories for brand management, FMCG, service, and B2B 
don't easily fit in with current thinking in pharmaceutical branding, and this in itself is 
the source of much industry confusion. Pharmaceutical marketers have to skilfully 
integrate different parts of the classical categories to achieve their results Direct-to-
Consumer advertising (DTCa) and Internet communication are close to FMCG 
practice, but are much more regulated. Many pharmaceutical activities are service 
based (such as provision of clinical outcomes data and disease management advice), 
whereas the traditional customer of the industry (the physician) works on a branding 
model closer to B2B than anything else. The prescribing decision is highly complex, 
the product is used by a third party, and there are many other influencers on the 
decision making process nowadays, from formularies, insurance institutions, or 
reimbursement decisions to key opinion leader advice. As a result of this complexity 
and the need to demonstrate efficacy, safety, and tolerability to achieve marketing 
authorizations, we have fallen into the product attribute trap of Marketing. Figure 3.3 
illustrates some of the complexity seen in the prescribing decision in the twenty-first 
century. 
Figure 3.5: The pharmaceutical buying process 
• Sales calls 
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• KOL brands 
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3.3.2 Branding in Pharmaceutical Industry 
A plethora of academic literature exists surrounding the topic of branding, brand 
loyalty and equity development, but there is paucity of specific research engaging 
pharmaceutical brands with traditional branding academia. Most of this research has 
been focused on the International perspective and very little for Indian Pharmaceutical 
industry Branding and brand equity have long been topics of interest to marketers and 
researchers. 
3.3.2.1 International perspective 
Current research is done in the area of Pharmaceutical marketing as a whole, which 
focus on all aspects of marketing 
in comparison to consumer brands, it is argued that pharmaceutical brands were 
relatively young as 64 per cent of the best known consumer brands in the US are more 
than 50 years old Aakcr (1991). 
The pharmaceutical industry has traditionally focused on marketing products than  
medicines according to Giles Moss (2001). Moss reviewed the drugs industry in 
considerable detail, and his findings strongly support the existence of `brands' despite 
the lack of research into pharmaceutical brand management. 
Pharmaceutical brand development- is it really necessary? Moss G (2001) studies and 
states that there is without doubt a complicated interaction between the different 
aspects that make up pharmaceutical promotion, sales-force interaction and brands, 
and this will only increase as DTC advertising develops. Experience from other 
industries has taught us that a simple focus on product attributes does not maximize 
either the product sales potential or its associated value as far as shareholder value is 
concerned. Product differentiation is quickly challenged now days but brand loyalty 
can be created through factors that are snore difficult to challenge. 
The drug industry has so far been successful with classical marketing techniques and 
an R&D focus, allowing it to alleviate the issues caused by lack of longevity and 
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therefore profit protection of products. Three distinct branding levels, corporate, 
therapy area and product brands are recognizable but, in general, they are not well 
understood Moss G (2001). 
Lessons have been learned at a rudimentary level but little research has been 
conducted into pharmaceutical brand management, and it may be inherently risky not 
to manage brands actively in the future. 
Traditionally when a pharmaceutical product is launched the product positioning is 
based on the product license i.e. its indications and the established efficacy, safety and 
tolerability seen in registration clinical studies. Post launch studies then tend to lead to 
a broadening of the indications, the development of new dosage forms and the 
strengthening of claims versus the competition (Moss 2001). 
Blackest (2001) reinforces that careful brand management will play an increasingly 
important role in the future of value creation in the pharmaceutical industry — much as 
it does in the majority of industries where the supply of goods and services is 
unrestricted and consumer choice is paramount. 
Chandler and Owen (2002) looked at the rapidly advancing recognition of the 
importance of brands within the international pharmaceutical arena. In essence authors 
recognized the fact that the challenges faced by brand development in the 
pharmaceutical arena are not fundamentally different from those found elsewhere, but 
the imperative for new brands with an international resonance is particularly strong 
here. 
Smith et al (2002) provided a comprehensive and well organized description of the 
marketing in the pharmaceutical industry. It focused on the traditional four Ps of 
marketing: product, price, place, and promotion. The book did not mention much 
building a pharmaceutical brand. 
In the recent past, some pharmaceutical firms have been investigating how to develop 
brands but there is still much confusion in the way brands are defined, thought about 
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and managed. At its simplest some prescription drug marketers believe that giving a 
name to a certain product will make it a brand. Others believe that adding a bit of 
symbolism to a product will be sufficient to create a brand (Chandler and Owen 
2002). 
Morton FMS (2002) studied at horizontal integration between brand and generic firms 
in the International pharmaceutical industry. The evidence showed that integrated 
corporations- those producing both innovative branded products and low cost 
generics-are relatively rare. In addition, these corporations do not appear to be using 
the brand to help generic enter the market more efficiently, more frequently or earlier. 
Pharmaceutical products usually fit into one of the following categories: 
1. Proprietary drugs (over-the-counter): lots of advertising, little research 
Example: Preparation H 
2. Generic drugs: lots of price competition Example: aspirin 
3. Patented drugs: distributed by prescription Example: CRESTOR, Lipitor (got 
off patent on 30 Nov 201 1) 
It was the third group that most interested larger drug companies. The profits from 
group three far exceeded those of groups one and two (Russakoff A and Gould J, 
2005) The marketing and branding clearly differs in above groups. 
It is evident that the competitive environment is becoming more intense in the 
pharmaceutical industry. As a result Schuiling and Moss (2004) consider that branding 
can represent a new competitive advantage, and that pharmaceutical companies must 
embrace marketing and branding strategies to a greater extent than ever before. 
Hollis (2005) examines the price effects of generic drugs that are produced by brand-
name drug firms and that are labeled, priced, and marketed to compete against 
independent generics. The strategy of introducing such "pseudo-generics" — also 
known as "authorized generics" — has raised some antitrust concerns. One defense of 
this strategy has been that the additional competition created by pseudo-generics 
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should lead to lower prices. Author developed a simple model to show that pseudo-
generics can be expected to have exactly the opposite effect and then examined 
empirical evidence on this point from the Canadian pharmaceutical market, showing 
that there appears to be a positive relationship between drug prices and the share of 
generic sales made by the brand's own pseudo-generic. 
Naigamwalla, D. (2005) believes in keeping the brand alive. By identifying and 
evaluating new indications for marketed drugs, product managers have an opportunity 
to lengthen the brand's most productive years and holds of its inevitable decline. 
Author proposes one of the key methods for extending the life of a brand-and helping 
it realize it maximum revenue potential-is a systemic approach to identifying and 
evaluating new indications. Nearly every brand team should explore such growth 
opportunities and exploit them as aggressively as possible. 
Does brand differentiate pharmaceuticals? Pharmaceutical brand is likely to develop 
differently than the same of consumer goods products-it seems to be built 
predominantly on long-term positive experience. Marketing role in this process should 
lie in finding relevant product position and building brand identity complaint with real 
product capabilities (Bednarik, J. 2005). 
Kellogg on Branding (2006), impress upon the fact that brands can be company's 
most valuable asset, creating lasting customer loyalty and preferences strong enough 
to overcome intense competition and price differences. However, nothing as such is 
discussed on Pharmaceutical industry. 
Ladha, Z. (2007) establishes the fact that branding can help protect the brand against 
generics by building brand loyalty prior to patent expiry and influencing the behavior 
and attitudes of patients and doctors. The branding strategies of FMCG are not 
sufficient for success and survival in the Pharma industry. Therefore, unique strategies 
need to be implemented regarding promotion, packaging, naming drugs, advertising, 
through use of slogans, logos and other tools and finally, corporate branding. 
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Kapfcrer (2007), discuss and provides a thorough understanding of the new rules of 
brand management and how to put them into practice. In this book there is a mention 
of pharmaceutical industry but nothing concrete is focused on branding itself. 
Reiffen & Ward (2007) impresses an the branded generics as a strategy to limit 
cannibalization of pharmaceutical markets. By introducing a generic version of its 
patented product, a branded firm can influence the equilibrium in the generic segment 
of the market for the product. This in turn can increase the firm's profits from selling 
the branded version. 
We need to build brands within our brand. While prescribing behavior is complex, it's 
a good thing that healthcare professionals have unique reasons for selecting the  
appropriate product for each individual patient Otherwise, there would not be the need 
of pharmaceutical marketing (Rehal, D. 2007).  
Many researchers are confident that in order to return to significant growth, branding 
could represent a new competitive edge that the industry should leverage. It will 
enable firms to differentiate their products from those of their competitors using both 
tangible and intangible benefits. Branding can also help to protect the brand against 
generics by building brand loyalty prior to patent expiry and influencing the behaviour 
and attitudes of patients and doctors. The relatively limited lifetime of pharmaceutical 
brands should be compensated for by linking brand names more strongly to corporate  
names (Ladha, Z. 2007). The author here did a good focus on branding. 
Griffiths (2007), did research in UK market and found Brand Loyalty as a reason for 
prescribing more expensive branded medicines over cheaper generics alternatives. 
Robins (2007), focuses on the fact that pharmaceutical industry brings great scientific 
advances to the public. But once these products are approved, are we really taking an 
advantage of their potential as great brands'?. The battle for brand differentiation may 
be hard fought, but it will be won on the most fundamental of brand principles-clarity 
of propositions and consistency of communicating that propositions Phamra brands 
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are about building relationships — meaningful and enduring relationships- that will 
position the brand not just for launch but for life. 
Angelmar et al., (2007)., goes a little beyond then just product branding but also -' 
condition branding. That Pharmaceutical can be branded like any other product or 
service is well understood by pharmaceutical marketers. But authors argue that 
effective product branding is not the only reason for the success of megabrands as 
Pfizer's Liptor, AstraZeneca's Nexium or GSK's Advair. Their success is also based 
on the widespread awareness and appreciation of the conditions — high cholesterol, 
acid reflux, and asthma respectively- which these product addresses. 
People have always been concerned about the quality of the products they use-
especially those products that are consumed or used for medicine purposes. The 
quality of drug is an essential element of drug safety and efficacy. With a statuary 
mission to provide safe and effective medications to public US Food and Drug 
Administration has always focused on drug quality (Shah and Khan, 2007). 
Perceived Quality will directly influence purchase decisions and brand loyalty, 
especially when a buyer is not motivated or able to conduct a detailed analysis. It can 
also support a premium price which, in turn, can create gross margin that can be 
reinvested in brand equity (Aaker 1991).  
Moss C (2008), clarifies that strategic brand management within pharmaceutical 
industry could utilize much of the consumer brand theory to strengthen core skills and 
extend the longevity of pharmaceutical brands beyond their current perceived 
boundaries. 
3.3.2.2 Indian perspective 
There has been very little research done on Indian Pharmaceutical marketing when 
gone through literature. This is in view of plethora of data in an International 
perspective. 
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Chaganti (2005) did a pioneering job dedicated to the cause of scientific marketing in 
the India Pharmaceutical industry. He wrote the first ever book that deals with all key 
issues pertaining to marketing pharmaceutical in the Indian context. The book covers 
the traditional marketing elements of 4 P's and adds prescription, policy and 
publication relations in context to Pharma. Most of the focus has been on Marketing 
as a whole rather than brand building in particular. 
Chataway et al (2007), studied frameworks for Pharmaceutical innovation in 
developing countries with focus on Indian Pharma. Authors argue that there is an 
opportunity for developing country public policy around improved healthcare systems 
to integrate with local industrial policy to build bio-medical and health innovation 
capabilities. Indian firms seem to be growing rapidly and the bigger ones are 
responding to TRIPs by building innovative capabilities. Not much in this study was 
focused on branding building even after the advent of patent era. 
Gilles Valentin and Emmanuelle Berthemet (2007), discussed how Indian 
pharmaceutical sector is reinventing itself. Most of the discussion is towards 
operational excellence and none has been discussed on marketing and branding. The 
reason being, that the industry has been developing and flourishing based on the 
production of pharmaceutical copies and rather focusing on real marketing and 
branding. Although now with the most recent and decisive factor change of enactment 
in 2005 of patent acts can change the situation a little bit. 
Kumar V and Singh N (2008), studied Internationalization and Performance of Indian 
Pharmaceutical firms. The study sheds new light on the relationship between 
internationalization and firm performance of emerging-market multinationals. 
Evidence suggests that the current focus of pharmaceutical innovation in India is more 
`catch-up' than it is leadership towards a new trajectory Indian pharmaceutical 
companies have, however, shown some interesting and important initiatives. 
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Chaturvedi et al (2007), emphasize clearly the catch-up' element of Indian 
pharmaceutical firms. They also emphasize the relatively weak R&D spend of the top 
firms until very recently, indeed—from around 2-3% of sales in 1999-2000 to around 
7-8% in 2004-2005. Strategies have included attacking global markets from their 
relatively secure local market shares. Ranbaxy pioneered international entry into - 
commodity generics markets, a pattern that has been followed by others Chaturvedi et 
al, chart the attempts of firms to `move up the drug discovery chain and participate in 
new drug discovery research'. 
Bhangale, V (2007), discussed Pharma Marketing in India- opportunities; challenge 
and way forward. Author talks about key challenges as the industry is still plagued by 
some very serious strategic and operational-level issues. Some of the most prominent 
performance-related issues are listed below:  
• Increased competition and shortened window of opportunity 
• Low level of customer knowledge (Doctors, Retailers, Wholesalers) 
• Busy physicians giving less time for sales calls 
• Very high attrition rate of the sales personnel 
• Very high territory development costs 	 H. 
• High training and re-training costs of sales personnel 
• The number and the quality of medical representatives 
• Poor customer acquisition, development and retention strategies  
• Unclear value of prescription from each doctor in the list of each sales person 
• Unknown value of revenue from each retailer in the territory 
• Absence of analysis on the amount of time invested on profitable and not-so-
profitable 
 
customers and lack of time-share planning towards developing a 
customer base for future markets 
• Manual and cumbersome administrative systems and processes designed that 
do not facilitate optimal efficiency levels in sales teams  
Above all, the pharma industry also faces challenges with respect to ethical marketing 
and promotional practices. 
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Kale and Little (2007) analyze the 1970s onwards imitation to innovation' model of 
Indian firms, beginning by copying and innovating around patents, then more creative 
imitation, to the recent tentative beginnings with innovative R&D Kale and Little see 
the TRIPs agreement sign-up as a positive trigger to force innovative behaviour 
among leading Indian fins. 
Bower and Sulej (2006) go on to show how Indian company successes do not fit the 
patterns of Western pharmaceutical evolution. They show that the triggers for big 
pharmaceutical firms (intellectual property protection, venture capital, health 
reimbursement schemes, etc) do not explain Indian success. They suggest a different 
strategic trajectory: first, make generics to sell in India; second, obtain approval for 
and market generics in the USA and Europe; and then develop in-house capability in 
discovery—inventing and developing new patented drugs. 
The International studies have been focusing on innovation or globalization but not on 
Indian pharmaceutical marketing or branding in the generic, me-too situation.  
M G Parameswaran (2006) focuses on Building brand value based on five intrinsic 
steps for developing a new brand and for making an existing brand stronger and more 
valuable. Besides this authors here provides insights on positioning options, BRAND 
audit, and more, that can be of use to marketing. 
In a special report Special Report from the 60th Indian Pharmaceutical Congress 2008 
highlighted that quality of medicines played a major role in the healthcare of patients, 
so for quality drugs better regulations for development of safe drugs are need of hour. 
Today the quality is definitely associated with MNCs and also to some of the top most 
India companies Brand in this case is assumed to play a certain role. 
When discussed with key industry experts, it was found that. There is not much 
prescribed format on branding in Indian companies. Where it is actually followed is 
the MNCs marketing the products either at an expensive price than generics or with 
different brand name at India pricing. Some MNCs have really done and taken ahead 
the benefit of branding and effective brand communications based on global model 
and have been successful. 
An extensive reports survey was also done to see whether independent Research 
Agency has done some work on the above subjects. It was found that research 
companies like `Business Monitor International", ORG IMS have done an 
independent analysis of the Pharmaceutical industry. 
Usually these reports have focused on how pharmaceutical industry wilt look like few 
years from now. 
One of the major healthcare reports provider `Baines insights limited have discussed 
on Lifecycie management strategies of the pharmaceutical brands. The report comes 
from Global perspective and focus on lifecycle management post patent expiry and 
entry of generics. 
Leading lifecycle management strategies include indication expansion, reformulation, 
second-generation launch, Rx-to-OTC switch, generic launch and divestiture. Other 
ways branded manufacturers can maximize sales include effective branding 
campaigns to foster loyalty, which is particularly true in the US where manufacturers 
may advertise directly to consumers, and strategic pricing which can be implemented 
to raise, maintain or cut drug prices upon patent expiration. 
The usage of generics can vary considerably across different countries, depending 
upon the size of the market, degree of free market pricing and structure of the health 
care system. Usage of generics is strong and rising in the US, where both public and 
private health care plans continue to focus on cost containment. In the UK, high-
selling drugs that are available in multiple formulations attract a higher number of 
generic competitors than other products. Intense competition for larger brands in 
Germany drives generics out of the market. Although usage of generics has been low 
in Italy, implementation of a new reference price system in 2003 basing reference 
prices on the cost of the lowest priced generic is likely to stimulate usage. 
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This gives some idea how a brand's tifecycle can be extended in context to global 
market, which could then be reference point for Indian Pharmaceutical set up. 
33.2.3 The research Gal 
After completing the survey of literature, it was clearly evident that there is need to 
study the branding and brand communication in India context. Indian market is 
completely different where the competition is within the same molecule; unlike in 
global context the competition is between molecules vs. molecule. Also in western  
context there is only brand where the (ask of branding is comparatively easier. 
Indian market will for some time see many brands coming up especially in lifestyle 
disease which is catching up fast like cardiovascular and diabetes. Maximum 
competition will be seen in these chronic therapy areas where the opportunity for the 
companies is that the prescription written by the once is usually followed for the 
whole lifetime. Unlike infection, antibiotics have a limited course. 
The scope of branding opportunities although lies in every therapeutic segment but it 
is most challenging in chronic therapy like cardiovascular and diabetes. 
Current data show insufficiency in understanding the in-depth process of branding and 
model being used to make brands successful. It is good opportunity with this study to 
understand the current situation of branding and brand communication process in 
specific to Indian Pharmaceutical market and propose models which has been used to 
make brand successful and recommend models till India sec patent protected market 
and Exclusive Marketing rights.  
} 
54 
90 	I  
3.3.3 Importance of communication in pharmaceutical marketing 
The nature of competition and its intensity in the India pharmaceutical industry have 
made personal selling the crucial determinant factor for success that it is today. In a 
market where both products and strategies are "me-too", rather me-me-too" in nature, 
the battle is more between talents of different selling teams. A well trained, highly 
motivated sales force plays a decisive role in winning marketing wars A Pharma 
company's medical representative is its most important source of communication to 
its prospective customers (Chaganti, SR, 2005). 
Done well, detailing is generally accepted to be the most effective form of 
pharmaceutical promotion. Comparison and contrasts between this form of promotion 
and print advertising are shown in table below (Smith, MC, Kolasa EM, Perkins, G, 
and Siecker, B, 2004). 
Table 3.1: Advertising and detailing: similarities and contrasts 
Characteristics Advertising differences Similarities Detailing differences 
Functional One-way 	communication. Both 	must 	be Two-way communication. Some 
Abundant 	noise 	in 	the understandable, 	interesting, control 	over 	"noise". 	Can 	be 
communication 	channels, believable, persuasive tailored to the situation. Difficult 
Relatively 	inflexible. 	Good to maintain company control of 
control 	over 	the 	message. the 	message. 	Physician 	may 
Almost 	impossible 	for refuse to see. 
physician 	to 	avoid 	some 
exposure to the message 
Perceptual Difficult 	to 	reinforce 	the Both must penetrate sensory May stimulate all five senses as 
message during the course of mechanisms 	of 	the well 	as 	vary 	them 	selectively. 
presentation physician, 	with 	careful May reinforce and repeat in a 
selection 	of 	stimuli 
necessary' 
single cell. 
Cognitive Works primarily by suggestion. Both attempt to present firm May 	carry 	physician 	through 
Primarily 	an 	interest-arousing and product as different and reasoning 	process. 	May 	be 
technique better than competition problem solving technique. 
Feeling state Single 	message 	may 	elicit Both 	attempts 	to 	induce May evaluate and take advantage 
varying feelings. No possibility favorable feelings of either favorable or unfavorable 
to adapt. feelings. 
Transactional Primarily pretransactional, with Both important as reminders May also effect a prescription s a 
posttransactional 	activity continue to use. direct results sales call. Possible 
primarily limited to dissonance to supply sample for patient in 
reduction, the office at the time. 
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Changati (2005) reinforces that Personal selling is the crucial determinant factor for 
the success in pharmaceutical marketing. The major reason for this is that 
pharmaceutical marketing is highly a specialized form of direct marketing which does 
not lend itself to mass advertising. It markets products and services to intermediary 
customers like physicians who advice and recommend products to the end-users 
(patients) through their prescriptions. The ever-intensifying competition and the 
unending proliferation of brands place a premium on the personal selling of 
pharmaceutical marketing. The competition is between the talent of one company and 
another Personal selling is indeed a crucial determinant factor of success. 
Overall, Credibility and communication came out as a very important attribute for 
building brand equity and was need to be studied here. By doing this we have been 
able to get the attributes to 4 most important ones and also the questionnaire much 
more effective for getting a good data for the study. 
3.2.4 Chapter Summary 
Literature survey has indicated lack of relevant studies regarding marketing, role of 
branding and communication in the Indian pharmaceutical industry, in specific. Hence 
there is a need to understand the relevance of the findings of the literature review for 
the Indian Pharma branding. In order to address the conceptual framework has been 
built in next to build the research study. 
Chapter 4 
Theoretical Framework and hypothesis development 
4.1 Introduction 
After a thorough review of the literature pertaining to this research in the previous 
chapter, the following paragraphs shall focus on four major concepts of branding. 
Further, this chapter proposes to develop a conceptual framework of the research and 
develop hypothesis. 
4.2 Conceptual Framework 
According to Miles and Huberman (1994), the conceptual framework explains the 
main concepts that are being studied and shows how key variables relate to each other. 
They also claim that research questions may be stated before or after the conceptual 
framework. For this study, discussing the research problem and research questions has 
provided the foundation for the conceptual framework.  
In general, it seems that most of the researches have shown that there is some role of 
branding in Pharmaceutical industry mostly in the International context. It is 
considered as an important way to create awareness among potential benefits of drugs 
and medicines. The global pharmaceutical industry is experiencing a profound change. 
As a result, pharmaceutical companies must embrace marketing and branding 
strategies to a greater extent than they have in the past (Blackett, T, 2005). It also 
comes through in review that role of branding will also be needed to evaluate from an 
Indian perspective. 
The research will try to understand the role of branding and communication in Indian 
Pharmaceutical industry. Branding strategies is very important because it is clear 
branding strategy alone, that a marketer can communicate the "extra plus" of his 
product identification. Thus branding is mainly a means of product identification, 
helping the consumer to know the differentiated augmented product from "me-too" 
maze of innumerable products. 
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There are a number of reasons why role of pharmaceutical branding have become 
more important; first to create more value from your molecule above and beyond the 
obvious benefit, Secondly to create an entity that is differentiable from competitors 
and creates a sustainable entity to leverage the value of the brand. 
It is communication that makes a brand and gives it a distinct personality. Until the 
communication about the product is transmitted and received, accepted and found 
rewarding, it will not be a brand. A product thus provides specific benefits (leading to 
rewarding experience) to a large enough number of users, to he perceived satisfying. 
Only then it can become a brand. The consumer does not care about pharmaceutical 
`brands'. They care about the benefits and what 'brand' means to them; How would it 
help me? How would it ease the horrific pain that my grandmother suffers from 
rheumatoid arthritis? How would it make my cancer treatments more bearable?. 
Pharmaceutical companies need to clearly define the value that their brands have in 
the marketplace above-and-beyond that of the competition. Only by clearly defining 
and managing that value can they begin to build and leverage brand equity moving 
forward. 
Building successful pharmaceutical brands requires an understanding that 
pharmaceutical markets are different to other consumer markets that branding efforts 
should be global, that brand teams must be inclusive and that brand names are 
important for building brand equity. 
The effective communication of pharmaceutical brands requires an understanding that 
patients require a personal touch, which the media reflects the public perception and 
that word of mouth communications must be tracked and managed. 
As we know the cost of R&D rising and the success rate static at best, the need to 
exploit fully those new products that come to market has never been so crucial. A way 
in which such successes can be enhanced is branding. 
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A powerful branding provides the platform to build a strong relationship with 
customers. 
A powerful branding provides significant competitive differentiation of type that is 
extremely difficult for rivals to copy. A powerful branding can influence behaviors 
and attitudes. A powerful branding which attracts customer loyalty can provide 
greatest sources of wealth for business. 
4.3 Concepts used to develop frames in Pharma context for this study 
4.3.1 Brand and product 
A product can be said to be a bundle of benefits, and a need satisfying entity. A person 
who buys some "aspirin", is not buying aspirin, as such, he is buying "relief' from 
headache (a benefit). Similarly when a doctor prescribes a recent antibiotic like 
eiptofloxacin, he is not prescribing because it is the latest antibiotic. He is prescribing 
it because of its superior anti-bacterial power and its ability to control the infection, 
better and faster (Chaganti, S.R., 2005). 
4.3.2 Branded or Generic product 
While a generic product is an undifferentiated product, a brand is the differentiated 
product. For example °ranitidine", the anti-ulcer drug is a generic product, but when 
you call it "Zantac", a totally different image is conjured up before us: the image of 
the world's largest selling prescription drug; a very effective anti-ulcer drug "Zantae" 
is the brand. The next question is, the difference between a product and the brand — is 
it only in the name? No, there is more. The brand name gives a distinct identity to the 
product. But this mere christening of the product does not give or create brand image. 
Creating and building up a brand image is a more complex, painstaking process. This 
is known as "branding a product". A brand is not a mere name that you give a 
generic product and put on the label for the purpose of differentiating it physically 
from other similar products.  
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4.3.3 Generic brand or branded generic 
The terms generic brand or branded generic look seemingly contradictory. The 
branded generic in the pharmaceutical industry in India are identified by the company 
name (Chaganti. S.R., 2005). Due to intense competition in the Indian Pharma 
industry company's brand name becomes a big differentiator. A majority of the 
dispensing doctors prefer giving (dispense) drugs that the patient cannot identify. 
However, they use "reputed brands" when it comes to prescription. Some companies 
are reorganizing themselves structurally to manage branded generics. 
The first step in building the framework was to identify Drs who prescribe a product 
or brand, which in this could be generic or brand name: 
Figure 4.1: Step I Diagram for the framework 
4.3.4 Brand Equity and branding 
Brand Equity is a set of brand assets and liabilities linked to a brand, its name and 
symbol that add to or subtract from the value provided by a product or service to a 
firm and/or to that firm's customers. For assets and liabilities to underlie brand equity 
they must be linked to the name or symbol should change, some or all of the assets or 
60 
liabilities could be affected and even lost, although some might be shifted to new 
name and symbol. The assets and liabilities on which brand equity is based will differ 
from context to context. However, they can be usefully grouped into five categories: 
David Aaker (1991) grouped assets and liabilities on which brand equity is based into 
five categories: 
1. Brand Loyalty 
2. Brand Awareness 
3. Perceived Quality 
4. Brand associations in addition to perceived quality 
5. Other proprietary assets-patents, trademark, channel relationship, etc 
Most of these are being studied in largely FMCG or a consumer level context. When 
we compared this to Indian pharmaceutical industry, we clearly found as per literature 
first three equity parameters relevant even in Indian Pharma. The big difference here 
is that the consumer is not the customer Doctors associate and differentiate the brand 
with respect to rational benefit. 
Branding can help to sustain the brand against generics after patent expiration. A 
strong brand will benefit from a high consumer loyalty (Aaker 1991, Kapferer 2001). 
This confirms that Loyalty is important to be considered in the research. 
Given the fundamental importance of demonstrating that a newly discovered 
substance will work and be safe, it is not surprising that main emphasis of the industry 
has been in promoting functional brand values particularly efficacy, safety, 
convenience and cost-effectiveness (Blackett, T. 2001). 
4.3.4.1 Brand Loyalty 
The brand loyalty of the customer base is often the core of a brand's equity. If 
customers are indifferent to the brand and, in fact, buy with respect to features, price, 
and convenience with little concern to the brand name, there is likely little equity. If, 
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on the other hand, they continue to purchase the brand in face of competitors with 
superior features, price and convenience, substantial value exists in the brand and 
perhaps in the brand and its symbol and slogans (Aaker, D. 1991). 
It is important to understand the level of brand loyalty in the Pharma industry, 
especially in Indian case because there many "Me-too" products challenges. That is 
why was an important attribute to be part of brand equity in terms of relevance. 
4.3.4.2 Brand Awareness 
Brand awareness consists of brand recognition and brand recall performance (Keller, 
K. L., 2008). It is the ability of a potential buyer to recognize or recall that a brand is a 
member of a certain product category. A link between product class and brand is 
involved Brand awareness involves a continuum ranging from an uncertain feeling 
that the brand is recognized, to a belief that it is the only one in the product class 
(Aaker, D. 1991). 
Brand awareness is clearly important in bringing the product in the market and is an 
important attribute to assess brand equity. Higher the awareness, higher is the 
likeliness of being prescribed by a loyal customer. 
In the Indian pharmaceutical industry, product augmentation is must for survival and 
growth of brands. Branding by product augmentation, in the Pharma industry, is 
achieved by differentiation in the manufacturing process, changes in the formulation, 
packaging, communication and by giving an appropriate, suggestive, memorable 
brand name (Chaganti, S. R., 2005). 
Brand awareness therefore was considered as the second important attribute to be part 
of the research. 
4.3.4.3 Perceived quality 
Perceived quality can be defined as customer's perception of the overall quality or 
superiority of the product or service with respect to its intended purpose, relative to 
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......._......... 
Reason to buy 
Brand Extensions 
alternatives. Perceived quality is, first, a perception by customers. It cannot 
necessarily be objectively determined, in part because it is a perception and also 
because judgment about what is important to customers are involved. Perceived 
quality is an intangible, overall feeling about a brand. However, it usually will be 
based on underlying dimensions which include characteristics of the products to 
which the brand is attached such as reliability and performance (Aaker, D. 1991). 
When quality differences exists among competing brands may "pay a price" for 
employing simple choice heuristics such as brand awareness in the interest of 
economizing time and effort. However, building brand awareness is a viable strategy 
for advertising aimed at increasing brand choice probabilities. (Wayne, D. H. and 
Steven P. B., 1990) To understand perceived quality, the identification and 
measurement of the underlying dimensions will be useful. Perceived quality can 
generate a lot of value in several ways as shown the figure below (Aaker, D. 1991). 
Figure 4.2: The value of perceived quality 
..... _....... __ ... 
Perceived 
Quality 
A perceived quality advantage provides the option of charging a premium price. The 
price premium can increase profits, and/or provide resources with which to reinvest in 
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the brand Instead of price premium a customer may be offered a superior value at a 
competitive price. This added value should result in a larger customer base, higher 
brand loyalty, and a more effective and efficient marketing programs. 
In Pharma industry, quality perception is the most important differentiator between 
brands/products. It is especially important to bring this differentiation between 
branded generic and branded products. It is also important to note that perceived 
quality is firstly in mind of the prescribing physician as he would not use the product 
by himself but will give to his patient. The judgment of the drug is made by the 
predictability of action and if there any adverse side effects in comparison to others. 
Bence, this attribute of Aaker was also found relevant and was considered as one of 
the attribute to assess brand equity and become part of this research. 
4.3.4.4 Credibility and communication 
The nature of competition and its intensity in the India pharmaceutical industry have 
made personal selling the crucial determinant factor for success that it is today. In a 
market where both products and strategies are "me-Wo", rather me-me-too" in nature, 
the battle is more between talents of different selling teams. A well trained, highly 
motivated sales force plays a decisive role in winning marketing wars. A Pharma 
company's medical representative is its most important source of communication to 
its prospective customers (Chaganti, S.R., 2005). 
Done well, detailing is generally accepted to be the most effective form of 
pharmaceutical promotion. Comparison and contrasts between this form of promotion 
and print advertising are shown in table below (Smith, MC, Kolasa EM, Perkins, G, 
and Siecker, B, 2004). Overall, Credibility and communication came out as a very 
important attribute for building brand equity and was need to be studied here. By 
doing this we have been able to get the attributes to 4 most important ones and also 
the questionnaire much more effective for getting a good data for the study. 
Figure 4.3 Brand Equity frameworks for Research 
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4.3.4.5 Customer based brand equity 
Keller (1993) presented a conceptual model of brand equity from the perspective of 
the individual customer. Customer based brand equity is defined as the differential 
effects of brand knowledge on consumer response to the marketing of the brand. A 
brand is said to have positive (negative) customer based brand equity when consumers 
react more (less) favorably to an element of the marketing mix for the brand than they 
do to same marketing mix element when it is attributed to a fictitiously named or 
unnamed version of the product or service. Customer based brand equity occurs when 
the consumer is familiar with the brand and holds some favorable, strong, and unique 
brand associations in memory (Keller, K. L, 1993). 
In case of Pharma industry the customer is primarily the Prescribing Doctor and not 
the patient Pharma industry is a knowledge based in industry. The customer and 
selling is knowledge based in this industry. Hence, to understand the concept of brand 
equity we further applied the customer based brand equity. 
Figure 4.4: Step 2 Diagram for the framework 
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4.4 Final Frame of reference 
Researches in Indian Pharmaceutical Industry have been mainly on the overall 
marketing as a whole. Researchers have not much paid attention to the branding or 	-.. 
brand equity as an overall perspective especially comparing branded vs. generics in 
India. A thorough review of literature reveals that no framework testing the effects of 
brand equity on the customer prescribing behavior has been proposed till date. This is 
a novel attempt to arrive at a conceptual framework to test the relationship of brand 
equity in Branded Medicine vs. Branded generics above mentioned concepts. Figure 
below proposes a simple framework which will be tested further in the research. 
The figure 4.5 gives the attributes which were to be tested for each element of brand 
equity from the David Aaker with modification and applying the concept of Keller on 
the customer based to suit this research. 
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Figure 43; Final Frame of reference: Conceptual framework 
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Conceptual framework for understanding role of branding in Pharma industry measured by brand equity 
of MNC and India brands 
4.5 Hypothesis Development 
This discussion leads to the following general hypothesis: 
GENERAL (OVERALL BRAND EQUITY) 
Hlo: Branding in Pharma industry plays no role in building brand equity. 
111: Branding in Pharma industry plays a role in building brand equity. 
112: Brand equity is sarne for both Innovator (MNC) brand & generics brands. 
I12: There is a difference in brand equity for MNC and Generic brand. 
H30: Marketing Communication has no impact on building brand equity. 
H3: Marketing Communication helps in building brand equity. 
SPECIFIC (BRAND EQUITY ELEMENTS) 
114,: There is no difference in brand awareness for MNC & generics brands. 
H4 : There is a difference in brand awareness for MNC and Generics brands. 
H5o: There is no difference in brand loyalty for MNC & generics brands. 
H5 : There is a difference in brand loyalty for MNC Generics brands. 
H69: There is no difference in Perceived quality for MNC & generics brands 
H6 : There is a difference in Perceived quality MNC & generics brands 
SPECIFIC (Geographic & Doctor specialty) 
H7o: There is no difference in brand equity in Metro and Non Metro towns for MNC 
and generic brands. 	 - 	 - 
117: There is a difference in Brand equity in Metro and Non Metro towns for MNC 
and generic brands. 
H80: There is no difference in Brand equity in Metro and Non Metro towns for 
Cardiologists and Physicians. 	 p 	- 
H8: There is a difference in Metro and Non Metro towns for Cardiologists and 
Physicians.  
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4.6 Chapter Summary 
The theoretical framework was discussed in this chapter based on the literature review 
in earlier chapter. The model was made based on the prescription flow and thinking in 
the mind of customer. Doctors usually after seeing any disease condition will diagnose 
and then make up the mind for the class of drug he would like to prescribe. After 
which he will decide on the brand which comes as Top of his mind. The drug will 
either be an MNC drug or generic and the choice of brand will depend on the brand 
equity parameter which has created the most positive impact in his mind. This could 
either because of awareness, loyalty or experiences with the drug, quality measures 
and more importantly the type of credible communication that reaches him. All these 
have become the hypothesis which has been drafted for study. The research 
conceptual framework will test these hypotheses and more specifically understand 
difference between MNC and branded generic drugs which he chooses. 
The hypothesis is broad based to test all aspects of brand building and also is specific 
to equity elements, geography and doctor specialty that prescribes them. Next chapter 
will focus on the research methodology to test these hypotheses. 
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Chapter 5 
Research Methodology 
5.1 Introduction 
The Research is based on a well thought out and scientifically designed research 
model. Using this research model and subsequent designing of suitable instruments for 
data collection including a structured questionnaire, the present study is carried over a 
period of two years involving in-depth interviews with the Doctors based on the 
questionnaire. 
We employed SPSS software data and SEM with AMOS for the analysis. The 
literature review shows that there is a role of branding to certain extent in the western 
context where there is patent and that is that we wanted to test in case of Indian 
Pharmaceutical industry. 
The main focus of the study is to understand the role of branding in the India 
Pharmaceutical Industry comparing the Branded vs. generic products. By integrating 
David Aaker's 4 elements of branding and communication, the relationships between 
MNC vs. Indian generic on brand equity are seen. 
Therefore, of prime importance to the design of the empirical test of the model is the 
reliability and validity of the measurements. Additionally, for the model to have 
theoretical value, it must also have relevance in terms of its practical application. As 
such, the empirical test must have a high degree of "mundane realism" (Liefeld, 
1993). While the empirical test of the model strives for the highest degree of 
reliability and realism, the limits of market research (eg time, budget, respondent 
accessibility) dictate the need for some concessions. 
The various aspects related to the methodology of research for the purpose of the 
present study are discussed in this chapter. Later, research problem has been stated, 
scope of study defined, and data analysis techniques have been highlighted. The 
71 
formulation of research objectives, research design, sample design, methods of data 
collection and accompanying problems are stated. 
5.2 Research Objectives: 
The research will try to illuminate the role of branding in Indian Pharmaceutical 
industry where there are no patents and generic play an important role. 
This research has been conducted with a view to understand the role of branding in the 
Indian Pharmaceutical Industry and see the Interrelationship of brand equity between 
Branded Medicines from MNCs and Generic brands from Indian companies. 
1. To understand the Role of branding in India Pharma industry 
2. To understand the role communication plays in building brand equity 
3. To understand if the drivers of brand equity are same in generic and branded 
categories 
4. To develop a model of pharmaceutical branding in the Indian context for both 
generic and branded categories 
5.3 Research questions: 
The research tries to address the following questions: 
Research Question 1: What is the role of branding in Indian Pharmaceutical 
Industry? 
Research Question 2: What is the difference in Brand Equity its drivers when 
compared between branded & generic categories? 
Research Question 3: What is the impact of communication in Indian Pharmaceutical 
Industry? 
Each question has a 7-8 subset questions on which each respondent had to rate for 
MNC vs. generic brand on a scale of 1-5 
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5.4 Research Design: 
This study is exploratory in nature as this research construct is being employed for the 
first time 
5.5 Research Process: 
The research process (see Figure 4.1) shows the approaches, strategies, and data 
collection methods that are available in research. The choices for this thesis are 
underlined. 
Table: 5.1: Layers of research 
Layers of Research 
Deductive 
Inductive 
Qualitative 
Quantitative 
Case studies 
Experiment 
Survey 
Ethnography 
Action Research 
  . Grounded Theory 
Interviews 
Secondary data 
Observations 
Questionnaires 
sr-:= 	:x~:,fix • ?~ 	<~~4 
5.6 Research Approach: 
This thesis follows the deductive approach. Deduction means that "a clear theoretical 
position is developed prior to the collection of data" (Saunders et al, 2003, p 28). 
Although deduction is usually connected to a positivistic standpoint, it is adopted for this 
study. Existing theory could be used to develop a conceptual framework, which means 
that a deductive approach is possible. It also takes less time to execute than the inductive 
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approach (Saunders et. al., 2003). Through deduction, theory can be generated or tested 
(Bryman, 2002). 
The role of branding and brand equity that is described in this study is mainly understood 
through the interpretation of how respondents perceive elements of branding for an MNC 
vs. Generic brands. To understand individual actions, thoughts, feelings, beliefs, and 
values, face-to-face interaction is needed (Marshall & Rossman, 1999). Even if complete 
objectivity is impossible to achieve in qualitative research, the researcher must prove that 
he or she has acted in good faith (Bryman, 2002). We study role of branding by using the 
qualitative approach and by way of survey questionnaire Marshall and Rossman (1999) 
argue that the qualitative approach is appropriate for research that deeply studies 
processes, a phenomenon where little research has been conducted, research on informal 
and unstructured linkages within an organization, and when relevant variables are yet to 
be identified. These arguments do all apply for this study. 
Furthermore, qualitative research is applicable to this study's exploratory and descriptive 
nature and highlights the importance of context, setting, and participants' frame of 
reference, which are also important factors for this study. 
5.7 Research Strategy 
The research strategy is a plan of how the researcher will go about to answer the research 
questions (Saunders et al, 2003). The strategy chosen for this study is the survey 
approach. 
A number of research strategies are available for conducting brand equity researches: 
Experiments, surveys, histories, case studies, and the analysis of archival information The 
kinds of research strategies adopted in a study should be dependent on three conditions: 
The type of research questions, the control an investigator has over actual behavioural 
events and the focus on contemporary, as opposed to historical, phenomena. Based on the 
research questions proposed from David Aaker Model in this study, the following strategy 
is proposed: 
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I. Thorough review of the literature on branding and brand equity drivers in order to 
comprehend the concepts in a better and an efficient way 
2. To study the above mentioned concepts in Indian Pharmaceutical context contexts 
with the help of data collection forms (Questionnaire) to be filled by respondents, 
which in this case are doctors. The model of David Aaker was tested with 
questions prior to rolling out the final questions. 
3. Establishing the reliability of the instrument. 
4. Employing Descriptive and inferential Data Analysis Techniques to achieve the 
research objectives 
5.8 Research Structure 
After formulating broad strategies research structure is developed to further simplify 
the problem. The first element considered is development of research instrument, as 
this was directly determined by the study objective. Next, measurement procedure is 
established followed by sampling process Subsequently Pre-test and Instrument 
refinement were carried out. The data collection method is reviewed, and lastly, 
statistical methods of analysis are presented. 
Figure 5.1: Research structure  
Research Structure 
Development of Instrument 
Measurement & Scaling Procedure 
U. 
Sampling Process 
U. 
Pre-test 
Instrument Refinement 
Data Collection 
Data Analysis 
Data Screening 
Descriptive Analysis 
Inferential Analysis 
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5.8.1 Development of Instrument 
Construct indicators were selected based upon a thorough review of branding 
literatures both from International & Indian context and elements of brand equity to be 
tested in the study. 
Brand Equity items 
Interest in brands is motivated by looking at the underlying value they create Figure 
5.2 shows how value can be created for the customer and the firm, i.e., the 23 brand 
equity (Aaker, 1996). Businesses seek profits, and the only way to succeed with this is 
through value creation Aaker (1996, pp7-8) defines brand equity as "a set of assets 
(and liabilities) linked to a brand's name and symbol that adds to (or subtracts from) 
the value provided by a product or service to a firm and/or that firm's customers" 
Figure 5.2: How brand equity generates value 
Brand Loyalty 
 
e.g. Reduced Cost, 
Trade Leverage 
Value for the 
Customer 
Brand e.g. Anchor to 
Awareness Other Associations 
BRAND 
EQUITY Jr ____________ 	
Percieved e.g. Differentiates, 
Quality Reason-to-Buy 
Value for the 
Firm 
Brand ...J Associations 
e.g. Creates Positive 
Attitude 
Source: Adapted from Aaker, 1996, p9 
Aaker (1996) divides these assets into four categories. Brand loyalty among customers 
will reduce costs and create trade leverage. Brand awareness is described as the 
strength of a brand's presence in the minds of customers; it is prerequisite for creating 
associations. Brand associations are perhaps the most important asset for brand equity 
and are driven by the brand's identity Individuals can form associations to the brand 
7-goS3 
through product attributes, celebrity spokespersons, symbols, etc. Perceived quality is 
the only association that has been found to drive financial performance 
Keller (2003) views brand equity from the perspective of customer-based brand equity 
(See Figure 5.3). The associative network model describes how the human mind 
creates associations towards brands. Brand knowledge is comprised of brand 
awareness and brand image. Brand awareness is related to the strength of the brand; 
stronger awareness increases the customer's ability to remember the brand. Brand 
recognition means that the consumer recognizes the brand to which they are exposed. 
Brand recall is another form of awareness that refers to the consumer's ability to 
recall the brand from memory when given a relevant cue. Furthermore, brand image 
will be determined by the type, favourability, strength, and uniqueness of brand 
associations, which are described as memory links. 
Figure 5.3: Customer based brand equity 
Source: Adapted from Keller, 2003, p59 
A brand is represented by a node, and the related associations are represented by links 
to other nodes. A strong brand has many positive and emotional links/associations to 
other nodes that strengthen the brand. These associations represent customer-based 
brand equity, which is regarded as positive when the brand knowledge has a 
differential response on purchasing decisions (Keller, 2003). 
This means that a certain brand is preferred over competing brands, when similar 
products are being considered Upshaw (1995) divides brand equity into brand 
valuation and brand identity. Brand valuation concerns factors that impact the 
financial worth of the company 
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Upshaw describes brand identity as external benefits that increase its attraction. He 
uses the analogy of a house to explain the difference between these types of brand 
equity. The total financial worth is the brand equity, part of which is comprises its 
identity, its attractive architecture, interior, condition, and how it is compared to other 
neighbours. If the house becomes shabby, this means that the identity has degraded, 
along with its financial worth. 
Aaker (1997) proposed a five-dimensional measure that is made up of 15 facets and 
42 items (traits). The scale has become widely adopted, and has been used extensively 
as a measurement of brand equity, and by proxy, for brand image. The use of the BPS 
has been featured in articles that have examined numerous marketing issues in a 
variety of contexts. For example, the scale has been used in brand loyalty behavior 
research (Mader et al, 2000; Kim et at, 2001), to examine consumer — brand 
relationships (Hayes et at 2001), in an array of cultural research (eg Ferrandi et al, 
2000; Murase & Bojanic, 2004; Aaker et al, 2001), in the sports domain (eg Musante 
et al, 1999), and in advertising research (eg Farhargmehr & Azevedo, 2000; Ang & 
Lim, 2006). Recent research using the BPS has examined the impact of brand 
extensions on brand personality (Diamantopoulos et al, 2005), and how consumers 
update inferences about brands (Johar et al, 2005). 
However, for the purpose of our study based on the judgmental method we have 
modified the original scale. Keeping in view the product category for the study (i.e. 
Pharma brands) we have taken 29 items (traits) which are further modified to suit the 
pharmaceutical brands. 
Brand Equity scales by David Aaker 
We used David Aaker's Model and used the author's scale to measure the following 
• Brand Awareness 
• Brand Loyalty 
• Perceived quality 
• Credibility and communication 
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Each of the above have 7 items or attributes which need to be rated for MNC and 
generic brands as shown below. We had to modify the elements of Aaker's model to 
suit to the pharmaceutical Industry as below 
Table 5.2: Modification of questions for the study 
BE Elements Questions as per Aaker's Model Modifications for the research 
Brand Awareness I know what X'looks like The brand name is easy to remember and 
recall 
I recognize X among the conmpetinc 'the cotnpary 	gives me high number ol 
brands exposures & adequate visits for the brand 
I Ain aware of X This brand is the reference in class & is 
the choice of thought leaders 	In. 
Perceived Quality X is of hieh quality I am giving best quality product to my 
pa1ientS 
The likely quality of X is very high I am reassured by the predictability of 
action of this drug 
the 	likelihood 	that 	S 	%could 	be I he 	brand 	is 	supported 	by 	wealth 	of 
functional is very high original 	scientific 	data 	to 	back 	its 
superiority 
X must be of very good quality I am giving my patients best treatment 
available for their conditions 
Brand Loyalty I consider myself to be loyal to X I 	consider 	myself loyal 	to 	this brand 
because,. 
X would be my first choice 	- I really identify with Drs who recommend 
this brand 8 is prescribed by Drs iikeme 
I 	ould not buy other brands if X I 	am 	proud 	to 	have 	others 	know 	I 
available prescribe this brand 
Brand Some characteristics of X came to Credibility & communication used in this 
Associations my mind as per modification 
Other BE Not used in the current stud' 
The above questions were then tested by analytical tools and with a pilot survey to 
make it relevant to the study of branding in the pharmaceutical industry. We also had 
to add few more questions to make the questionnaire complete and ensure that the 
most relevant information is captured in the instrument. 
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Brand associations was modified to 'Credibility and Communication" since 
communication in pharmaceutical industry is one of the most important tool for 
branding. Unlike US, where communication is also possible through DTC, India has 
to still rely on representative communication only. This attribute was required to be 
added in the brand equity analysis. We also took away the Other Brand Equity (OBE) 
items as it was more relevant to consumer goods and not too much to pharmaceuticals. 
Overall, the David Aaker model was very helpful in designing the study analysis 
model and capturing the well tested attributes for measuring brand equity. 
Table 5.3: Research study Questionnaire 
I have high awareness & I prescribe/ prefer this brand because 
BAI The company gives me high number of exposures & adequate visits for this brand 
BA2 The brand name is easy to remember and recall 
BA) The brand is widely distributed and is easily available 
BA4 The company has been in business for long time & is trustworthy, reliable c . ethical 
BA5 The company keeps me up to date through well run CME courses 
BA6 The company involves me in new Clinical trials 
BA7 The company have a high level of scientific approach in promotion 
BA8 This brand is the reference in class & is the choice of thought leaders 
I prescribelprefer this brand because I feel 
PQI 
PQ2 
1 am giving best quality product to my patients 
I am giving my patients best treatment available for their conditions 
PQ3 I help reduce risk of my patients from future events & side effects 
PQ4 I am reassured by predictability of action of this drug 
PQ5 The brand is supported with wealth of original scientific data to back its superiority 
PQ6 Is priced which is cost effective for my patient & is worth paying more for 
PQ7 Is priced lower than that of generics 
I consider myself loyal to this brand because 
BL1 I really identify with Drs who recommend this brand & is prescribed by Drs like me 
BL2 I am proud to have others know I prescribe this brand 
BL3 I am comfortable because of my experience with it & faith on it over time 
BL4 1 let others know that I am a forward thinker in this therapy area by 	 rescribin 	it 
BL5 I feel more comfortable than when prescribing a generic products 
BL6 I will be recognized as a good physician 
BL7 I like/admire this brand verymuch & I really like to talk about this brand 
The company representatives who communicate about this brand 
CC 1 Always keep doctors updated on latest information & has superior knowledge 
CC2 Support patient education with useful materials & is able highlight patient benefits 
CC3 Is willing to provide enough samples for doctors to tiy  
CC4 Is honest when promoting products & is not too pushy  
CC5 Has integrity, does not speak ill of competitors' products 
CC6 Has an ability to deliver key information within the time frame & meets frequently  
CC7 Has a pleasant & friendly 	 ersonalit • and is reliable 
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5.8.2 Measurement and Scaling Procedure 
The study instrument is a "structured questionnaire " comprising of brand equity 
elements of David Aaker. All these are scale variable which comprises of 29-items. 
Whereas non-scale variable (demographic section) captured type of specialty of 
Doctors, practice, place of practice, town class, branded vs. generic brands. 
The Scale selected for the measurement was "Non- Comparative Multiple Itemized 
Likert Scale ", in which respondents were asked to rate their degree of agreement with 
carefully selected series of statements/adjectives ranging from strongly agrees to 
strongly disagree. Later, we assign number for the purpose of analysis as in instrument 
none of the item is negatively-stated. So, there is no need to follow any reversing 
exercise. 
It was generally a 7 point scale which we reduced to 5 point. This had been done 
because of: 
■ 5 point scale is easier to understand whereas 7 point scale is more 
ambiguous 
■ It helps us to restrict the questionnaire within one page 
5.8.3 Sampling Process 
A sample plan is developed to ensure that certain type of respondents will be included 
in this study. Specialty of about the Doctors who treat cardiovascular diseases was the 
primary criteria in developing the sampling plan. Cardiologists and MD (Doctor of 
Medicine) were the chosen from the Cardiological Society of India list from across the 
country (defined towns as per RKSBBDO) to make a good representation of the 
population. 
Moreover, sampling units consists of different specialties practicing in different types 
of clinic setting and different places across the country. Method chosen for sampling 
is Probability because it is a good estimate of population characteristics. Further, in 
probability sampling technique "Random Sampling Method" with "Multistage 
sample" was adopted because it attempts to obtain a sample of convenient elements. 
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Often, the respondents selected were because they happen to be in the right place at 
the right time. A sample of 152 respondents was considered appropriate keeping in 
view the resource constraints. Given below is the breakup of the sample 
Table 5.4: Sample distrihtutit~n 
' I ' 
Metros (:AAA Category) 
Al Rank 
by MPV 
State 	 "* 
Rank by • •: 
MPV 	 k , 
1 i 	Murnbai 	 18 
2 1 	Delhi  
3 1 	Kolkata 	 7 
Total 
Metros (AA Category) 
. 
4 	1 	Chennai  
5 1 	Hyderabad 17 
6 
7 
1 	Bangalore 
,lhrttedahad 
:' 11 
30 
Total 
Cities (A Category) 
12 1 	Jaipur 15 
Total 15 
Cities (B Category) 
4$ 6 	Gliaziahad 14 
I 	DehraDun 9 
Total 23 
Cities (C Category) 
243 26 	Bulandshahr 
Total 4 
GRAND Total 152 
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Sampling unit: Cardiologists & Physicians bent on cardiovascular practice and 
Diabetologists either in hospital or clinic. The universe of these Drs as per 
Cardiological Society of India (CSI) is 2500 of Cardiologists & Physicians with 
Cardiac Practice (80% of the practice is Cardiac). 
For the above study, we focused on specialists involved in chronic therapy treatment, 
use prescription drug (No OTC) where the impact of branding is the most important. 
This is because in chronic treatment therapies like cardiovascular disease and diabetes, 
the market is very cluttered and undifferentiated. Many companies would like to enter 
to chronic segment because they benefit from long-term prescription (usually life-
time). 
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Figure 5,4: Therapy Area selection for the study 
Top 5 therapy Area 	Chronic diseases 	Identified condition 	Rx Medicine 
Since there are many disease areas that can be studied, cardiovascular disease area was chosen. Since CV diseases amongst one of the 
most prevalent and esaiphons for CV disease management are for WIong, branding can #ay an important role. Within CV, hypertension 
has the highest prevalence' (17.1% in 2008) and hence the products selected were from hypertension area. 
'Source: Business Insights, The Asian Cardiovascular Market Outlook to 2010 by Revati Nehru & James Fox Tucker 
Figure 5,5: Customer Sample selection model for the study 
Dr treating Hypertension 	Identified Drs 	Identified centres 	Final sample 
5.8.4 Pre-test 
After instrument development, the questionnaire was formatted and a pilot-test was 
conducted. 30 doctors were selected from 2 different centers from the country. The 
Doctors selected were mostly from Hyderabad & Ghaziabad representing two zones 
of the country and two classes of town defined by RKSBBDO. The pre-test had five 
primary objectives: 
1. To evaluate content validity in terms of sequence and /low of questions 
2. Ambiguity or bias of verbiage 
3. Ease of understanding 
4. Appropriateness of scale levels and anchoring words 
5. Familiarity with the treatment of chronic cardiovascular disease and Brands 
which are prescribed from  A4NC & generic categories 
The Doctors were asked to mark their responses and provide feedback on different 
aspects of the questionnaire. 
5.8.5 Instrument Refinement 
Based on the feedback and analysis of pilot study following changes were made in the 
questionnaire in order to refine it for final data collection: 
a. Table 5.5: Number of questions section wise 
Section 	 Before 	After Refinement 
Perceived Quality 	 39 	 7 
Brand Loyalty 	 18 	7 
Credibility & 	 24 	 7 
Communication 
The feedback was to take away all questions which look very similar and combine 
them to make more simple questions. The challenge also came because the 
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respondents which are doctors are very busy and will not be able to give time. Also if 
time is a limitation and questions are more the responses might get compromised. 
b. Table 5.6: Change in scaling definition 
Excellent 	Strongiy Agree 
2 	Very Good 
3 Good 
4 	 Average 
5 	BelowAverage 
Agree 
NeitherAgree nor Disagree 
Disagree 
Strongly disagree 
c. Table 5.7: Number of pages 
Before 	After Refinement 
d. Table 5.8: Change is specific questions 
Brand Awareness 
What brands do you think of when you 
prescribe an antihypertensive? 
The company gives high number of 
exposures for this brand 
The brand is widely distributed 
Perceived Quality I like to visit the website for this brand 
Is paced wh ch is cost effective for my 
patient 
Brand Loyalty 	I feel this is the only brand of this product need 
Have an improved QOL & will not 
complain 
a. Adapts the product presentation to suit 
Credibility & 	your needs; 
Communication 	b. Visits you with the appropriate 
frequency of calls  
Which brands do you think of the most when you 
prescribe an antihypertensive? 
The company gives me high number of exposures & 
adequate visits for this brand 
The brand is widely distributed and is easily available 
DELETED 
Is priced which is cost effective for my patient & is 
worth paying more for 
ADD-0: Is priced lower than that of generics 
I am comfortable because of my experience with it & 
faith on it over time 
DELETED because of not much relevance 
COMBINED as ONE QUESTION 
Has an ability to deliver key information within the 
time frame & meets frequently 
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5.8.6 Data Collection 
Data Collection for the purpose of this study was performed from three different parts 
of the country in order to obtain heterogeneous data. 
We looked at the most trusted RKS BBDO Marketing white book as given in belov 
figure in order to select centers for data collection. We also looked at the sales fron 
IMS ORG for these centers and taking into consideration both the parameters, th, 
centers were identified: 
Three types of places were identified which should provide a Zone wise representatioi 
which is North. East, West and South: 
a) Metro who fall under AAA Category- The rationale for taking are that place 
where the population is more that 10 million and MPV is more than 600. Ii 
these places, most of the Cardiologists from CST list & Key Opinion leader 
with specialty practice will be based. There are three towns in this category 
viz. Mumbai, Delhi & Kolkata and all were chosen. 
b) Metro who fall under AA Category- The rationale for taking are that places 
where the population is approximately 6 million and MPV is approximately 
close to 200. In these places also, the next level of important Cardiologists 
from CSI list and Key Opinion leaders with specialty practice will be based in 
these towns. We selected four towns from this category viz. Chennai, 
Hyderabad, Bangalore, Ahmedabad 
c) Other towns which fall in A, B, C Category- The rationale for selecting these 
centers was to have a representation from smaller towns and from rural India. 
The centers were Jaipur, Ghaziabad, Dehradun and Bulandshahr 
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North, East, West, South 
Zone wise representation 
Metros (AAA Category) 
RKSBBDO 	 Delhi, Mumbai, 
(MPV data) Kolkala, India with at least 	& 	 Metros (AA Category) 
5% of the 	 Metros AAA & M category Chennal, Hyderabad IMS 
	
	 ry 	BtWgtkxa,Ahmelobad 
Markets total sample 	(CV sales in & A (AMAAIM 
key producls as per 	rates as per RKSBBDO) 	Cities A & B Category 
Zones) 	 Jar, Ghaiiabad, DehiaD 
SmaNrural India cues 	Cities C Category 
(A, B, C Category) Bulandshahr 
5.8.7 Data Analysis Techniques 
In order to achieve the purpose of this study and test the hypotheses, SPSS 18.0 was 
employed and Structural Equation Modeling (SEM) with AMOS was applied 
Validity and reliability of data 
Validity: To ascertain the validity of our draft questionnaire, we gathered the opinions 
of Doctors for each item, given in the questionnaire. In light of their valuable opinions 
only the valid relevant and meaningful questions were retained, as could serve to elicit 
valuable data and information from the respondent. Therefore, our questionnaire has 
content validity. 
Reliability: Reliability reflects the consistency of a set of scale items in measuring a 
particular concept. Reliability measurement is very important to check the internal 
consistency of all items, concerning the impact on the brand equity on both MNC and 
generic brands. 
SEM approach was applied for reliability analysis, since the reliability estimate from 
the SEM approach tends to be higher than Cronbach's a. 
1. Composite Reliability (CR) 
2. Average Variance Explained (AVE) 
Table 5.9: Overall for Brand X & Brand Y 
CR AVE 
Brand X 0.97345 0.61078 
Brand Y 0.97562 0.62987 
Table 5.10: Reliability statics for Brand X (attribute wise) 
Standardized Regression Weights: (Brand X - Default model) 
Estimate (1-^2) (A2) 
BA7 <--- BA 0.822 0.324 0.676 
BA6 <--- BA 0.49 0.76 0.24 
BA5 <--- BA 0.753 0.433 0.567 
BA4 <--- BA 0.697 0.514 0.486 
BA3 <--- BA 0.599 0.641 0.359 
BA2 <--- BA 0.491 0.759 0.241 
PQ5 <--- PQ 0.816 0.334 0.666 
PQ4 <--- PQ 0.886 0.215 0.785 
PQ3 <--- PQ 0.911 0.17 0.83 
PQ2 <--- PQ 0.867 0.248 0.752 
PQ1 <--- PQ 0.943 0.111 0.889 
BL7 <--- BL 0.838 0.298 0.702 
BL6 <--- BL 0.802 0.357 0.643 
BL5 <--- BL 0.595 0.646 0.354 
BL4 <--- BL 0.771 0.406 0.594 
BL2 <--- BL 0.702 0.507 0.493 
BLI <--- BL 0.609 0.629 0.371 
CC7 <--- CC 0.871 0.241 0.759 
CC6 <--- CC 0.877 0.231 0.769 
CC5 <--- CC 0.841 0.293 0.707 
CC4 <--- CC 0.85 0.278 0.723 
CC3 <--- CC 0.744 0.446 0.554 
CC2 <--- CC 0.836 0.301 0.699 
CC 1 <--- CC 0.895 0.199 0.801 
Sum 18.506 9.341 14.66 
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Table 5.12: Reliability statics for Brand Y (attribute wise) 
Standardized Regression Weights: (Brand Y - Default model) 
Estimate (1-^2) (^2) 
BA7 <--- BA 0.843 0.289 0.711 
BA6 <--- BA 0.457 0.791 0.209 
BA5 <--- BA 0.758 0.425 0.575 
BA4 <--- BA 0.73 0.467 0.533 
BA3 <--- BA 0.703 0.506 0.494 
BA2 <--- BA 0.553 0.694 0.306 
PQ5 <--- PQ 0.652 0.575 0.425 
PQ4 <--- PQ 0.81 0.344 0.656 
PQ3 <--- PQ 0.9 0.19 0.81 
PQ2 <--- PQ 0.938 0.12 0.88 
PQI <--- PQ 0.916 0.161 0.839 
BL7 <--- BL 0.848 0.281 0.719 
BL6 <--- BL 0.818 0.331 0.669 
BL5 <--- BL 0.691 0.523 0.477 
BL4 <--- BL 0.838 0.298 0.702 
BL2 <--- BL 0.785 0.384 0.616 
BL 1 <--- BL 0.692 0.521 0.479 
CC7 <--- CC 0.861 0.259 0.741 
CC6 <--- CC 0.896 0.197 0.803 
CC5 <--- CC 0.827 0.316 0.684 
CC4 <--- CC 0.824 0.321 0.679 
CC3 <--- CC 0.797 0.365 0.635 
CC2 <--- CC 0.842 0.291 0.709 
CC 1 <--- CC 0.875 0.234 0.766 
Sum 18.854 8.883 15.12 
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5.9 Statistical measures 
Structural Equation Modeling (SEM) has been used to test the model's validity 
(Bagozzi, 1996; Hoyle, 1995). This procedure allows a researcher to test the proposed 
structure of the model as a whole for the set oC relationships between dependent 
variable and independent relationships for hypothesis testing. Each latent variable has 
been covered by a set of measured variables in the questionnaire. SEM is highly 
appropriate for having a confirmatory data analysis for individual constructs and their 
measured variables. A brief concept of SEM is presented below. Advantages of using 
SEM are also mentioned. 
5.9.1 Theory of Structural Equation Modeling 
Structural Equation Modeling (SEM) is a statistical methodology that takes a 
confirmatory (i.e. hypothesis testing) approach to the multivariate analysis of a 
structural model bearing on some phenomenon (Byrne, 2010). The term SEM does not 
designate a single statistical technique; instead it refers to a family of related 
procedures. Other terms such as analysis of covariance structures, causal modeling 
with unobservable or latent variable, covariance structure analysis, covariance 
structure modeling, latent variable structural modeling, linear structural relations, or 
moment's structure modeling are also used in literature to classify these various 
techniques together under a single label (Kline, 1998). 
In SEM, interest is usually focused on latent constructs rather than on the manifest 
variable used to measure the constructs. Latent constructs refer to the unobserved or 
theoretical constructs; for example, abstract psychological variables like "enablers" or 
motivators". Whereas manifest variables refer to the observed or measured variables, 
since these variables reflect latent variables; and they are known as reflective 
indicators. SEM techniques are more flexible than comparable statistical techniques 
that are based on multiple regressions. 
Secondly and perhaps more importantly, SEM provides a unique analysis that 
simultaneously considers questions of both measurement and prediction. For the 
typical `latent variable models', SEM provides a flexible and powerful means of 
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simultaneously assessing the quality of measurement and examining predictive 
relationships among constructs. For doing a Confirmatory Factor Analysis (CFA) and 
path analysis at the same time, SEM allows researchers to frame increasingly precise 
questions about the phenomena in which they are interested. Such analysis, offer 
considerable advantages for estimating predictive relationships among latent 
constructs, that are uncontaminated by measurement error. 
5.9.2 Structural Equation Modeling Software, AMOS 
Computer software is important tool for SEM. AMOS is short for Analysis of Moment 
Structures. The researcher used AMOS 18.0. It implements the general approach to 
data analysis, knows as structural equation modeling (SEM), also known as analysis 
of covariance structures, or causal modeling. AMOS integrates an easy-to-use 
graphical interface with an advanced computing engine for SEM. With AMOS, 
researcher can quickly specify, view, and modify the model graphically using simple 
drawing tools. Then one can assess model's fit, make any modifications, and print out 
a publication-quality graphic of the final model. 
5.9.2.1 Definition of various estimates 
For the sake of clarity, given below are the definitions of various parameters which 
have been derived from SEM program AMOS 18.0 and used in further analysis.  
a) Standardized regression weights: 
The standardized regression weight is regression of an observed variable onto an 
unobserved variable or factor. It is defined variously as standardized path 
coefficient in AMOS (Barbara Byrne, 2000) or Coefficient Beta in SPSS (Norusis, 
1993) or Indicator Loading l (Joreskog and Sorbom, 1988) and used 
interchangeably in this research. 
Operationally, before calculating the multiple regression equation, all variable 
(observed and unobserved) are standardized. This is done by subtracting the mean 
from the variables and then dividing them by the standard deviation. This yields 
the standardized regression weight which shows the magnitude of expected change 
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in the observed variable for every change in the related unobserved variable or 
factor. 
b) Clinical Ration (CR) — It is a test static which is obtained by dividing the 
parameter estimate with the standard error and operates as a Z statistic 
different from zero. The value of CR has to be greater than or equal to I S. 
c) Indicator Error Variance (0) — Variance in the observed variable that is not 
explained by the unobserved variable. 
5.10 Testing for Reliability and Validity 
5.10.1 Reliability 
Reliability can be defined as the degree to which measurements are free from error 
and, therefore, yield consistent results. Operationally, reliability is defined as the 
internal consistency of a scale, which assesses the degree to which the items are 
homogenous. The composite reliability measure (pc) proposed by Werts, Linn and 
Joreskog (Joreskog and Sorbom, 1989) represents the proportion of measure variance 
attributable to the underlying trait Scales with p, greater than 70 percent are 
considerable to be reliable (Normally, 1978). 
5.10.2 Composite Reliability (Construct Reliability) 
The formula for calculating the Composite Reliability is as follows: 
pc = (EX)2/ [(EA)2 + E (0)] 
where 
pc = composite reliability 
7, = indicator loadings 
0 — indicator error variances 
Y = summation over indicators of the latent variable 
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5.11 Estimates for evaluating Goodness of Fit of structural models: 
One of the measures of absolute fit is the chi-square (O2) in association with its 
degrees of freedom (do and probability (p) of significant difference (Hair et al, 1998). 
It represents the amount of discrepancy between the unrestricted sample covariance 
matrix and the restricted covariance matrix (Byrne, 2001). An insignificant (p>0.05) 
❑zsuggests a satisfactory fit of the model (Holm-smith, 2002) and higher the 
probability closer, the model is to a perfect fit. 
This research has used a Named chi square (''Zldf) to reduce the sensitivity of the chi 
square statistic to sample size. The minimum acceptable value is 1, where as the 
maximum value should be less than or equal to 3.0 (Kline, 1998).  
The structural mode is sometimes accepted to provide justified fit even when the 
nonmed chi square (O2/df) value is statistically significant. In such a situation, the 
judgment is supported by additional goodness of fit viz. RMSEA, NFI, TLI and CFI 
which are explained below. 
RMSEA 
This research has used Root Mean Square of Approximate Error (RMSEA), which is 
an index based on non-centrality and compensates for the chi square statistic in large 
samples (Hair et a[, 1998). It expresses model fit per degree of freedom (Rao, 2002). 
This is, it expresses model fit for the whole population and not just the sample 
researcher uses to fit the model (Baungartner and Romberg, 1996). Values up to 0.08 
are acceptable for the research (Byrne, 201; Holmes-Smith, 2002). 
NFI, TLI and CFI 
Bentler-Bonnet's Nonmed Fit [ndex (NFI) values indicate the proportion of 
improvement of the overall fit of the model relative to the null model (Kline, 1998; 
Schumacher and Lomax, 1996). The NFI was used to compare the proposed model to 
the null model (Rao, 2002). in that it resealed the chi square statistic range from zero 
(poor fit) to one (perfect fit) (Schumacher and Lomax, 1996). Values above 0.8 and 
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close to 0.9 indicated acceptable fit for this research (Baumgartner and Homburg, 
1996; Hair et al, 1998). 
The Tucker Lewis fit Index (Ti!) is another measure used for comparison between the 
proposed models to the null model. It expresses fit per degree of freedom and hence is 
unaffected by model complexity (Baumgartner and Homburg, 1996; Kline, 1995) TLI 
used in this research is 0.8 to 0.9 for acceptable model fit (Rao, 2002). 
Bentler's Comparative Fit Index (CFI) estimated the comparative difference in non-
centrality between the proposed and base line models (Schumacher and Lomax, 
1996). It is interpreted the same way as NFI hut may be less affected by the sample 
size (Rao 2002). Thus, CF1 index prevented underestimation of fir in small sample 
(Arbukle, 1997). Values used in this research are 08 to 09 for acceptable fit (Hulland 
eta], 1996; Baumgartner and Homburg, 1996; Kline, 1998) 
5.12 Chapter summary 
This chapter explains the research methodology followed by the researcher. The 
conceptual models developed in the earlier chapter need to be tested and validated by 
administering a quantitative study on the Doctors The researcher adopted survey 
method, developed and administered a questionnaire on the doctors, collated the data 
and analyzed the data using Structural Equation Modeling. The questionnaire 
developed by the researcher has undergone rigorous validation by Doctors, pilot 
testing and focus group discussions. The respondents were selected from the list of 
Cardiological Society of India at random, based on the convenience of their 
availability for the survey. Data was collected from 152 Doctors, spread across 
various Metros and Non-Metros of the country. 
The various statistical measures for testing reliability and validity has been explained. 
The steps used in Structural Equation Modeling for evaluation of measurement and 
structural models have been explained along with criteria for acceptability. The next 
chapter deals with analysis of data, testing of hypothesis and evaluation of structural 
models. 
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Chapter 6 
Analysis and Interpretation 
6.1 Introduction 
This chapter is to highlight the data collected by administering the questionnaire into 
statistical analysis with graphical version. Most of the analysis and interpretation has 
been done through Structural Equation Modeling with AMOS. 
6.2 Testing for the factorial equivalence of scores 
(First-order CFA model) 
In this first multigroup application, we test hypotheses related to the invariance of a 
single measuring instrument across two data sets — for Product X and Product Y.... 
Specifically, we test for equivalency of the factor, loading of factors (ie, Brand 
Awareness, Brand Loyalty, Communication and Product Quality) on overall equity of 
Product X and Product Y 
The application to be examined in this chapter addresses equivalency of the factor 
loadings of four dimensions representing overall equity - 
• Brand Awareness (BA) 
• Brand Loyalty (BL) 
• Communication (CC) 
• Product Quality (PQ) 
... across Product X and Product Y over all doctors interviewed for this exercise 
Initial hypothesized model for developing the baseline model is shown below in figure 
6.1 
Figure 6.1 Initially hypothesized model for Product X and Product Y 
6.2.1 Establishing the baseline models: Product X and Product Y 
First goodness-of-fit related to the hypothesized model (Figure 6.1) was tested 
separately for Product X and Product Y. Model fit statistics indicated only a not so 
well-fitting model for both groups (Product X, CMIN = 637.172 with degrees of 
freedom 250 (CMIN/DF = 2.549). CFI = 0.852, I4MSEA = 0.101; Product Y, 
CMIN = 593.383 with degrees of freedom 250 (CMIN/DF = 2.374), CFI = 0.866, 
RMSEA = 0.095). 
When the initial hypothesized model shown above was run, large modification indices 
were seen for both Product X and Y. Product X's Large Modification Indices are E6 
<_> E7 (BA2 and BA]) — 31.879, E21 <-> E22 (BL! and BL2) = 26.122, E3 <-> E4 
(BA5 and BA6) = 30.059. Similarly, Product Y's Large Modification Indices are E3 
<_> E4 (BA5 and BA6) = 32.222, Ell <-> E12 (PQ4 and PQ5) = 21.488, E21 <-> 
E22 (BLI and BL2) = 19.742. 
The originally hypothesized model was revised and estimated again for each group. 
Testing of these new models resulted in a much better results. Goodness of fit 
estimates is given herewith: (Product X, CMIN = 478.258 with degrees of freedom 
242 (CMIN/DF=1.976), CFI = .910, RMSEA = .080; Product Y, CMIN = 429.737 
with degrees of freedom 242 (CMIN/DF=1.776), CFI = .927, RMSEA = .071). This 
final baseline model (which is same for each group) serves as the model to be tested 
for its equivalence across Product X and Product Y; it is schematically portrayed in 
Figure 6.2 
Figure 6.2: Final baseline model schematically portrayed 
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6.2.2 The configural model 
In the process of testing for invariance of latent means, we need to start with a 
configural model which tells us the extent to which the same factors represents the 
data for both groups i.e., Product X and Y here. As such, no equality constraints are 
imposed and judgment is based on the adequacy of the goodness-of-fit statistics only. 
In our case, the configural model of Product X and Y adequate goodness of fit in 
representation of the multigroup Product X and Y Unconstrained(CMIN = 865.905 
with degrees of freedom 476 (CMIN/DF=1.819), CFI = 0.925; RMSEA = 0.052). 
This conveys that the model can be accepted as a configural model. 
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Figure 6.3: Configural Model for Product X & Product Y 
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6.2.3 Model assessment 
Despite the multigroup structure of this and subsequent models, analyses yield only 
one set of fit statistics for overall model fit. When ML estimation is used, the y,2 
statistics are srmtmative and, thus, the overall x2 value for the multigroup model 
should equal the sum of the X2 values obtained when the baseline model is tested 
separately for each group of data sets. Consistent with single-group analyses, 
goodness-of-fit for this multigroup parameterization should exhibit a good fit to the 
data for both groups. Realistically, however, these multigroup fit statistics can never 
be better than those determined for each group separately. CMIN / OF and CFI indices 
below represent very good fit for these models. 
Having established goodness-of-fit for the configural model (also shown as 
Unconstrained model below), we now proceed in testing for the invariance of factorial 
measurement and structure across groups. 
Testing for measurement and structural invariance: The specification process 
In testing for configural invariance, interest focused on the extent to which the number 
of factors and pattern of their structure were similar across Product X and Product Y. 
This testing process is accomplished by assigning equality constraints on particular 
parameters (i.e. the parameters are constrained equal across groups). The procedure 
operates in such a way that these parameters are estimated for the first group only; 
estimates for all remaining groups are cunstrained equal to those of the first group. 
In this exercise, 5 models were developed:- i  
1) factor loadings of all 4 factors (i.e. PQ, BA, BL and CC) were constrained  
equal 
2) factor loadings of only BA were constrained equal 	- 	 _ 
3) factor loadings of only BL were constrained equal 
4) factor loadings of only PQ were constrained equal 	 '. 
5) factor loadings of only CC were constrained equal  
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Goodness of fit estimates for these models is given herewith:- 
Table 6.1: Model fit Summary 
CMIN 
Model NPAR CMIN DF P CMINIDF 
Unconstrained 124 865.905 476 .000 1.819 
All Weights 104 879.847 496 .000 1.774 
Model A only BA 119 869.194 481 .000 1.807 
Model A only PQ 120 872.633 480 .000 1.818 
Model A only BL 119 868.359 481 .000 1.805 
Model A only CC 118 867.286 482 .000 1.799 
Saturated model 600 000 0 
Independent Model 48 _5725.317 552 .000 10.732 
Table 6.2: Base line comparison 
Model NFI 
Delta I 
RFI 
rho I 
IFI 
Delta 2 
TLI 
rho 2 
CFI 
Unconstrained .849 .825 .926 .913 .925 
All Weights .846 .829 .927 .917 .926 
Model A only BA .848 .826 .926 .914 .925 
Model A only PQ .848 .825 .925 .913 .924 
Model A only BL .848 .826 .926 .914 .925 
Model A only CC .849 .827 .927 .915 .926 
Saturated model 1.000 1.000 1.000 
Independent Model .000 .000 .000 .000 .000 
105 
Table 6.3: RMSEA 
Model RMSEA LO 90 HI 90 PCLOSE 
Unconstrained .052 .046 .057 .271 
All Weights .051 .045 .056 .429 
Model A only BA .052 .046 .057 .309 
Model A only PQ .052 .046 .057 .273 
Model A only BL .052 .046 .057 .315 
Model A only CC .051 .046 .057 .336 
Independent Model .176 .172 .180 .000 
The goodness of fit statistics shown above clearly demonstrates that all the equations 
developed above are valid equations. All the equations shown above have CFI and 
CMIN / DF and RMSEA is in the acceptance band. Let's now look at interpretation of 
these results for non invariance of Product X and Product Y. 
Testing for measurement and structural invariance: Model assessment 
Major function of the configural model is that it provides the baseline against which 
all subsequent tests for invariance are compared. The classical approach in arguing for 
evidence of non invariance (or non- equivalence) is based on the 0x2 (Chi square) 
difference. The value related to this test represents the difference between the X2 
values for the configural and other models in which equality constraints have 
been imposed on particular parameters. This difference value is distributed as x2 
with degrees of freedom equal to the difference in degrees of freedom. Evidence of 
non invariance is claimed if this x2 difference value is statistically significant. 
These estimates of chi square values and their differences, as spread across difference 
of DFs for these models vis-a-vis configural model are given herewith. As these 
models show that all the models are non significant — thus indicating that there is no 
evidence of non-invariance. In other words, the factor loading of these 4 variables 
i.e., BA, BL, CC and PQ are working in a similar manner across Product X and 
Product Y. 
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One significant point of interest here is that for the model which constraints only 
factor PQ, p value of the model (of difference from configural model) is 0.151 
suggesting confidence of 85%. While this is lower than statistical significance norms 
of 90% or 95%, still it indicates that this one factor is operating somewhat differently 
across Product X and Product Y. 
Table 6.4: Assuming model unconstrained to be correct 
Model DF CMIN P NFI 
Delta-1 
IFI 
Delta-2 
RFI 
Rho-1 
TLI 
rho-2 
All Weights 20 13.943 .833 .002 .003 -.004 -.005 
Model A only BA 5 3.290 .655 .001 .001 -.001 -.001 
Model A only PQ 4 6.728 .151 .001 .001 .000 .000 
Model A only BL 5 2.455 .783 .000 .000 -.001 -.001 
Model A only CC 6 1.381 .967 .000 .000 -.002 -.002 
Conclusions 
Key takeout from this analysis is that the 4 parameters of Brand Equity i.e., Brand 
awareness, Brand Loyalty, Product Quality and Credibility & Communication are 
working towards contributing to overall brand equity. Since this model is accepted, it 
is confirmed that all these factors have a relevant role in contributing to brand equity. 
Further analysis done to check non-invariance (i.e., non equivalence) of the 
model operating across MNC brands and generics indicates that there is no 
evidence of non-invariance. In other words, the model and the factor loading of the 4 
pillars of brand equity i.e., BA, BL, CC and PQ are working in a similar manner 
across MNC brands and generics. 
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6.3 Testing for the equivalence of latent mean structures 
(First-order CFA model) 
We have used AMOS graphics to see how the identified factors like Brand 
Awareness, Brand Loyalty, Communication, and Product quality contributing to 
overall brand equity of Product X and Product Y. Here, we have tested for differences 
in the latent means of these factors - Brand Awareness, Brand Loyalty, 
Communication, and Product quality across Product X and Product Y amongst all 
doctors. 
Additionally, we also test for differences in the latent means of Brand Awareness, 
Brand Loyalty, Communication, and Product quality across Product X and Product Y 
in metros vs. non metros and in physicians vs. cardiologists. 
In typical univariate or multivariate analyses involving multigroup comparisons, we 
usually test whether the observed means representing the various groups are 
statistically significantly different from each other. Because these values are directly 
calculable from the raw data, i.e. they are considered to be observed values. However, 
means of latent variables (i.e., latent constructs or factors as we have identified Brand 
Awareness, Brand Loyalty, Communication, and Product quality) are unobservable; 
that is, they are not directly observed or measured. These latent factors derive their 
structure from their individual attributes representing these factors. The individual 
attributes are directly measured but the latent factors are not. 
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6.3.1 Estimation of latent variable means 
Now theoretically, any models involving mean structures will usually cover the 
following parameters: 	 -. 
• Regression coefficients 
• Variances and covariance of the independent variables 
• Intercepts of the dependent variables  
• Means of the independent variables 
Therefore, the model to assess invariance of latent means across 2 groups of data 
involves the analysis of both covariance and mean structures. , 
As with the invariance applications presented earlier, this application of a structured 
means model involves testing simultaneously across two groups. The multigroup 
model illustrated in this chapter is used when one is interested in testing for group 
differences in the means of particular latent constructs. Testing for latent mean 
differences across groups X and Y is to be done through model identification and 
factor identification — both are detailed herewith. 
6.3.2 Model identification 
Multigroup analyses provide the mechanism for imposing restrictions on the model 
such that the estimation of latent means is possible. This happens because equality 
constraints are specified across groups. These equality constraints derive are specified 
with the assumption that the observed variable intercepts and the factor loadings are 
invariant (i.e., same) across groups (Product X and Y in our case). 
6.3.3 Factor identification 	-'° 
This specifies restriction that intercepts for one group be fixed to zero, this group then 
operates as a reference group against which latent means for the other group(s) are 
compared The reason, for this re-conceptualization is that when the intercepts of the 
measured variables are constrained equal across groups, this leads to the latent 
factor Intercepts having no definite origin (i.e., they are undefined in a statistical 
sense). A standard way affixing the origin, then, is to set the factor intercepts of one 
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group to zero (Bender, 2005: Joreskog & Sorhom, 1996). As a consequence, factor 
intercepts are interpretable only inn relative sense. 
This means that it is possible to test for latent mean differences between, say, Product 
X and Product Y on Brand Loyalty or other such factors, it is not possible to estimate 
the mean of each factor for both Product X and Product Y. 
The application to be examined in this chapter addresses equivalency of the latent 
factor means of four dimensions representing overall equity — 
• Brand Awareness (BA) 
• Brand Loyalty (BL) 
• Communication (CC) 
• Perceived Quality (PQ) 
... across Product X and Product Y perceptions over all doctors and separately in 
metro vs. non metro and cardiologists vs. physicians. 
CFA model developed for this is portrayed below in Figure 6.4. As is evident in the 
figure, BL is measured by 7 parameters, PQ is measured by 7 parameters, BA is 
measured by 8 parameters and CC is measured by 7 parameters. 
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Figure 6.4: Four-factor model of overall brand equity for X vs. Y 
6.3.4 The baseline models 
First goodness-of-fit related to the hypothesized model (Figure 6.4) was tested 
separately for Product X and Product Y. Model fit statistics indicated only a not so 
well-fitting model for both groups (Product X, CMIN = 637.172 with degrees of 
freedom 250 (CMIN/D}' = 2.549), CFI = .852, RMSEA = .101; Product Y, CMIN 
= 593.383 with degrees of freedom 250 (CMIN/DF = 2.374), CFI = .866, RMSEA 
= .095). 
The originally hypothesized model was revised and estimated again for each group. 
Testing of these new models resulted in a much better results. Goodness of fit 
estimates is given herewith: (Product X, CMIN = 478.258 with degrees of freedom 
242 (CMIN/DF=1.976), CFI = .910, RMSEA = .080); (Product Y, CMIN = 
429.737 with degrees of freedom 242 (CMINIDF=1.776), CFI = .927, RMSEA = 
.071). This final baseline model (which is same for each group) serves as the model to 
be tested for its equivalence across Product X and Product Y; it is schematically 
portrayed in Figure 6.5 
Figure 6.5: Schematic portrayal of final baseline model tested for its equivalence 
across product X & Product Y 
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The structured means model needs a labeling system and in this process, some 
parameters are constrained to be equal across groups, while others are not. This 
requirement includes the observed variable intercepts in addition to the factor loadings 
(i.e., regression weights) - both are constrained equal across both groups. 
6.3.5 Testing for configural invariance 
In the process of testing for invariance of latent means, we need to start with a 
configural model which tells us the extent to which the same factors represents the 	-. 
data for both groups i.e., Product X and Y here. As such, no equality constraints are 
imposed and judgment is based on the adequacy of the goodness-of-fit statistics only. 
In our case, the configural model of Product X and Y adequate goodness of fit in 
representation of the multigroup Brand X and Y Measurement Intercepts(CMIIst = 
891,292 with degrees of freedom 516 (CMINIDF=1.727), CFI = .927; RMSEA = 
.049). This conveys that the model can be accepted as a configural model. 
1I4 
Figure 6.6: Configural invariance Model 
0. v6_1 	161 
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6.3.5 Testing for latent mean differences 
After the configural model is accepted, tests for invariance need to he done and this 
needs imposition of equality constraints across groups. For this we need to use Multi 
Group Analysis option in AMOS Graphics for this. 
As already discussed, it is necessary to constrain both the factor loadings and the 
observed variable intercepts equal across the groups. This is done by activating the 
Analysis Properties dialog box, either by clicking on its related icon or by selecting it 
from the Analysis drop-down menu. Once the Analysis Properties dialog box is open, 
we click on the Estimation tab and then select the Estimate Means and Intercepts 
option. After this we select the Multiple Group Analysis option from the Analysis 
drop-down menu. We place a checkmark in Column 1 for only the measurement 
weights and we additionally check off Column 2, which incorporates measurement 
weights and measurement intercepts.  
Now AMOS assigns a zero followed by a comma (0,) to each factor for both groups. 
We remove these fixed factor values for one group. The decision of which group will 
be fixed to zero is an arbitrary one and has no bearing on the final estimated mean 
values. We elect to use the Product Y group as the reference group (i.e., the latent 
means were fixed to a value of 00) and remove the mean constraints for Product Y. 
The final model we have arrived upon to assess latent mean differences is shown in 
Figure 8.11 as it relates to the Product X group. If we click on Product Y label in the 
directory tree, the same model will come for Product Y, with the zero values assigned 
to each of the factors as these are constrained to zero. 
There are 2 key analysis of interest here:- 
a) Goodness of fit indices 
b) The latent mean estimates in product X file. Since Y values are constrained to zero, 
values shown in X are to be taken as higher as or lower than Y 
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To provI l6ide with a basis of comparison between the structured means model and 
the configural model, goodness-of-fit statistics related to each are reported in Table 
below. Given the adequate goodness of fit, we can confidently interpret the estimates 
delivered by the model. 
Table 6.5: CMIN 
Model NPAR CMIN DF 	P CMIN/DF 
Measurement intercepts 132 891.29 516 	.00 1.73 
Structural means 128 896.85 520 .00 1.72 
Structural covariance 118 904.28 530 .00 1.71 
Measurement residuals 86 960.28 562 .00 1.71 
Saturated model 648 .00 0 
Independence model 96 5725.32 552 .00 	10.37 
Table 6.6: RMSEA 
Model RMSEA LO 90 111 90 P CLOSE 
Measurement intercepts 
Structural means 
.05 .04 .05 
.05 
.61 
.05 .04 .62 
Structural covariance .05 .04 .05 .70 
Measurement residuals .05 .04 .05 .69 
Independence model .18 .17 .18 .00 
This analysis is being.done to understand if the estimates of the key blocks of brand 
equity i.e., the 4 factors - Brand awareness, Brand Loyalty, Communication and 
Product Quality - are invariant between Product X and Y or not. Therefore, output of 
key interest are latent mean estimates reported for product X. As already mentioned 
that Product Y was designated as the reference group and thus their factor means were 
fixed to zero, the values reported here represent latent mean differences between the 
two groups. 
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Table 6.7: Standardized regression Weights: (Brand X- Model 1) 
Estimate 
BA7 <-------BA .768 
BA6 <-------BA .401 
BA5 <-------BA .691 
BA4 <-------BA .692 
BA3 <-------BA .622 
BA2 <-------BA .478 
PQ5 <-------PQ .697 
PQ4 <-------PQ .819 
PQ3 <-------PQ .868 
PQ2 <-------PQ .822 
PQ 1 <-------PQ .898 
BL7 <-------BL .824 
BL6 <-------BL .770 
BL5 <-------BL .611 
BL4 <-------BL .762 
BL2 <-------BL .708 
BL1 <-------BL .616 
CC7 <-------CC .853 
CC6 <-------CC .862 
CC5 <-------CC .813 
CC4 <-------CC .818 
CC3 <-------CC .727 
CC2 <-------CC .812 
CC 1 <-------CC .881 
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Table 6.S: Means: (Brand X- Model 1) 
Estimate SE CR P Label 
BA .185 .111 1.662 .097 ha 
PQ .186 .087 2.146 .032 pq 
BL .162 .116 1.395 .163 	bl 
CC .202 .106 1.907 .057 	cc 
Basis the output shown above, conclusions are: 
• BA— X is significantly higher than Y at 90% 
• PQ — X is significantly higher than Y at 97% 
• BL — X is not significantly higher than Y even at 90% 
• CC — X is significantly higher than Y at 94% 
6.3.6 Differences between latent means between X and Y in metros vs. non 
metros 
Table 6.9: Means: (Brand X Metro - Measurement intercepts) 
Estimate SE CR P Label 
BA .86 .15 5.54 *** BA 
PQ .52 .12 4.44 *** PQ 
BL .51 .16 3.21 .00 BL 
CC .57 .14 4.12 *** CC 
• On all parameters, X is significantly higher than Y 
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Table 6.10 Means: (Brand X Non Metro - Measurement intercepts) 
Estimate SE CR P Label 
BA .20 .16 1.31 .19 BA 
PQ .18 .14 	1.35 .18 PQ 
BL .09 .16 .57 .57 BL 
CC .33 .16 2.04 .04 CC 
■ BA - X is not significantly higher than Y even at 90% 
■ PQ - X is not significantly higher than Y even at 90% 
■ BL - X is not significantly higher than Y even at 90% 
■ CC - X is significantly higher than Y at 96% 
6.3.7 Differences between latent means between X and Y amongst cardiologists 
and physicians 
Table 6.11 Means: (Brand X CD - Measurement intercepts) 
Estimate SE CR P Label 
BA .20 .18 1.10 .27 BA 
PQ .23 .12 1.91 .06 PQ 
BL .25 .18 1.38 .17 BL 
CC .22 .14 1.58 .11 CC 
■ BA - X is not significantly higher than Y even at 90% 
■ PQ - X is significantly higher than Y at 94% 
■ BL - X is not significantly higher than Y even at 90% 
■ CC - X is not significantly higher than Y even at 90% 
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Table 6.12 Means: (Brand X PY - Measurement intercepts) 
Estimate SE CR P Label 
BA .17 .14 1.20 .23 BA 
PQ .14 .12 1.16 .25 PQ 
BL .08 .15 .51 .61 BL 
CC .18 .16 1.11 .27 CC 
■ No differences are significant even at 90% 
6.4 Conclusions 
This chapter thus helps conclude that at an overall level, Product quality of MNC 
brands is significantly higher than generics MNC brands estimates are marginally 
higher than generics on other brands This implies that overall equity of MNC brands 
in higher This is much higher in metros But there is not much significant differences 
amongst doctors in non metros, and by specialties 
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6.5 AMOS analysis to check the hypotheses generated 
6.5.1 The hypothesized model 
The CFA structure in Figure 6.7 comprises four self-concept (SC) factors—academic 
SC (ASC), social SC (SSC), physical SC (PSC), and emotional SC (ESC). Each SC 
factor is measured by three observed variables, the reliability of which is influenced 
by random measurement error, as indicated by the associated error term. Each of these 
observed variables is regressed onto its respective factor. Finally, the four factors are 
shown to be inter-related. 
6.6 Testing hypothesis 
Now the eight hypotheses developed were tested using the AMOS programming 
6.6.1 Validating Hypothesis I (Overall level Brand Equity) 
Hlp: Branding in Pharma industry plays no role in building brand equity.  
Hl: Branding in Pharma industry plays a role in building brand equity.  
Model as shown in figure 6.8 was used with 2 branding parameters – Brand 
Awareness and Brand Loyalty, along with Product Quality and Credibility / 
Communication. Figure below shows this for Brand X. 
Results for this model are: 
Product X, CMIN = 478.258 with degrees of freedom 242 (CMIN(DF=1.976), CFI = 
.910, RMSEA = .080); Product Y, CMIN – 429.737 with degrees of freedom 242 
(CMINTDF=1.776), CFI = .927, RMSEA = .071) 
This indicates an acceptable solution and hence it may be concluded that parameters 
used are all relevant. 
Alternate hypothesis is accepted - Branding in Pharma industry 
plays a role in building brand equity 
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Figure 6.7: Model for Hypothesis 1 
Brand X 
Standardized estimates 
CV = 478.258 
df = 242 
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6.6.2 Validating Hypothesis 2 
H2o: Brand equity is same for both Innovator (MNC) brand & generics brands. 
H2: There is a difference in brand equity for MNC and Generic brands. 
Difference between MNC brands and Generics on latent means of 4 pillars of brand 
equity as shown in Section 6.3 is shown herewith. 
Table 6.8: Means: (Brand X- Model 1) 
Estimate SE CR P Label 
BA .185 .111 1.662 .097 ba 
PQ .186 .087 2.146 .032 pq 
BL .162 .116 1.395 .163 bl 
CC .202 .106 1.907 057 cc 
'Estimate' above shows = latent mean of MNC, benchmarked to Generics as `0' 
P on the table above shows significance level (confidence level — I — Significance 
level). 
Only significant difference between MNC brands is on PQ. All other estimates are 
statistically not significant. 
Alternate hypothesis is accepted — Equity of MNC brands is higher than 
Generics, though it is driven only by PQ 
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6.6.3 Validating Hypothesis 3 (Overall level Brand equity) 
H30: Marketing Communication has no impact on building brand equity. 
H3: Marketing Communication helps in building brand equity. 
Model shown for Hypothesis 1 shows an acceptable solution This solution has been 
arrived upon using 2 legs of Brand equity — Brand awareness, Brand Loyalty, 
Communication, Product Quality. Since all parameters have together given an 
acceptable solution, it can be deduced that all these parameters are impacting equity. 
MRs as the communication channel for the brands is an important factor impacting 
overall brand appeal for pharma brands. While it is less important than brand and 
product factors, it does play a significant role for both patent & generic brands. 
Alternate hypothesis accepted — Communication support brand building and 
brand equity 
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6.6.4 Validating Hypothesis 4 (SPECIFIC BRAND EQUITY-ELEMENTS 1) 
H40: There is no difference in brand awareness for MNC & generics brands. 
114: There is a difference in brand awareness for MNC and Generics brands. 
Difference between MNC brands and Generics on latent means of 4 pillars of brand 
equity as shown in Section 6.3 is shown herewith, 
Table 6.8: Means: (Brand X- Model 1) 
Estimate SE CR P Label 
BA .185 .111 1.662 .097, ba 
PQ .186 .087 2.146 .032 pq 
BL .162 .116 1.395 .163 bl 
CC .202 .106 1.907 	.057 cc 
`Estimate' above shows = latent mean of MNC. benchmarked to Generics as '0' 
P on the table above shows significance level (confidence level = I — Significance 
level). 
On BA (i.e., Brand awareness) estimates of MNCs are marginally higher than generics 
and statistically significant at 90%, P value is .097 i.e., confidence level on the 
estimate is 90%. 
Alternate hypothesis is accepted — Brand awareness for MNC brands is higher 
for MNC brand vs. Generics 
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6.6.5 Validating Hypothesis 5 (SPECIFIC (BRAND EQUITY ELEMENTS 3) 
H5o: There is no difference in brand loyalty for MNC & generics brands. 
H5 : There is a difference in brand loyalty for MNC Generics brands. 
Difference between MNC brands and Generics on latent means of 4 pillars of brand 
equity as shown in Section 6.3 is shown herewith 
Table 6.8: Means: (Brand X- Model 1) 
Estimate SE CR P Label 
BA .185 .111 1.662 .097 ba 
PQ .186 .087 2.146 .032 pq 
BL .162 .116 1.395 .163 bl 
CC .202 .106 1.907 .057 cc 
`Estimate' above shows = latent mean of MNC, benchmarked to Generics as `0' 
P on the table above shows significance level (confidence level = I — Significance 
level) 
On BL (ie., Brand Loyalty) estimates of MNCs are marginally higher than generics 
but the estimate is statistically not significant. P value is .163 ie., confidence level on 
the estimate is 84%. This is considered not significant as it is lower than accepted 
norm of 95% confidence. 
Null hypothesis failed to reject — There is brand loyalty parity for MNC & 
generics brands 
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6.6.6 Validating Hypothesis 6 (SPECIFIC (BRAND EQUITY ELEMENTS 4) 
H60 : There is no difference in Perceived quality for MNC & generics brands 
H6: There is a difference in Perceived quality MNC & generics brands 
Differences between MNC brands and Generics on latent means of 4 pillars of brand 
equity as shown in Section 6.3 are given herewith. 
Table 6.8; Means: (Brand X- Model 1) 
Estimate SE CR P Label 
BA .185 .111 L662 .097 ha 
PQ .186 _087 2.146 .032 pq 
BL .162 .116 1.395 .163 bl 
CC .202 .106 1.907 .057 cc 
`Estimate' above shows = latent mean of MNC, benchmarked to Generics as '0' P on 
the table above shows significance level (confidence level = I — Significance level) 
On PQ (i.e., Product Quality) estimates of MNCs are significant higher than generics. 
P value is .032 i.e., confidence level on the estimatt. is 97%. This is considered 
significant as it is higher than accepted norm of 95% confidence. 
Alternate hypothesis is accepted — Perceived quality for MNC brands is higher for 
MNC brand vs. Generics 
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6.6.7 Validating Hypothesis 7 (SPECIFIC- Geographic Specific) 
B70: There is no difference in brand equity in Metro and Non Metro towns for MNC 
and generic brands. 
117: There is a difference in Brand equity in Metro and Non Metro towns for MNC 
and generic brands. 
Means: (Brand X Metro - Measurement intercepts) 
Differences between MNC brands and Generics on latent means of 4 pillars of brand 
equity as shown in Section 6.3 are given herewith for metros. 
Table 6.9: Means: (Brand X Metro - Measurement intercepts) 
4 
Estimate SE CR P Label 
BA .86 .15 5.54 *** BA 
PQ .52 .12 4.44 *** PQ 
BL .51 .16 3.21 .00 BL 
CC .57 .14 4.12 *** CC 
`Estimate' above shows = latent mean of MNC, benchmarked to Generics as 
P on the table above shows significance level (confidence Level = 1 — Significance 
Level) 
On all parameters of brand equity, estimates of MNCs are significant higher than 
generics. P value is .000 ie., confidence level on the estimate is 100%. This is 
considered significant as it is higher than accepted norm of 90-95% confidence. 
Alternate hypothesis is accepted — Brand equity is higher for MNC brands in Metro 
Means: (Brand X Non Metro - Measurement intercepts) 
Difference between MNC brands and Generics on latent means of 4 pillars of brand 
equity as shown in Section 6.3 is given herewith for non metros. 
Table 6.10 Means: (Brand X Non Metro - Measurement intercepts) 
Estimate SE CR P Label 
BA .20 .16 1.31 .19 BA 
PQ .18 .14 1.35 .18 PQ 
BL .09 .16 .57 .57 BL 
CC .33 .16 2.04 .04 CC 
On all parameters of brand equity, estimates of MNCs are marginally higher than 
generics. But on all parameters except on CC, other are non significant. On CC, P 
value of the estimate is .04 ie., confidence level on the estimate is 96%. This is 
- considered significant as it is higher than accepted norm of 95% confidence. 
Alternate hypothesis is accepted — Brand equity is higher for MNC brands in non 
metros also on one parameter 
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6.6.8 Validating Hypothesis'8 (SPECIFIC - Doctor Specialty) 
H8u: There is no difference in Brand equity in Metro and Non Metro towns for 
Cardiologists and Physicians. 
H8: There is a difference in Metro and Non Metro towns for Cardiologists and 
Means: (Brand X CD - Measurement intercepts) 
Difference between MNC brands and Generics on latent means of 4 pillars of brand 
equity as shown in Section 6.3 are shown herewith for cardiologists 
Table 6.11 Means: (Brand X CD - Measurement intercepts) 
Estimate SE CR P Label 
BA .20 .18 1.10 .27 BA 
PQ .23 .12 1.91 .06 PQ 
BL .25 .18 1.38 .17 BL 
CC .22 .14 1.58 .11 CC 
`Estimate' above shows = latent mean of MNC, benchmarked to Generics as 
P on the table above shows significance level (confidence level = I — Significance 
level) 
On all parameters of brand equity, estimates of MNCs are marginally higher than 
generics amongst cardiologists. But none of the differences are statistically significant. 
Null hypothesis failed to reject- There is no difference in Brand equity in Metro and 
Non Metro towns for Cardioloeists. 
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Means: (Brand X PY - Measurement intercepts) 
Difference between MNC brands and Generics on latent means of 4 pillars of brand 
equity as shown in Section 6.3 are shown herewith for physicians. 
Table 6.12 Means: (Brand X PY - Measurement intercepts) 
Estimate SE CR P Label 
BA .17 .14 1.20 .23 BA 
PQ .14 .12 1.16 .25 PQ 
BL .08 .15 .51 .61 BL 
CC .18 .16 1.11 .27 CC 
`Estimate' above shows = latent mean of MNC, benchmarked to Generics as `0' 
P on the table above shows significance level (confidence level = 1 — Significance 
level) 
On all parameters of brand equity, estimates of MNCs are marginally higher than 
generics amongst cardiologists. But none of the differences are statistically significant. 
Null hypothesis failed to reject - There is no difference in Brand equity in Metro and 
Non Metro towns for Physicians. 
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6.7 Chapter summary 
Confirmatory Factor Analysis has validated the constructs' reliability and validity of 
the measurement of the constructs Structural Equation modeling has been used for 
testing of hypothesis and evaluating the structural models. Out of the eight 
hypotheses, seven has been accepted and the hypothesis regarding brand equity parity 
amongst Cardiologists and Physicians has been rejected. Both the structural models 
have met the goodness of the criteria. The results and key findings have been 
discussed in the next chapter. 
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Chapter 7 
Findings, Recommendations, Conclusions and Managerial 
implications 
This chapter will examine the conclusions and findings of this study. Conclusions are 
based on the analysis of the primary research and understanding for the secondary 
research study. Overall findings connected to the research problem will first be 
discussed, followed by the findings connected to each research question; theoretical 
and managerial implications of this study will then be presented. 
7.1 Overall findings 
This chapter will examine the conclusions and findings of this study. Conclusions are 
based on the analysis of the primary research and understanding for the secondary 
research study. Overall findings connected to the research problem will first be 
discussed, followed by the findings connected to each research question; theoretical 
and managerial implications of this study will then be presented. 
According to Schuiling, 1. and Moss, G. (2004), branding theory and practice in 
pharmaceuticals is still ten years behind the FMCG area. The research expects that 
pressure towards globalisation Will continue, and this will effect changes in the 
pharmaceutical industry in time. 
The mounting evidence from consumer markets is that the brand-loyal repeat user--or 
prescriber, in pharma's case--deserves much greater sales focus. No matter what the 
industry studies show that profit and ROI increase in direct proportion to the loyalty 
reinforcement customers receive. In the pharma industry, those reinforcements can be 
as simple as helping physicians emotionally identify with a growing medical trend or 
with the anticipated fulfillment of a chronically underserved medical need. Seasoned 
marketers can develop even more sophisticated loyalty reinforcements as long as they 
remain within regulatory guidelines. The key is to move prescribing physicians farther 
along the brand loyalty curve until they become "brand advocates,' actively recruiting 
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their peers to become new users. Like all consumers, doctors who are highly satisfied 
and loyal to a brand will share their success stories and encourage peers to prescribe it. 
When that happens, the brand acquires new users at virtually no incremental cost. 
Many researchers are confident that in order to return to significant growth, branding 
could represent a new competitive edge that the industry should leverage. It will 
enable firms to differentiate their products from those of their competitors using both 
tangible and intangible benefits. Branding can also help protect the brand against 
generics by building brand loyalty prior to patent expiry and influencing the behavior 
and attitudes of patients and doctors. 
According to Aaker, the brand loyalty of the customer base is often the core of a 
brand's equity. If customers are different to the brand, in fact, buy with respect to 
features, price, and convenience with little concern to the brand name, there is likely 
little equity. If, on the other hand, they continue to purchase the brand even in the face 
of competitors with superior features, price, and convenience, substantial value exists 
in the brand and perhaps in its symbol and slogans. 
Brand loyalty, long a central construct in marketing, is a measure of the attachment 
that a customer has to a brand. It reflects how likely a customer will be to switch to 
another brand, especially when that brand make a change, either in price or in product 
features. As brand loyalty increases, the vulnerability of the customer base to 
competitive action is reduced. It is one indicator of brand equity which demonstrably 
linked to future profits, since brand loyalty directly into future sales 
It was very apparent that doctors were loyal to a branded medicine if they perceived it 
as better than a branded generic and would like/admire this brand very much & would 
really like to talk about this brand, despite the external influences imposed upon them 
to prescribe cheap generic drugs. 
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The use of statistical analysis such as chi-square, Canonical Discriminant analysis and 
SEM (Structural Equation Modeling) allowed a higher degree of accuracy in the 
results and minimized the risk of coincidence. 
Brand loyalty is qualitatively different from other major dimensions of brand equity in 
that it is tied more closely to the use of experience. Brand loyalty cannot exist without 
prior purchase and experience. In contrast, awareness, associations, and perceived 
quality are characteristics of many that a person has never used. 
According to Aaker to more clearly understand brand loyalty and its management, it is 
useful to consider approaches to its measurement. One approach is to consider actual 
behavior with additional approaches being based upon the loyalty constructs of 
satisfaction, liking and commitment. 
Through the results obtained from both the author's secondary and primary research, 
seven major conclusions can firmly be made, followed by recommendations to the 
pharmaceutical companies. 
First, it is evident that branding does play a significant role in the success of 
pharmaceutical companies and branding is a necessary tool in the pharmaceutical 
industry. The examples cited in the research, clearly shows that to build brand equity, 
brand loyalty, awareness, perceived quality and credibility and communication are the 
key components. This was especially significant for the branded products vs. generics. 
This means that the hypothesis that branding plays a role in Indian Pharma industry is 
true. This was also evident by statistical significance of the four attributes when 
analysis was done through SEM with AMOS and concluding that at an overall level 
showing brand equity was higher which was in fact very prominent in case of brand 
awareness, perceived quality and communication. 
Secondly, the results revealed that as per Canonical Discriminant analysis and stated 
importance Brand Awareness was the most important attribute. There was a clear 
overall difference found between Branded vs. Branded generic medicine when 
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comparison was made on the subset attributes of the Brand Awareness. The attributes 
ranked in term of importance based on the variable of Branded vs. branded generics as 
per the choice made by Doctors. 
The most important attribute which was bringing discrimination between was 
that the brand was the reference in the class and is the choice of thought leaders. 
This was followed by the trust of the company, reliability and ethical behavior. 
Further this showed that branding plays an important role increasing brand equity 
which was our hypothesis to be tested. The increase in brand awareness based on the 
distance in mean score in the Canonical Discriminant Function Coefficients analysis 
was in the attribute where company can show a high level of scientific approach in 
promotion and companies who keep Doctors updated with well run CMEs. The next 
most important was on the behavior of the company based on the trustworthiness and 
ethical approach they take. 
Overall. Brand awareness increase brand equity and it was seen in case of MNC 
branded products it was higher with a good significance for most of the attributes. 
When the same Brand Awareness attributes were measure by SEM with AMOS, the 
results clearly showed that brand awareness help build brand equity for innovator 
branded vs. branded generics in India. 
Thirdly, Perceived quality is clearly high for branded drugs and that emerges from a 
good communication about the quality and its benefit to patients. This can be achieved 
also with highlight the wealth of original data which product has. This was evident the 
highest difference in means as per Canonical Discriminant analysis when compared 
between branded and branded generics. 
Overall, on PQ, Branded medicines clearly scored over generics on all attributes 
except when asked on whether lower price makes a difference and this was mostly 
expected result. However, physicians intend to prescribe the drug even at higher price 
for branded or generics if it is found cost-effective and is it is worth paying more for 
patients benefit. Hence this seems to become an important point when it comes 
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specifically to price. -Moreover, physicians do realize the right and emphasized 
perceived quality communications does help in increasing perception for branded 
products 
Fourthly, price does not skew the data and does not impact the overall brand equity for 
either for branded or branded generics. When it comes to benefit of the patient 
physicians are ready to prescribe a more expensive drug provide the benefit of paying 
more has been effectively communicated. Hence, to conclude and important to note 
price is not impacting overall draw for either branded or branded generic 
molecules 
Fifthly, the increase in brand Loyalty is seen when there are increased repeat 
purchases leading to liking and admiration. In addition this leads to satisfaction in 
terms of really liking to talk about this brand. This is one of the measures stated by 
Aaker as mentioned earlier. 
The most important attribute which was bringing increase loyalty for branded vs. 
generic is the one that states "lam comfortable because of my experience with it & 
faith on it". Further, this showed that branding plays an important role increasing 
brand I which was our hypothesis to be tested. 
The increase in brand Loyalty based on the distance in mean score in the Canonical 
Discriminant Function Coefficients analysis was in the attribute I likeladmire this 
brand very much & I really like to talk about this brand" and "I will be 
recognized as a good physician". The next most important was I am proud to have 
others know I prescribe this brand over time". This was followed by "I 
like/admire this brand very much & I realty like to talk about this brand" 
The results from SEM analysis also suggested Brand Loyalty attributes scored to be 
higher for Branded products vs. generics. There was a clear overall difference found 
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between Branded vs. Branded generic medicine when comparison was made on the 
subset attributes of the Brand Loyalty. 
However, when evaluated with SEM analysis, the BL attribute did not reach statistical 
significance, which means that due to high clutter there can be parity and 
differentiation on this attribute will be little difficult. 
Sixthly, credibility and communication is emerging as the key driver of overall brand 
equity. It is significantly higher in case of branded products (CI; 94%) as per SF14 
analysis. As discussed earlier, impactful communication is key in pharmaceutical 
market since Medical Representative is an important tool in communicating about the 
drug and helps reinforce differentiation, unlike FMCG where Media advertising is 
strong. In a regulated market and in addition cluttered market with many "me-too" 
generics, Rep communication is vital. 
' 	When we looked which attribute was scoring the most on communication aspects, it 
came out to be "Always keep doctors updated on latest information & has 
superior knowledge" and "Support patient education with useful materials & is 
able highlight patient benefits". Looking at credibility parameters especially 	., 
focusing on the MRs, it came to be "Has an ability to deliver key information within 
the time frame & meets frequently", "Has a pleasant & friendly personality and is 
reliable" and finally "Is honest when promoting products & is not too pushy" and all 
in that sequence. 
What is coming as key for an MR when compared on branded vs. generics was 
important attributes like "frequency, reliability, honesty and pleasant personality. 
This is important to note because when communication vehicle is rep it is important 	'. 
the type of vehicle needs to have these attributes. 
Seventhly, since the study was done All India and bifurcated based on Metros and 
Non-Metros with differentiation amongst Cardiologists and Physicians practicing 
cardiology, it was important to see whether brand equity differs on above parameters. 
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When compared for two categories of products in two different types of town in India, 
on all parameters, branded product equity was significantly higher than branded 
generics in METROs. This was mostly coming because there are higher efforts in this 
area from NfNCs, also concentration of specialty doctors and the chronic disease of 
hypertension more prevalent in these types of towns. This also recommends the 
companies can get the best brand building in these areas. 
In case on Non-Metros, only credibility and communication (CC) was the most 
significant for branded products and that at a confidence level of 96% as per SEM 
analysis. 
Finally, type of Dr was making a little difference in building brand equity. At 
Cardiologists perceived quality was significantly higher. This means that at top 
specialty level like Cardiologists, quality of product is important and there is a high 
respect seen for branded products. 
7.2 Conclusions 
The research shows there is clear role of branding to play in India pharmaceutical 
industry. Although the branding is not as evolved due to high clutter, but if there is 
significant effort made on key attributes of branding like FMCG it could result giving 
companies a competitive advantage. Branded drugs to some extent have been able to 
secure a much better position and further, even better structured efforts made to 
capture both rational and emotional efforts can significantly go a long way in building 
a long term differentiated brand. Also to reinforce the point that price might not 
always play an important attribute to brand building. 
Much work has been done into brand equity to identify the prominent components 
such as customer loyalty, but this area of marketing management still requires more 
research into its existence and development within pharmaceutical brands. It is clear, 
however, that brand equity and its components do exist within the medical arena, to 
what extent is beyond the scope of this paper, but it is my opinion as a researcher that 
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we must continue to brand and consider the words of Tom Blacken wisely 'In the 21st 
century, branding ultimately will be the only unique differentiator between companies. 
Brand equity is now a key asset. 	 . 
According to Schuiling and Moss,4 branding theory and practice in pharmaceuticals is 
still ten years behind the FMCG area. The authors expect that pressure towards 
globalization will continue, and this will effect changes in the pharmaceutical industry 
in time. Through the results obtained from both the author's secondary and primary 
research, three major conclusions focusing on Case for branding and in which 
segment, followed by recommendations to the pharmaceutical companies on how to 
go about branding in this industry where there is generic pressure. 
7.2.1 Case for Branding in Indian Pharma  
Many researchers are confident that in order to return to significant growth, branding 
could represent a new competitive edge that the industry should leverage. It will 
enable firms to differentiate their products from those of their competitors using both 
tangible and intangible benefits. Branding can also help protect the brand against 
generics by building brand loyalty prior to patent expiry and influencing the behavior 
and attitudes of patients and doctors. 
We clearly saw in the research that branding if really focused can help build brand 
equity. What was seen in the research was that branding has helped brands to get a 
greater mindshare and top of the mind recall. This was evident because in 
hypertension market there are more 1000 choices for physician, customer was able 
to recall the brand either in case of Innovator (1vINC) or branded generic. In most 
cases, products of domestic companies do match up those of MNCs in terms of quality 
and benefits, but when it comes to image and branding, the latter are in a league of 
their own. The researchers also showed that Indian generic that have done serious 
branding have been to slot themselves to compete with MNC. 
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What is further compelling that when in a chronic disease area where the prescription 
is written for a long time and to make a brand shift during follow-up is really difficult; 
companies have to really fight to get that real Rx share opportunity. This is only 
achievable if branding is stronger for a brand vs. another. MNC have learnt it at global 
level and have been able to maximize that in Indian context and that's why in the 
research the findings have shown higher brand equity for MNCs. This was primarily 
driven by the brand awareness attribute and Credibility and Communication adopted 
by these companies but also more importantly on the perceived quality. It was also 
very pronounced to see that price which could have made a difference to me-too 
products have really not made a big difference to brand equity parameters. Overall this 
specific research is giving a lot of confidence that there is a role and a clear case of 
branding and can help competitive advantage to lead both mind and market share. In 
which segments to focus and how to go about is discussed further 
7.3 Case for Branding in Indian Pharma 
Which segments to focus? 
The research study was done across India and focused on Metro Towns where all four 
major Metros of India were covered in three additional were added to this list. Further 
there were 4 smaller towns were also added which are parts of smaller cities or non-
metro areas. 
The research also had a hypothesis that the Brand equity has no difference in Metro 
and Non-Metros. The alternate hypothesis was accepted, concluding that the brand 
equity for Innovator brand is higher in Metro and non-metros. The individual elements 
of BA, PQ and BL were significantly higher in Metro. On all parameters of brand 
equity, estimates of MNCs are significant higher than generics. P value is .000 i.e., 
confidence level on the estimate is 100%. This is considered significant as it is higher 
than accepted norm of 90-95% confidence. 
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In non-metros, although all parameters of brand equity were significantly higher but 
did not reach statistical significance. Credibility and Communication (CC) however, 
gained statistical significance. On CC, P value of the estimate is .04 i.e., confidence 
level on the estimate is 96%. This is considered significant as it is higher than 
accepted norm of 95% confidence. 
The study suggested that all parameters for branding can be extensively used in urban 
Metro towns were as smaller towns a strong credibility and communication can itself 
be a stronger driver of brand equity. The evidence to this also came from the fact 
finding from the research that MNC were able to make a big difference vs. generics. 
In practical world this becomes important because the non-intro towns look up to 
Metro towns molecules and brands to get understanding from specialists in these areas 
on the usage of the drugs. Non-Metro towns can hence get confidence to prescribe and 
apply learning in their areas.  
7.4 Recommendations and answering key questions at the start of the research 
7.4.1 Brand Loyalty 
The impact of brand loyalty was very high on the brand equity parameter. The most 
important attribute which was bringing increase loyalty for branded vs. generic was "I 
am comfortable because of my experience with it & faith on it". Further, this showed 
that branding plays an important role increasing brand I which was our hypothesis to 
be tested. 
The key attributes for brand Loyalty which came out as important were, "I like/admire 
this brand very much & I really like to talk about this brand" and "I will be recognized 
as a good physician". The next most important was I am proud to have others know I •, 
prescribe this. 
The results from SEM analysis also suggested Brand Loyalty attributes scored to be 
higher for Branded products vs. generics. There was a clear overall difference found 
143 
between Branded vs. Branded generic medicine when comparison was made on the 
subset attributes of the Brand Loyalty. 
However, when evaluated with SEM analysis, the BL attribute did not reach statistical 
significance, which means that due to high clutter there can be parity and 
differentiation on this attribute will be little difficult. 
7.4.2 Perceived Quality 
Perceived quality is clearly high for branded drugs and that emerges from a good 
communication about the quality and its benefit to patients. This can be achieved also 
with highlight the wealth of original data which product has. 
Overall, on PQ, Branded medicines clearly scored over generics on all attributes 
except when asked on whether lower price makes a difference and this was mostly 
expected result. However, physicians intend to prescribe the drug even at higher price 
for branded or generics if it is found cost-effective and is it is worth paying more for 
patients benefit. Hence this seems to become an important point when it comes 
specifically to price. Moreover, physicians do realize the right and emphasized 
perceived quality communications does help in increasing perception for branded 
products. 
Physicians perceive the two types of products and differentiate in terms of support 
with wealth of original scientific data to back superiority of the brands, this was 
evident in the research, when the key parameters under perceived quality which were 
came out. The two attributes which were of significance were, "I am giving best 
quality to my patients" and the brand is supported with wealth of original scientific 
data." 
Price does not skew the data and does not impact the overall brand equity for either 
for branded or branded generics. When it comes to benefit of the patient physicians 
are ready to prescribe a more expensive drug provide the benefit of paying more has 
been effectively communicated. Hence, to conclude and important to note price is not 
impacting overall draw for either branded or branded generic molecules 
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7.4.3 Brand Awareness 
The research overall showed that Brand Awareness was the most important attribute. 
There was a clear overall difference found between Branded vs. Branded generic 
medicine when comparison was made on the subset attributes of the Brand 
Awareness. The most important attribute which was bringing discrimination between 
was that the brand was the reference in the class and is the choice of thought leaders. 
This was followed by the trust of the company, reliability and ethical behavior. Brand 
name which was easy to remember and high had wide distribution came out be an 
important differentiator. 
Company can show a "high level of scientific approach in promotion" and "companies 
who keep Doctors updated with well run CMEs". The next most important was on the 
behavior of the company based on the "trustworthiness and ethical approach". If 
worked on these attributes of Brand awareness, company can bring s strong branding 
vs. genencs. 
7.5 Suggested Model for Building brand Equity 
The below model suggest that FOUR parameters which were studied will be key to 
brand branding process in the Indian Pharma Industry. The below overall model is 
suggested with a proposed name as: 
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Proposed "Indian Pharma Branding Diamond" 
Figure:. 7.1: Indian Pharma branding Diamond 
The Diamond reflects the hypothesis tested and confirmed during the research and 
reinforces various parameters which should be looked at while branding in India. If 
companies are able to focus in all FOUR parameters with identified attributes under 
these, there is a clear opportunity to increase differentiation in the me-too market. 
Further. below there are two step model as an outcome of above diamond which can 
help industry to really understand which attributes to focus on while building brands 
in Indian Pharma Industry. 
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Figure: 7.2: Indian Pharma branding model 
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With this the companies can not only increase brand loyalty and improve perceive 
quality but also increase market share for their brands. 
Structural Equation Modeling done with these factors clearly gives an acceptable 
solution. : (Product X, CMIN = 478.258 with degrees of freedom 242 
(CMIN/DF=1.976), CFI = .910, RMSEA = .080; Product Y, CMIN = 429.737 with 
degrees of freedom 242 (CMIN/DF=1.776), CFI = .927, RMSEA = .071) . Thus 
SEM proves that these 4 parameters explain brand equity build up for both generics 
and originals. (While there are differences between these 2 sub classes and this has 
been separately presented). 
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7.6 Managerial Implications 
The role of branding and communication in Indian Pharmaceutical Industry has been , 
discussed in this study. It should be a prioritized area in any building brand equity—
an idea also supported by the literature review. Brand equity has been specially 
studied for both branded and branded generics. It should be remembered as an 
outcome of this study that branding plays an important role whether it is MNC or 
reputed branded generics. The brand is a promise to the customer which is then 
transferred to patient benefit. For pharmaceutical branding in India where a generic 
clutter is an added challenge to the industry brand building with a concentrated effort 
like FMCG can become an important differentiating tool. However, it should be 
remembered that a in brand building credibility and communication can play an 
important role, which only means that customer facing reps are also an important part 
of brand building and equity building process Otherwise, the brand may create 
expectations that are not being fulfilled from a Medical Representative. For Indian 
Pharmaceutical firms, it is especially important to build the brand in order to minimize 
the problems caused by clutter, me-too maze and regulatory challenge. This study also 
proves that building the brand can involve really identifying key attributes which can 
help in building equity, which was evident from the analysis of data and finding 
statistically significant attributes. The branding in Indian pharmaceutical is at an 
evolving stage and with patented products coming in India more in number than 
before it can really take a forefront step in equalizing the profile like Global market. 
Brand managers need to think more strongly and need to get convinced that brand 
equity like other industry can make a substantial difference and winning market share. 
This research study in addition to previous researches can be an added confidence 
builder and motivator to marketing team of Pharma industry and building the future 
strong and differentiated brands. 
THESIS 
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7.8 Chapter summary 
The interpretation of the results of confirmatory Factor Analysis has validated 
researcher's understanding of the constructs related to role of branding and 
communication in the Indian pharmaceutical industry The interpretation of results of 
Structural Equation Modeling and testing of hypotheses has provided the answers to 
two research issues concerning if there is a role of branding and communication in 
Indian Pharma industry and if yes, how does the related Brand Equity differ amongst a 
MNC branded and Indian branded generic 
It is clear that there is a role of branding in the Indian Pharma industry resulting in 
building brand equity for the promoted product even in the cluttered market However 
it was also evident that MNC have taken branding process supported by credible 
communication by Sales Representatives have shown to have higher levels of 
branding evidence measured by brand equity in this research 
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Chapter 8 
Contextualization and Directions for future research 
8.1 Contextualization 
The conceptual framework in this study was built on existing theory. In the research, 
brand equity was well applied to conceptualized branding and communication model 
for Indian Pharmaceutical Industry. The study supported brand equity (Aaker, 1996), 
customer based brand equity (Keller, 2003) and the differences in attitude to brand 
building in FMCG vs. Pharma industry (Moss, G. 2007). However, some attributes of 
brand equity did not always match like the FMCG industry. For instance, brand 
loyalty was one of the most important factors in building brand equity in FMCG 
industry, however it did not came as strongly in branding medicine. Concerning the 
fifth attribute of brand equity model (Aaker 1996), did not find exact match with the 
conceptualized model and hence it was replaced with a more relevant attribute for the 
study in pharmaceutical. Hence, other proprietary asset of brand equity model was 
replaced by credibility and communication attribute which is more important in 
context of Pharma industry and for brand building. This study also found that the 
branding do play an important role in "me-too" products and is present for both the 
generic and innovator brand. One of the key insights that clearly came was the 
perception around pricing as a key motivator in choosing brand. This study, clearly 
established the fact that setting price to build brand equity (Keller 2003) might not 
always be true in case of medicine. The study also discovered the fact that a strong 
ethical behavior of the pharmaceutical company really help in building brand equity 
and can be one of the most important attributes. Further it has also shown that the 
Market share is closely related to amount of branding done which was evident from 
the secondary research showing that innovator brand has a higher share in this 
industry vs. generic. Finally the study identified key attributes which will be important 
for building brand in pharmaceutical industry in India and which were actually found 
as a research gap in the literature review. 
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8.2 Directions for future research 
It is clear that there is a role of branding in India Pharma industry resulting in building 
brand equity for the promoted product even in the cluttered market. However, it is also 
evident that MNCs have taken branding process more seriously which is supported by 
credibility and communication by Sales representatives. 
The study was looked at one segment of branding in the chronic therapy focused in 
cardiovascular disease area. Further research can also focus on other disease areas and 
also acute therapies. While literature review supported the use of most appropriate 
brand equity model, other models can also used to have further reinforcement of brand 
equity. Sample size really didn't allow spreading research scope to smaller number of 
towns; this could be one of area of further research. Further research scope can also 
look at brand associations for a most prescribed brand and can also be similarly 
compared one of most selling FMCG brand. This as an independent research can bring 
out deeper attributes which Pharma industry can follow. 
The research could be further done on the following: 
• Family branding strategies 
• Branding of extension 
• Comparing patented product branding strategies vs. non patented 
• Brand in acute disease area vs. chronic disease are 
• Understanding the impact on branding from the eyes of retailers and patients 
Overall, this research is just a beginning and future researchers can focus on many 
more areas to understand the India pharmaceutical market dynamics even better. 
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Appendix 1: 
Brand Association merger to other attributes (PQ specifically) and 
adding Credibility and Communication to the study 
Several literature reviews in earlier sections reinforced the point that communication 
attribute is more important than Brand association which in FMCG is much stronger. 
David Aaker (1991) grouped assets and liabilities on which brand equity is based into 
five categories: 
1. Brand Loyalty 
2. Brand Awareness 
3. Perceived Quality 
4. Brand associations in addition to perceived quality 
5. Other proprietary assets-patents, trademark, channel relationship, etc. 
Most of these are being studied in largely FMCG or a consumer level context. When 
we compared this to Indian pharmaceutical i;idustry, we clearly found as per literature 
first three equity parameters relevant even in Indian Pharma. The big difference here 
is that the consumer is not the customer. Doctors associate and differentiate the brand 
with respect to rational benefit. 
Branding can help to sustain the brand against generics after patent expiration. A 
strong brand will benefit from a high consumer loyalty (Aaker 1991, Kapferer 2001). 
This confirms that Loyalty is important to be considered in the research. 
Given the fundamental importance of demonstrating that a newly discovered 
substance will work and be safe, it is not surprising that main emphasis of the industry 
has been in promoting functional brand values particularly efficacy, safety, 
convenience and cost-effectiveness (Blackett, T., 2001) 
17" 
It is rare for pharmaceutical companies to explore, develop and promote expressive 
values with which the brand might identify. This might be undertaken for such 
lifestyle products such as contraceptive pills, and to a lesser extent for hormone 
replacement therapy, but rarely always the expressive values — such as they are — will 
be directed at the physician and not the end user. (Blacken, T., 2001) 
This is because of the reason that pharmaceutical industry brands are still more 
attributed to functional difference between products which are more significant and 
sustainable so the traditional and rational product approach could flourish. 
As shown above brand associations are closely linked to perceived quality and 
hence we build some questions of association into perceived quality itself as 
below: 
PQ1 I am giving best quality product to my patients 
PQ2 I am giving my patients best treatment available for their conditions 
PQ5 The brand is supported with wealth of original scientific data to back its superiority 
In Pharma strong associations are made with quality and very much related with 
rationale benefits rather than emotional. 
If we see promotion strategy in pharmaceutical, Ethical drugs are perfectly suited for a 
personal selling strategy combined with advertising in specialty media like medical 
journals. Further when we look at medical advertising, the principles of 
communication are applicable like consumer, but the difference is that the target-
audience is not the ultimate beneficiaries (patients) of products that are advertised. 
The role Pharma advertising is to convince the physicians that the product will help 
them help their patients. (Chaganti, S.R., 2005) 
At present, the marketing communication activities of the pharmaceutical industry 
represents the major organized and comprehensive effort to update physicians and 
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other decision makers about availability, safety, efficacy, hazards, and techniques of 
using medicines. (Smith, M.C., Kolasa E.M., Perkins, G., and Siecker, B., 2004). This 
infers again that rationale communication supersedes the emotional and associations 
for the products are made via rationale communication more strongly. 
There is a clear recognised importance of medical sales representatives in 
communicating brand messages and their role in developing brand equity; this is a 
point worthy of highlighting (Blackest, T. and Robins, R., 2001) 
Association building: Association building takes time, effort, resources, striking 
creative support and most importantly, is NOT foolproof. Indian pharma companies 
reportedly spend as much as 1/6th to 1/5th of their turnover on promotional activity. 
Specialty areas such as oncology, neurology, cardiology and diabetology, owing to 
their continued developments, require greater amount of sales rep training and it is 
estimated that —75% of sales training budget is allocated to these areas. The danger is 
that, even in conventional branding, brands that got all the rules right still could not 
differentiate them because the market was too cluttered and the message was not 
strong or credible enough — which is the scenario in the prescription drugs industry 
today. Given the constant clutter in this industry, emotional resonance with brands 
is weak and most companies do not undertake any significant efforts in this 
direction. 
Many brands that are successful today in the Indian market today invest heavily in 
direct brand messaging. All of this implies couple of simple requirements in branding 
strategy in today's pharmaceutical sector in India: 
1. Direct rational benefit messaging — Experts agree unanimously that medical 
representatives who work hard to spend longer time detailing the effect of a drug 
to doctors are very few. The onus of clutter-breaking messaging is therefore on the 
ROUTE. Prescribers have very less time for one-on-one engagement and even 
lesser attention span when brands are too many and messaging unclear. Most 
prescribers claim that they do not have the patience for layered messaging. No 
longer do prescribers display interest in associations that leave the mental exercise 
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of analyzing the actual benefits on the prescriber. "Get to the point" is a very 
common refrain doctors use to express their dilemma. Therefore, use of layered 
messaging is today very definitely giving up its place to concise direct rational 
messaging. Lesser-time-higher-impact seems to be the new mantra. 
2. Credible Information support - Products require support (many times 
evidentiary support) to ensure knowledge flow to doctors. Credibility of claims is 
seen as a hygiene requirement by prescribers. Both companies and prescribers 
agree that medical representative can only go so far, and not farther. Thus, what 
starts to matter is whether the representative is equipped with supports and 
whether all claims are well-substantiated. 
In a fast world that is only getting faster and more & more cluttered, brands perhaps 
needs to appreciate the constraints of prescribers and understand why there is a 
draught in the capacity for emotional engagement in the prescriber community. 
Excessive clutter leaves little room for bonding and when bonding is weak, it is 
transparent branding communication that wins. 
After this literature review, we concluded that Brand associations should be merged 
with some of the PQ attributes and add another parameter which emerged as even 
more important while doing the study 
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Adding Credibility and Communication as a study attribute 
The nature of competition and its intensity in the India pharmaceutical industry have 
made personal selling the crucial determinant factor for success that it is today. In a 
market where both products and strategies are "me-too", rather me-me-too" in nature, 
the battle is more between talents of different selling teams. A well trained, highly 
motivated sales force plays a decisive role in winning marketing wars. A Pharma 
company's medical representative is its most important source of communication to 
its prospective customers (Chaganti, S.R., 2005) 
Done well, detailing is generally accepted to be the most effective form of 
pharmaceutical promotion. Comparison and contrasts between this form of promotion 
and print advertising are shown in table below. (Smith, M.C., Kolasa E.M., Perkins, 
G., and Siecker, B., 2004). 
Advertising and detailing: similarities and contrasts 
Characteristics Advertising differences Similarities Detailing differences 
Functional One-way 	communication.  Both 	must 	be Two-way communication. Some 
Abundant 	noise 	in 	the understandable, 	interesting, control 	over 	"noise". 	Can 	be 
communication 	channels, believable, persuasive tailored to the situation. Difficult 
Relatively 	inflexible. 	Good to maintain company control of 
control 	over 	the 	message. , the 	message. 	Physician 	may 
Almost 	impossible 	for refuse to see. 
physician 	to 	avoid 	some 
exposure to the message 
Perceptual Difficult 	to 	reinforce 	the Both must penetrate sensory May stimulate all five senses as 
message during the course of mechanisms 	of 	the well 	as 	vary them selectively. 
presentation physician, 	with 	careful May reinforce and repeat in a 
selection 	of 	stimuli single cell. 
necessary 
Cognitive Works primarily by suggestion. Both attempt to present firm May 	carry 	physician 	through 
Primarily 	an 	interest-arousing and product as different and reasoning 	process. 	May 	be 
technique better than competition problem solving technique. 
Feeling state Single 	message 	may 	elicit Both 	attempts 	to 	induce May evaluate and take advantage 
varying feelings. No possibility favorable feelings of either favorable or unfavorable 
to adapt. feelings. 
Transactional Primarily pretransactional, with Both important as reminders May also effect a prescription s a 
posttransactional 	activity continue to use. direct results sales call. Possible 
primarily limited to dissonance to supply sample for patient in 
reduction, the office at the time. 
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Overall, Credibility and communication came out as a very important attribute for 
building brand equity and was need to be studied here. By doing this we have been 
able to get the attributes to 4 most important ones and also the questionnaire much 
more effective for getting a good data for the study. 
Branding, with all emotional and core value appeal that can exist in the 
consumer market, improbable, if not impossible, in the healthcare arena. As a 
result branding has fundamentally meant life cycle optimisation. (Blackett and 
Harrison 2001) 
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Project. Brand Medicine  
Dear Doctor, 
To introduce myself, I am Sanjeev Panchal working as Regional Marketing Manager, Asia Pacific for AstraZeneca Singapore Pte Limited and currently 
pursuing a PhD project with Aligarh Muslim University on 'Role of Branding & communication in Indian Pharmaceutical Industry". 
To understand the role of branding, a simple questionnaire is developed and your response to the questions below will be very helpful. The 
questionnaire is divided into four parts based on famous David Aaker's Brand Equity Model: 
A. Brand Awareness Related 
B. Perceived Quality Related 
C. Brand Loyalty Related 
D. Credibility & Communication Related 
You would be required to rate against each question from 1 to 5 for two brands selected by you based on your usage. 
Guidance for each questions is given at start of section: 
Thanks a lot for your time! 
Doctor, to start with, could you say something about yourself and your practice? 
Name 	: 
Specialization  
Clinic Address  
# of years in practice :  
Location: 
Date: 
Sample #: 
Sanjeev Panchal, Project BRAND MEDICINE; Questionnaire, PhD 2009 
Brand Medicine attributes 	 a 	~, -;, ., 	~a 	,~ 	A. Brand Awareness Related 
1 	What brands do you think of when you prescribe an antihypertensive? 
'2 	Which brand have you heard the most amongst these hypertensives? Cardace, Aten, Envas, Seloken XL, 
3 	Which brands might you be likely to use the most as an antih 	rtensive? 
Please rate Brand X (Highly used) & Brand Y (other brand): 1: Strongly Agree, 2: Agree; 3: Don't know; 4: Disagre; 5: Strongly Agree 
p Why the chosen brand has the highest awareness vs. chi c::.e • The company gives high number of exposures for this brand • The company has been in the business for long time • The company keeps up to dale through well run CME courses • The company always keeps doctor updated on latest information 
4e The company involves in new Clinical trial 
• The company high level of scientific approach in promotion 
• The brand is widely distributed 
• The brand is successful and used by key opinion leaders 
How freauently do You think of this brand? 
Brand Medicine attributes 	'~t • 	.~ 	,~' ~,' 	B, Perceived Quality Related 
Please rate Brand X (Highly used) & Brand Y (other brand): 1: Excellent, 2: Very Good; 3; Good; 4: Average; 5: Below Average 
6 What is your overall opinion of this brand? 
7' What is your assessment of the product aualifv of this brand? 
Please rate Brand X (Highly used) & Brand Y (other brand): 1: Strongly Agree, 2: Agree; 3: Don't know; 4: Disagree; 5: Strongly Agree 
8 To what extent does this brand fully satisfy your products needs? 
8a - I am giving my patients best treatment available for their conditions 
8b - I help reduce risk of my patients from future events 
8c - I am confident that my patients will remain free of symptoms 
8d - I am reassured by predictability of action 
Be - I am protecting my patients against side effects 
~8~ • Is the supported with wealth of original scientific data to back it suo 
Please rate Brand X (Highly used) & Brand Y (other brand): 1: Very High, 2: Very Good; 3: Just right; 4: Lower; S: Economical 
' 	How goci a value is this trarid' 
Please rate Brand X (Highly used) & Brand Y (other brand): 1: Excellent, 2: Very Good; 3: Good; 4: Average; 5: Below Average 
, 9a Is price) ,vh ch is cost effective for my patient 
9b Is worth paying more for 
•'90 Keep within practice budgets & within practice guidelines 
90 Is readily available on maximum counters 
My patient does not come back asking for substitution because of non -
,9eavailability 
10 This brand is the one my patients are most often initiated for hypertension 
This brand is the reference in the class & is the choice of thought leaders in 
11 the field 
12. I really like to talk about this brand to others 
13 1 am always interested in learning more about this brand 
14.1 am proud to have other know I use this brand 
15 1 like to visit the website for this brand 
16 1 really identify with people who use this brand 
17 This brand is used by people like me 
181 feel a deep connection with others who use this brand 
20 The makers of this brand understand my needs 
21. The makers of this brand care about my opinions 
22 The makers of this brand have my scientific interest in mind 
'The makers of this brand consider me for scientific dissemination about of tf 
23 disease area 
24 The company who produces this brand 
Is trustworthy, innovative and confident 
Has a long experience & has a welldeveloped Therapy portfolio 
Invests in research and development & is ethical in its business approach 
Is available in all possible strengths for dosage convenience 
Has combinations available for better control of disease and convenience 
has once-a.day dosing & offers full range of strengths convenience 
that can be adopted in accordance to severity of the disease 
Brand Medicine attributes 	 C. Brand Loyalty Related 
Please rate Brand X (Highly used) & Brand Y (other brand): 1: Excellent, 2: Very Good; 3: Good; 4: Average; 5: Below Average 
I consider myself loyal to this brand 
130 I buy this brand wherever I can 
t31' I buy as much of this brand I can  
1 feel this is the only brand of this product I need 
33 This is one brand I would prefer to buy/use 
.34 I really like to talk about this brand to others 
35 lam always interested in learning more about this brand 
3,6 
 
lam proud to have other know I use this brand 
j37 1 like to visit the website for this brand 
.38 1 am comfortable because of my experience with k over time  
let other know that I am a forward thinker in this therapeutic area 
I feel more comfortable than when prescribing generic products 
Have an improved QOL & will not complain 
.42 I Will be recognized as a good physician 	 i 
Please rate Brand X (Highly used) & Brand Y (other brand): 1: Very Much liked, 2: Liked; 3: Can't say; 4: Less liked; 5: not very much liked 
How much do you like this brand 
How much do you admire this brand 
X45 How much do you respect this brand 
Please rate Brand X (Highly used) & Brand Y (other brand): 1: Very likely, 2: Likely; 3: Can't say; 4: Less likely; 5: likely 
0 How likely would you recommend tnis brand to others 
B and Medicine attributes "Credibility & Communication Related 
Please rate Brand X (Highly used) & Brand Y (other brand): 1: Excellent, 2: Very Good; 3: Good; 4: Average; 5: Below Average 
Keeps me up to date through well run medical education courses 
48 Has superior knowledge and bring valuable information 
49 Support patient education with useful materials 
Keeps good relation with Doctors like you 
51 Is knowledgeablelable to answer questions on own products 
52 Is not too pushy 
:53 Always follows up on agree actions/reliable 
.64 Is willing to provide samples for doctors to try 
55 Is willing to provide samples for doctors to try 
56 Always keeps doctor updated on latest information 
57 Is honest when promoting products 
58 Willing to provide the best possible level of service 
59 Has integrity, does not speak ill of competitors' products 
60 Adapts the product presentation to suit your needs 
61 Visits you with the appropriate frequency of calls 
62 Easily contactable 
63 Does not oversell 
64 Is knowledgeable on competitors' products 
65 Ability to deliver key information within the time frame 
66 Is knowledgeable on disease area 
67 Is interested and understands your business needs 
68 Able to highlight patient & product benefits 
69 Has a pleasant & friendly personality 
Please rate Brand X (Highly used) & Brand Y (other brand): 1: Very Much liked, 2: liked; 3: Can't say; 4: Less liked; 5: not very much liked 
How much do you like the communication for this brand as compared to 
others 
'"' A*A A A "* Aaa ltThank you very much for your flme 
Dear Doctor, 
The objective of the study is to understand the role and impact of branding in Pharma Industry. Hence a Questionnaire is developed to elicit 
the data required for the study. Your responses will be kept confidential and will be used for academic purpose only. Your cooperation and 
feedback for the same would be appreciated and highly valued. 
Thanks a lot for your timel 
------------------------------- 	--- 
ionl: Which brands do you think of the most when you prescribe an antihypertensive? 
(You can think of one kind of hypertensive patients you see the most, e.g., diabetic, essential, CAD etc.) 
Please choose Brand X 	as #1 prescribed & Brand Y 	as #2 prescribed for the chosen hypertensive patient 
(Cardace, Ramistar, Hopace, Seloken XL, Met XL, Prolomet XL, Aten, losar, Stamlo, Envas, Amlopres AT, Amlodac, , any other) 
Kindly rate (by ticking (V) in the appropriate box), Brand X & Brand Yfrom  1 to S where 
L Strongly Agree, 2- Agree, 3- Neither Agree nor Disagree, 4- Disagree, 5- Strongly Disagree 
s. No Statements Rate for brand X 
1 	2 	3 	4 	5 
Rate for brand Y 
1 	2 	3 	4 	5 
1 have high awareness & I prescribe/ refer this brand because 
BAI The company ives me high number of exposures & adequate visits for this brand 
BA2 The brand name is easy to remember and recall 
BA3 The brand is widely distributed and is easily available 
8A4 The company has been in business for tong time & is trustworthy, reliable & ethical 
8A5 The company keeps me up to date through well run CME courses 
BA6 The company involves me in new Clinical trials 
BA? The company have a high level of scientific approach in promotion 
BA8 This brand is the reference in class & is the choice of thought leaders 
I prescribe/prefer this brand because I feel 
PQ1 I am giving best quality product to my patients 
PQ2 I am giving my patients best treatment available for their conditions 
PQ3 I help reduce risk of my patients from future events & side effects 
PQ4 I am reassured by predictability of action of this drug 
PQ5 The brand is supported with wealth of original scientific data to back its superiority 
PQ6 Is priced which is cost effective for my patient & is worth paying more for 
PQ7 Is priced lower than that of generics 
I consider myself loyal to this brand because 
8L1 I really identify with Drs who recommend this brand & is prescribed by Drs like me 
812 I am 	roud to have others know I prescribe this brand 
813 1 am comfortable because of my experience with it & faith on it over time 
"L4 I let others know that I am a forward thinker in this therapy area by prescribing it 
8(3 1 feel more comfortable than when prescribing a genenc products 
BL6 I will be recognized as a good physician - - 
BL7 I like/admire this brand very much & I really like to talk about this brand 
The company representatives who communicate about this brand 
 
CCl Always keep doctors updated on latest information & has superior knowledge 
CC2 Support patient education with useful materials & is able highlight patient benefits 
CO Is willing to provide enough samples for doctors to try 
CC4 Is honest when promoting products & is not too pushy 
CC5 Has integrity, does not speak ill of competitors' products - - - 
CC6 Has an ability to deliver key information within the time frame & meets frequently -
CC7 Has a pleasant & friendly 	 rsonali 	and is reliable 
Name: 	 Clinic Stamp/Card 
Speciality: 
Place: 
Signature: 
•.•...•...•,••.••,•....Thank you very much for your time******•""00""50"" 
